VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Herpes simplex virus type 1 and 2

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. gD (Other)
    2. gB from HSV-1 KOS (Protective antigen)
    3. ICP27 from Herpes simplex virus type 1 (Protective antigen)
    4. ICP27 from Herpes simplex virus type 2 (Protective antigen)
    5. UL27 from Herpes simplex virus type 1 (Protective antigen)
    6. UL27 from Herpes simplex virus type 2 (Protective antigen)
    7. UL44 from HSV-1 (Protective antigen)
    8. UL44 from HSV-2 (Protective antigen)
    9. US4 (Protective antigen)
    10. US5 (Protective antigen)
    11. US6 (Protective antigen)
    12. US7 (Protective antigen)
    13. US8 (Protective antigen, Virmugen)
    14. gD (Virmugen)
    15. gH (Virmugen)
    16. ICP0 (Virmugen)
    17. TK (Virmugen)
    18. UL29 (Virmugen)
  3. Vaccine Related Host Genes
    1. IgG
    2. Ighv1-9
  4. Vaccine Information
    1. GSK1437173A
    2. Herpes simplex virus 1 gD mutant vaccine
    3. Herpes simplex virus 1 gH mutant vaccine
    4. Herpes simplex virus 1 TK mutant vaccine
    5. Herpes simplex virus 1 UL29 mutant vaccine
    6. Herpes Simplex Virus 2 DNA Vaccine encoding gD
    7. Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L
    8. Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2
    9. Herpes simplex virus 2 ICP0 mutant vaccine
    10. Herpes simplex virus DNA vaccine ∆gB-2 encoding gB
    11. Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis
    12. Herpes simplex virus DNA vaccine gB-DNA encoding gB
    13. Herpes simplex virus DNA vaccine gBDNA encoding gB
    14. Herpes simplex virus DNA vaccine gD-2 encoding gD
    15. Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27
    16. Herpes simplex virus DNA vaccine pCI-gB encoding gB
    17. Herpes simplex virus DNA vaccine pSIN-gB encoding gB
    18. Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP
    19. Herpes simplex virus type 1 DNA vaccine encoding GC
    20. Herpes simplex virus type 1 DNA vaccine encoding GD
    21. Herpes simplex virus type 1 DNA vaccine encoding GE
    22. Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21
    23. Herpes simplex virus type 2 DNA vaccine encoding GB
    24. Herpes simplex virus type 2 DNA vaccine encoding ICP27
    25. Herpes simplex virus type 2 vaccine using phage displaying GG protein
    26. HSV 2 DNA vaccine pVAX–HSV–2gD–Hsp70
    27. HSV glycoproteins subunit vaccine
    28. pRP-RSV-HSV-1-gB
    29. rOka-gD2- HSV-2
  5. References
I. General Information
1. NCBI Taxonomy ID:
10298
2. Disease:
Herpes
3. Introduction
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family, Herpesviridae, that infect humans. Both HSV-1 and -2 are ubiquitous and contagious. They can be spread when an infected person is producing and shedding the virus. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with a scab characteristic of herpetic disease. However, as neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body for the life of the carrier by becoming latent and hiding from the immune system in the cell bodies of nerves. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. In an outbreak, the virus in a nerve cell becomes active and is transported via the nerve's axon to the skin, where virus replication and shedding occur and cause new sores.
There is no known cure for HSV infection, but treatments can reduce the likelihood of viral shedding and spread (Wiki: Herpes simplex virus).
4. Microbial Pathogenesis
In the case of a herpes virus, initial interactions occur when a viral envelope glycoprotein called glycoprotein C (gC) binds to a cell surface particle called heparan sulfate. A second glycoprotein, glycoprotein D (gD), binds specifically to at least one of three known entry receptors. These include herpesvirus entry mediator(HVEM), nectin-1 and 3-O sulfated heparan sulfate. The receptor provides a strong, fixed attachment to the host cell. These interactions bring the membrane surfaces into mutual proximity and allow for other glycoproteins embedded in the viral envelope to interact with other cell surface molecules. HSVs may persist in a quiescent but persistent form known as latent infection, notably in neural ganglia. HSV-1 tends to reside in the trigeminal ganglia, while HSV-2 tends to reside in the sacral ganglia, but note that these are tendencies only, not fixed behavior (Wiki: Herpes simplex virus).
5. Host Ranges and Animal Models
HSV-1 and HSV-2 infect humans and mice are used as a model of protection in vaccine studies (Nass et al., 1998).
6. Host Protective Immunity
HSV evades the immune system through interference with MHC class I presentation of antigen on the cell surface. This is achieved through blockade of the TAP transporter induced by the secretion of ICP-47 by HSV. TAP maintains the integrity of the MHC class I molecule before it is transported via the golgi apparatus for recognition by CD8+ CTLs on the cell surface. ICP-47 disrupts this integrity, preventing the capture of cytosolic proteins for CTL recognition and thus evades CTL destruction (Wiki: Herpes simplex virus).
1. gB from HSV-1 KOS
  • Gene Name : gB from HSV-1 KOS
  • Sequence Strain (Species/Organism) : Human herpesvirus 1 strain KOS
  • NCBI Protein GI : 1353200
  • Other Database IDs : CDD:177560
  • Taxonomy ID : 10306
  • Gene Strand (Orientation) : ?
  • Protein Name : Envelope glycoprotein B
  • Protein Length : 904
  • Protein Note : gB-1; gB1
  • Protein Sequence : Show Sequence
    >gi|1353200|sp|P06437.2|GB_HHV1K RecName: Full=Envelope glycoprotein B; Short=gB; AltName: Full=gB-1; AltName: Full=gB1; Flags: Precursor
    MHQGAPSWGRRWFVVWALLGLTLGVLVASAAPTSPGTPGVAAATQAANGGPATPAPPPLGAAPTGDPKPK
    KNKKPKNPTPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPPTGATVVQFEQPRRCPTRPEGQ
    NYTEGIAVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINAKGVCRST
    AKYVRNNLETTAFHRDDHETDMELKPANAATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARS
    VYPYDEFVLATGDFVYMSPFYGYREGSHTEHTTYAADRFKQVDGFYARDLTTKARATAPTTRNLLTTPKF
    TVAWDWVPKRPSVCTMTKWQEVDEMLRSEYGGSFRFSSDAISTTFTTNLTEYPLSRVDLGDCIGKDARDA
    MDRIFARRYNATHIKVGQPQYYQANGGFLIAYQPLLSNTLAELYVREHLREQSRKPPNPTPPPPGASANA
    SVERIKTTSSIEFARLQFTYNHIQRHVNDMLGRVAIAWCELQNHELTLWNEARKLNPNAIASVTVGRRVS
    ARMLGDVMAVSTCVPVAADNVIVQNSMRISSRPGACYSRPLVSFRYEDQGPLVEGQLGENNELRLTRDAI
    EPCTVGHRRYFTFGGGYVYFEEYAYSHQLSRADITTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLL
    DYTEVQRRNQLHDLRFADIDTVIHADANAAMFAGLGAFFEGMGDLGRAVGKVVMGIVGGVVSAVSGVSSF
    MSNPFGALAVGLLVLAGLAAAFFAFRYVMRLQSNPMKALYPLTTKELKNPTNPDASGEGEEGGDFDEAKL
    AEAREMIRYMALVSAMERTEHKAKKKGTSALLSAKVTDMVMRKRRNTNYTQVPNKDGDADEDDL
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Herpes simplex virus DNA vaccine pCI-gB encoding gB , pRP-RSV-HSV-1-gB
2. gD
  • Gene Name : gD
  • NCBI Protein GI : 19548971
  • 3D structure: PDB ID : 1L2G
  • Other Database IDs : CDD:177571
    CDD:186820
  • Taxonomy ID : 10298
  • Gene Strand (Orientation) : ?
  • Protein Name : glycoprotein D
  • Protein Length : 394
  • Protein Note : envelope glycoprotein D; Provisional
  • Protein Sequence : Show Sequence
    >gi|19548971|gb|AAL90884.1|AF487902_1 glycoprotein D [human herpesvirus 1]
    MGGAAARLGAVILFVVIVGLHGVRGKYALADASLKMADPNRFRGKDLPVLDQLTDPPGVRRVYHIQAGLP
    NPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTIAWFRMGGNCAIPITVMEY
    TECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
    KGSCKYTLPLRIPPSACLSPQAYQQGVTVDSIGMLPRFIPENQRTVAVYSLKIAGWHGPKAPYTSTLLPP
    ELSETPNATQPELAPEDPEDSALLEDPVGTVAPQIPPNWHIPSIQDAATPYHPPATPNNMGLIAGAVGGS
    LLAALVICGIVYWMHRRTRKAPKPIRLPHIREDDQPSSHQPLFY
  • Molecule Role : Virmugen
  • Molecule Role Annotation : KOS-gDA3C is attenuated with mutations in gD gene in causing skin lesions at the inoculation and zosteriform sites, yet it is as effective as rKOS-gDA3C in protecting mice against HSV-1 challenge (Awasthi et al., 2008).
  • Related Vaccine(s): Herpes simplex virus 1 gD mutant vaccine , Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP , Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21
3. gD
  • Gene Name : gD
  • Sequence Strain (Species/Organism) : Human herpesvirus 2
  • NCBI Gene ID : 1487358
  • NCBI Protein GI : 9629336
  • Locus Tag : HHV2gp69
  • Genbank Accession : AY779751
  • Protein Accession : NP_044536
  • Taxonomy ID : 10310
  • Gene Starting Position : 141015
  • Gene Ending Position : 143591
  • Gene Strand (Orientation) : +
  • Protein Name : envelope glycoprotein D
  • Protein pI : 7.84
  • Protein Weight : 40611.38
  • Protein Length : 393
  • Protein Note : gD family
  • DNA Sequence : Show Sequence
    >gi|9629267:141015-143591 Human herpesvirus 2, complete genome
    CATGGGGCGTTTGACCTCCGGCGTCGGGACGGCGGCCCTGCTAGTTGTCGCGGTGGGACTCCGCGTCGTC
    TGCGCCAAATACGCCTTAGCAGACCCCTCGCTTAAGATGGCCGATCCCAATCGATTTCGCGGGAAGAACC
    TTCCGGTTTTGGACCAGCTGACCGACCCCCCCGGGGTGAAGCGTGTTTACCACATTCAGCCGAGCCTGGA
    GGACCCGTTCCAGCCCCCCAGCATCCCGATCACTGTGTACTACGCAGTGCTGGAACGTGCCTGCCGCAGC
    GTGCTCCTACATGCCCCATCGGAGGCCCCCCAGATCGTGCGCGGGGCTTCGGACGAGGCCCGAAAGCACA
    CGTACAACCTGACCATCGCCTGGTATCGCATGGGAGACAATTGCGCTATCCCCATCACGGTTATGGAATA
    CACCGAGTGCCCCTACAACAAGTCGTTGGGGGTCTGCCCCATCCGAACGCAGCCCCGCTGGAGCTACTAT
    GACAGCTTTAGCGCCGTCAGCGAGGATAACCTGGGATTCCTGATGCACGCCCCCGCCTTCGAGACCGCGG
    GTACGTACCTGCGGCTAGTGAAGATAAACGACTGGACGGAGATCACACAATTTATCCTGGAGCACCGGGC
    CCGCGCCTCCTGCAAGTACGCTCTCCCCCTGCGCATCCCCCCGGCAGCGTGCCTCACCTCGAAGGCCTAC
    CAACAGGGCGTGACGGTCGACAGCATCGGGATGCTACCCCGCTTTATCCCCGAAAACCAGCGCACCGTCG
    CCCTATACAGCTTAAAAATCGCCGGGTGGCACGGCCCCAAGCCCCCGTACACCAGCACCCTGCTGCCGCC
    GGAGCTGTCCGACACCACCAACGCCACGCAACCCGAACTCGTTCCGGAAGACCCCGAGGACTCGGCCCTC
    TTAGAGGATCCCGCCGGGACGGTGTCTTCGCAGATCCCCCCAAACTGGCACATCCCGTCGATCCAGGACG
    TCGCGCCGCACCACGCCCCCGCCGCCCCCAGCAACCCGGGCCTGATCATCGGCGCGCTGGCCGGCAGTAC
    CCTGGCGGTGCTGGTCATCGGCGGTATTGCGTTTTGGGTACGCCGCCGCGCTCAGATGGCCCCCAAGCGC
    CTACGTCTCCCCCACATCCGGGATGACGACGCGCCCCCCTCGCACCAGCCATTGTTTTACTAGAGGAGTT
    TCCCCGCTCCCGTGTACCTCTGGGCCCGTGTGGGAGGGTGGCTGGGGTATTTGGGTGGGACTTGGACTCC
    GCATAAAGGGAGTCTCGAAGGAGGGAAACTAGGACAGTTCATAGGCCGGGAGCGTGGGGCGCGCACCGCT
    GTCCCGACGATTAGCCACCGCGCCCACAGCCACCTCGACCCGTCCGATCCCGGTATGCCCGGCCGCTCGC
    TGCAGGGCCTGGCGATCCTGGGCCTGTGGGTCTGCGCCACCGGCCTGGTCGTCCGCGGCCCCACGGTCAG
    TCTGGTCTCAGACTCACTCGTGGATGCCGGGGCCGTGGGGCCCCAGGGCTTCGTGGAAGAGGACCTGCGT
    GTTTTCGGGGAGCTTCATTTTGTGGGGGCCCAGGTCCCCCATACAAACTACTACGACGGCATCATCGAGC
    TGTTTCACTACCCCCTGGGGAACCACTGCCCCCGCGTTGTACACGTGGTCACACTGACCGCATGCCCCCG
    CCGCCCCGCCGTGGCGTTCACCTTGTGTCGCTCGACGCACCACGCCCACAGCCCCGCCTATCCGACCCTG
    GAGCTGGGTCTGGCGCGGCAGCCGCTTCTGCGGGTTCGAACGGCAACGCGCGACTATGCCGGTCTGTATG
    TCCTGCGCGTATGGGTCGGCAGCGCGACGAACGCCAGCCGGTTTGTTTTGGGGGTGGCGCTCTCTGCCAA
    CGGGACGTTTGTGTATAACGGCTCGGACTACGGCTCCTGCGATCCGGCGCAGCTTCCCTTTTCGGCCCCG
    CGCCTGGGACCCTCGAGCGTATACACCCCCGGAGCCTCCCGACCCACCCCTCCACGGACAACGACACCCC
    CGTCCTCCCCCCGAGACCCGACCCCCGCCCCCGGGGACACAGGGACGCCCGCGCCCGCGAGCGGCGAGAT
    AGCCCCGCCCAATTCCACGCGATCGGCCAGCGAATCGAGACACAGGCTAACCGTAGCCCAGGTAATCCAG
    ATCGCCATACCGGCGTCCATCATCGCCTTTGTGTTTCTGGGCAGCTGTATCTGCTTCATCCATAGATGCC
    AGCGCCGATACAGGCGCCCCCGCGGCCAGATTTACAACCCCGGGGGCGTTTCCTGCGCGGTCAACGAGGC
    GGCCATGGCCCGCCTCGGAGCCGAGCTGCGATCCCACCCAAACACCCCCCCCAAACCCCGACGCCGTTCG
    TCGTCGTCCACGACCATGCCTTCCCTAACGTCGATAGCTGAGGAATCGGAGCCAGGTCCAGTCGTGCTGC
    TGTCCGTCAGTCCTCGGCCCCGCAGTGGCCCGACGGCCCCCCAAGAGGTCTAGGTCCAAGCGGGCCGTTC
    GGCAGGCCCGCCCCACCGCCCCCATCGTGGTTATTTCCCCCCCCCCCCCCCCAATAA
  • Protein Sequence : Show Sequence
    >gi|9629336|ref|NP_044536.1| envelope glycoprotein D [Human herpesvirus 2]
    MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLE
    DPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEY
    TECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
    RASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPP
    ELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALAGST
    LAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY
  • Molecule Role : Other
  • Related Vaccine(s): Herpes Simplex Virus 2 DNA Vaccine encoding gD , Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L , Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2 , Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis , Herpes simplex virus DNA vaccine gD-2 encoding gD , HSV 2 DNA vaccine pVAX–HSV–2gD–Hsp70 , rOka-gD2- HSV-2
4. gH
  • Gene Name : gH
  • NCBI Protein GI : 138315
  • Other Database IDs : CDD:177579
  • Taxonomy ID : 10299
  • Gene Strand (Orientation) : ?
  • Protein Name : Envelope glycoprotein H
  • Protein Length : 838
  • Protein Note : envelope glycoprotein H; Provisional
  • Protein Sequence : Show Sequence
    >gi|138315|sp|P06477.1|GH_HHV11 RecName: Full=Envelope glycoprotein H; Short=gH; Flags: Precursor
    MGNGLWFVGVIILGVAWGQVHDWTEQTDPWFLDGLGMDRMYWRDTNTGRLWLPNTPDPQKPPRGFLAPPD
    ELNLTTASLPLLRWYEERFCFVLVTTAEFPRDPGQLLYIPKTYLLGRPPNASLPAPTTVEPTAQPPPSVA
    PLKGLLHNPAASVLLRSRAWVTFSAVPDPEALTFPRGDNVATASHPSGPRDTPPPRPPVGARRHPTTELD
    ITHLHNASTTWLATRGLLRSPGRYVYFSPSASTWPVGIWTTGELVLGCDAALVRARYGREFMGLVISMHD
    SPPVEVMVVPAGQTLDRVGDPADENPPGALPGPPGGPRYRVFVLGSLTRADNGSALDALRRVGGYPEEGT
    NYAQFLSRAYAEFFSGDAGAEQGPRPPLFWRLTGLLATSGFAFVNAAHANGAVCLSDLLGFLAHSRALAG
    LAARGAAGCAADSVFFNVSVLDPTARLQLEARLQHLVAEILEREQSLALHALGYQLAFVLDSPSAYDAVA
    PSAAHLIDALYAEFLGGRVLTTPVVHRALFYASAVLRQPFLAGVPSAVQRERARRSLLIASALCTSDVAA
    ATNADLRTALARADHQKTLFWLPDHFSPCAASLRFDLDESVFILDALAQATRSETPVEVLAQQTHGLAST
    LTRWAHYNALIRAFVPEASHRCGGQSANVEPRILVPITHNASYVVTHSPLPRGIGYKLTGVDVRRPLFLT
    YLTATCEGSTRDIESKRLVRTQNQRDLGLVGAVFMRYTPAGEVMSVLLVDTDNTQQQIAAGPTEGAPSVF
    SSDVPSTALLLFPNGTVIHLLAFDTQPVAAIAPGFLAASALGVVMITAALAGILKVLRTSVPFFWRRE
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A gH mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 (Farrell et al., 1994).
  • Related Vaccine(s): Herpes simplex virus 1 gH mutant vaccine
5. ICP0
  • Gene Name : ICP0
  • Sequence Strain (Species/Organism) : Human herpesvirus 2
  • NCBI Gene ID : 1487289
  • NCBI Protein GI : 109676722
  • Locus Tag : HHV2gp61
  • Genbank Accession : Z86099
  • Protein Accession : NP_044528
  • Taxonomy ID : 10310
  • Gene Starting Position : 121626
  • Gene Ending Position : 124946
  • Gene Strand (Orientation) : -
  • Protein Name : ubiquitin E3 ligase ICP0
  • Protein pI : 8.18
  • Protein Weight : 77292.34
  • Protein Length : 824
  • DNA Sequence : Show Sequence
    >gi|9629267:121626-124946 Human herpesvirus 2, complete genome
    CTTTATTGTAAAATTTTTATAAATATAAAGTTTTTTTTTTCCTCAAGTTTTCAACAAGGCCAGAAAGTCC
    ATAACAAAATGCTGGTGTGTGTTGCTGTTCGGGGCCGTGTCCGTCCCCCCCCCCCACTCCCACCCCCACT
    TCCTGTCTCCTCCCCGTCTTTCCCCCCCCCCACCTCCCCCTGCCCCCGAGGCGCCTCGGCCGGTGGTCCG
    GTGGGGGGCGGCTTCCTTCGGGCAGCAAGCCGAGTGTTAGCTCCCCCTACTCCCCGTGGCCCGCGGGGGC
    GTCGCCGGCCGGCGCGGGCGCGCCCTGCTCCCGAGACCACGGGTGGCGCGACCGGAGGCCGTGGAAGTCC
    AGCGCGCCCACCAGGGTGCCCTGGTCAAAGAGCATGTTGCCCACCGGGGTCATCCAGAGGCTGTTCCACT
    CCGACGCGGGGGGCGTCGGGTAGTCGGGGGGCCTCACGCAGTTGCGCGCGTGCTCGGGGAGCAGGGTGCG
    GCGGCTCCACGCGGGGGCCGCGGCCCGCAGCAGGTCCGCCACGTTCCCCGTCTGGTCCACGAGGACCACG
    TAGGCCCCTATGTGGCCCGTCTCCATGTCCAGGACGGGCAGGCAGTCCCCCGTGACCGTCTTGTTCACGT
    AAGGCGCCAGGGCCACGACGCTCGAGACCCCCGCGATGGGCAGGTAGCGCGTGAGGCCGGGCGCCGGGTC
    GCGGGCCCCGGGCTCGGGGCCGCCCTCCGCGTGGCGCGTCTTCCTGGCACACTTCCTCGGCCCCCGCGGC
    GCAGCAGCGCGGGGGCCGAGGGAGGTTTCTCGTCTCTCCCCAGCGCCGGACGCGGACGCGACGCTCCCAC
    CAGCCCCGCCCGCAGAGGAAGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGC
    GGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGAGGAGGAGGAGGCGGCGGCGACC
    GCGGCCTGGGACGACGGAGACGCCGACGGGGGCGCGGCGCCCGCGGACGCCGGGGCGAGCGGCCCGTGGC
    CGCGGTCGCCCGAGTCCGAGTCCGGGGCCCGGCGCGGCGCCGCCCTCTTGGCCCCCACCCCCTGGGGGGC
    GAGGGGCGAGCGCGGGGCGGCGGAGGAAGAGGCGGAGGACGAGGCCGCGGGGCCCGAGTCCGACCCGCGC
    CTCTTCCGGGGGCGGGCCGCCGCCCCCTCCGCGGCGTGGGGGGCGGCACCGGGGGTGTTGGTGCCGCGGG
    GGACCCCGGGTCCTCCCTCCGCGCCCGGCCCTCCCGACCCGCGCGCGTCGGTCGCGCCTGCCCGGCCCAG
    ACTCTGTGCTTGGGTGTCGGTCTGAGCCTGGGTCATGCGCGACCGGGGCGCGCGGTGCGCGTCCACCGGC
    ACGGCGGGCGGCGCGGGCCCGGCCGCGTCCGCGCTCGCAGACACCACGGGGGCGGCGGCGGCGCGGGGCG
    GACTCCGGACGCGCGGGGCGACGGCCGCGCGGGGGCGCGCGGCGCGCCCCGACGACTGTGGCAGACCTCC
    CCCCCCGGGGCCCGAGGACACCTGTGCGGAGGAGGAGGAGACAAAGGAGAGCGGCCCGGGGCCCGCGGGG
    CGGCGCGGAGACGGCGGGGGAGAGTCGCTGATGACTATGGGGGGCTCCTGGGCCGCGCGGGGCTGTCTCG
    CGGGGGGCGTCCTGCCCTCCGCCGCCGCGGCGTCTTCGCCCACCCGCCGCGCCTGCGCGCGCCCCCCGCC
    GGCCGCAGGGGGAAGAGAGGCCACTCTCGGCACGACGGCCGCGACGGCAGGGCCGCCCCCAGACCCAGAT
    CCCACCCCCGCCCGCAACGGGGCGCCGCCGCTGCTGCTGCTCCGCGGGGCGCCAGGGGGCGCCGGTCGGG
    TCGCGGCGGGCTGGGAGGTTCCGCGGGTCGCCCCCGCACCGCCGCCCCCGCGCCGGGGCGCTCTTCGGGG
    GGCGGGCGGGACGTAGTCCACTGCAGAGGGAGACAGAGACGGGAGCCCCCGGTTAGTGCCCGACCCCCGC
    CCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGACCCCCGCCCGA
    CCCCCGCCCGACCCCCGCCCGACCCCCGCCCGCCCCCCGCCCGACCCCCGCCCGCCCTCACCGTCGGCCA
    GGTCATCGTCCTCGTCGTCCGTGCCGGGCCACGGGGGGGTGGGCGACAGGGCGCGGACCGTGTGTCCCCC
    CAGCGACAGGGAGCGCGGGGCCGTCCGCGGGTTGCCCGTCCAGATAAAGTCCACGGCCGTGCCGGCCCGC
    ACGGCCGCCTCGGCCTCCACGCGGGTCCGGGGGTCGTTCACTATCGGGATGGTGCTGAACGACCCGCTGG
    CGGTCACGCCCACTATCAGGTACGCCACCGGGGTGTTGCACAGGGGACACGTGTTGCGCAACGGAATCCA
    GGTCTTCATGCACGGGATGCAGAAGGGGTGCAGGCAGGGAAAACTCTGGCAGCGCAGGGGCGGGGCGATC
    TCGTCCGTGCACACGGCACACACGTCGCCCCCCCCTCCCGCTTCCGCTTCCTCCTCACCCACGGGCCCAC
    CCCCACAGGATCCCTGCGCGTCGGCGGGCGTGGGGCTGCCCTGGCGCTCGGCCGGGGGCCGGGCCGGGGG
    CGTGGCCGCGTCCATCAGGCCCGCCTCGAACATCTCCGTGTCCGTGCTGCCCGCCTCGGAGGTGGAGTCG
    CGGTGAAGGTCGTCGTCAGAGATTCCCACCTCGGTCTCCTCCTCCGAGTCGCTGCTGGCGAGCCACTGCA
    TGTCGTTGAGCATCCCCCAGGCGTGCGGGGCGGCGGGCTGCTTGACAAAGCAACGGGGGGGATTTAGAGG
    GCGCGGGGCGTGAGGCGGGACCCCCGCGCCGTGTCCCCCGTGTCCCTCCCTCACCCCGGCCCCCCGCCCG
    CTGCTTTTTGTTCGGAAGGGGGGGAGAAAGGGGTCCGTAACCAAAGGTGGTCTGCGTCCTTTGGATTCCG
    ACCCCTCGTCTCCCCCCCTGTCCCCCGCTCTCGGGCTCCTCCCTGCCTCCCTCGCCCCCCCAGAGGGTCG
    GGGGGCGGCGCACGGCCCACGGGGGTCCCCCGACCGCTTAAGCGGGCCGGGGGTCGGCCCCGTCAAGCGT
    CCCCGCCCCCGAGCCCACCGCCCGCGACCACCCCCAACCCGCAGCCGGGTGGTCCGGGGAAAAGGGGGGG
    CCTGAGACCCGGGGGTCGCCCTCTCACCGTGCCGGGGGTCTGCCGCGGCGGCCGCTCGGGGCCGGGGTCC
    GCCCGGGAGCTCGTGCCGGGCCGGGGTTCCA
  • Protein Sequence : Show Sequence
    >gi|109676722|ref|NP_044528.2| ubiquitin E3 ligase ICP0 [Human herpesvirus 2]
    MEPRPGTSSRADPGPERPPRQTPGTPAAPHAWGMLNDMQWLASSDSEEETEVGISDDDLHRDSTSEAGST
    DTEMFEAGLMDAATPPARPPAERQGSPTPADAQGSCGGGPVGEEEAEAGGGGDVCAVCTDEIAPPLRCQS
    FPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDPRTRVEAEAAVRAGTAVDFI
    WTGNPRTAPRSLSLGGHTVRALSPTPPWPGTDDEDDDLADVDYVPPAPRRAPRRGGGGAGATRGTSQPAA
    TRPAPPGAPRSSSSGGAPLRAGVGSGSGGGPAVAAVVPRVASLPPAAGGGRAQARRVGEDAAAAEGRTPP
    ARQPRAAQEPPIVISDSPPPSPRRPAGPGPLSFVSSSSAQVSSGPGGGGLPQSSGRAARPRAAVAPRVRS
    PPRAAAAPVVSASADAAGPAPPAVPVDAHRAPRSRMTQAQTDTQAQSLGRAGATDARGSGGPGAEGGPGV
    PRGTNTPGAAPHAAEGAAARPRKRRGSDSGPAASSSASSSAAPRSPLAPQGVGAKRAAPRRAPDSDSGDR
    GHGPLAPASAGAAPPSASPSSQAAVAAASSSSASSSSASSSSASSSSASSSSASSSSASSSSASSSAGGA
    GGSVASASGAGERRETSLGPRAAAPRGPRKCARKTRHAEGGPEPGARDPAPGLTRYLPIAGVSSVVALAP
    YVNKTVTGDCLPVLDMETGHIGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHARNCVRPPDYPTPPAS
    EWNSLWMTPVGNMLFDQGTLVGALDFHGLRSRHPWSREQGAPAPAGDAPAGHGE
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A live-attenuated HSV-2 ICP0 virus provides significant protection against wild-type HSV-2 (MS strain) challenge in mice (Halford et al., 2011).
  • Related Vaccine(s): Herpes simplex virus 2 ICP0 mutant vaccine
6. ICP27 from Herpes simplex virus type 1
  • Gene Name : ICP27 from Herpes simplex virus type 1
  • Sequence Strain (Species/Organism) : Herpes simplex virus type 1
  • VO ID : VO_0011101
  • NCBI Protein GI : 75812153
  • Other Database IDs : CDD:147571
  • Taxonomy ID : 10298
  • Gene Strand (Orientation) : ?
  • Protein Name : ICP27
  • Protein Length : 512
  • Protein Note : Identical sequence is also seen in starin: BBY-C-1802; laboratory host: Vero cell, human embryonic lung cell
  • Protein Sequence : Show Sequence
    >gi|75812153|dbj|BAE44982.1| ICP27 [Human herpesvirus 1]
    MATDIDMLIDLGLDLSDSDLDEDPPEPAESRRDDLASDSSGECSSSDEDMEDPHGEDGPEPILDAARPAV
    RPSRPEDPGVPSTQTPRPTERQGPNDPQPAPHSVWSRLGARRPSCSPEQHGGKVARLQPPPTKAQPARGG
    RRGRRRGRGRGGPGAADGLSDPRRRAPRTNRNPGGPRPGAGWTDGPGAPHGEAWRGSEQPDPPGGPRTRG
    VRQAPPPLMTLAIAPPPADPRAPAPERKAPAADTIDATTRLVLRSISERAAVDRISESFGRSAQVMHDPF
    GGQPFPAANSPWAPVLADQGGPFDAETRRVSWETLVAHGPSLYRTFAGNPRAASTAKAMRDCVLRQENFI
    EALASADETLAWCKMCIHHNLPLRPQDPIIGTAAAVLDNLATRLRPFLQCYLKARGLCGLDELCSRRRLA
    DIKDIASFVFVILARLANRVERGVAEIDYATLGVGVGEKMHFYLPGACMAGLIEILDTHRQECSSRVCEL
    TASHIVAPPYVHGKYFYCNSLF
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Epitopes from the ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins of HSV-1 were attached to either the J TCBL/ICBL or the G TCBL/ICBL. The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge with HSV (Goel et al., 2005).
  • Related Vaccine(s): Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27
7. ICP27 from Herpes simplex virus type 2
  • Gene Name : ICP27 from Herpes simplex virus type 2
  • Sequence Strain (Species/Organism) : Herpes simplex virus type 2
  • VO ID : VO_0011100
  • NCBI Protein GI : 124181
  • Other Database IDs : CDD:147571
  • Taxonomy ID : 10315
  • Gene Strand (Orientation) : ?
  • Protein Name : Transcriptional regulator ICP27
  • Protein Length : 512
  • Protein Note : Infected cell protein 27; Immediate-early protein IE63; VMW63; ICP27
  • Protein Sequence : Show Sequence
    >gi|124181|sp|P28276.1|ICP27_HHV2H RecName: Full=Transcriptional regulator ICP27; AltName: Full=Infected cell protein 27; Short=ICP27; AltName: Full=Immediate-early protein IE63; AltName: Full=VMW63
    MATDIDMLIDLGLDLSDSELEEDALERDEEGRRDDPESDSSGECSSSDEDMEDPCGDGGAEAIDAAIPKG
    PPARPEDAGTPEASTPRPAARRGADDPPPATTGVWSRLGTRRSASPREPHGGKVARIQPPSTKAPHPRGG
    RRGRRRGRGRYGPGGADSTPKPRRRVSRNAHNQGGRHPASARTDGPGATHGEARRGGEQLDVSGGPRPRG
    TRQAPPPLMALSLTPPHADGRAPVPERKAPSADTIDPAVRAVLRSISERAAVERISESFGRSALVMQDPF
    GGMPFPAANSPWAPVLATQAGGFDAETRRVSWETLVAHGPSLYRTFAANPRAASTAKAMRDCVLRQENLI
    EALASADETLAWCKMCIHHNLPLRPQDPIIGTAAAVLENLATRLRPFLQCYLKARGLCGLDDLCSRRRLS
    DIKDIASFVLVILARLANRVERGVSEIDYTTVGVGAGETMHFYIPGACMAGLIEILDTHRQECSSRVCEL
    TASHTIAPLYVHGKYFYCNSLF
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality (Haynes et al., 2006).
  • Related Vaccine(s): Herpes simplex virus type 2 DNA vaccine encoding ICP27
8. TK
  • Gene Name : TK
  • Sequence Strain (Species/Organism) : Human herpesvirus 1
  • NCBI Gene ID : 2703374
  • NCBI Protein GI : 9629403
  • Locus Tag : HHV1gp034
  • Genbank Accession : X14112
  • Protein Accession : NP_044624
  • 3D structure: PDB ID : 1KIM
  • Taxonomy ID : 10298
  • Gene Starting Position : 46607
  • Gene Ending Position : 47910
  • Gene Strand (Orientation) : -
  • Protein Name : thymidine kinase
  • Protein pI : 8.59
  • Protein Weight : 38836.64
  • Protein Length : 376
  • Protein Note : 2.7.1.21
  • DNA Sequence : Show Sequence
    >gi|9629378:46607-47910 Human herpesvirus 1, complete genome
    TTTTATTCTGTCTTTTTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTCTCCTTCCGTGTTTCAGT
    TAGCCTCCCCCATCTCCCGGGCAAACGTGCGCGCCAGGTCGCAGATCGTCGGTATGGAGCCTGGGGTGGT
    GACGTGGGTCTGGACCATCCCGGAGGTAAGTTGCAGCAGGGCGTCCCGGCAGCCGGCGGGCGATTGGTCG
    TAATCCAGGATAAAGACATGCATGGGACGGAGGCGTTTGGCCAAGACGTCCAAAGCCCAGGCAAACACGT
    TATACAGGTCGCCGTTGGGGGCCAGCAACTCGGGGGCCCGAAACAGGGTAAATAACGTGTCCCCGATATG
    GGGTCGTGGGCCCGCGTTGCTCTGGGGCTCGGCACCCTGGGGCGGCACGGCCGCCCCCGAAAGCTGTCCC
    CAATCCTCCCGCCACGACCCGCCGCCCTGCAGATACCGCACCGTATTGGCAAGCAGCCCATAAACGCGGC
    GAATCGCGGCCAGCATAGCCAGGTCAAGCCGCTCGCCGGGGCGCTGGCGTTTGGCCAGGCGGTCGATGTG
    TCTGTCCTCCGGAAGGGCCCCCAACACGATGTTTGTGCCGGGCAAGGTCGGCGGGATGAGGGCCACGAAC
    GCCAGCACGGCCTGGGGGGTCATGCTGCCCATAAGGTATCGCGCGGCCGGGTAGCACAGGAGGGCGGCGA
    TGGGATGGCGGTCGAAGATGAGGGTGAGGGCCGGGGGCGGGGCATGTGAGCTCCCAGCCTCCCCCCCGAT
    ATGAGGAGCCAGAACGGCGTCGGTCACGGCATAAGGCATGCCCATTGTTATCTGGGCGCTTGTCATTACC
    ACCGCCGCGTCCCCGGCCGATATCTCACCCTGGTCGAGGCGGTGTTGTGTGGTGTAGATGTTCGCGATTG
    TCTCGGAAGCCCCCAACACCCGCCAGTAAGTCATCGGCTCGGGTACGTAGACGATATCGTCGCGCGAACC
    CAGGGCCACCAGCAGTTGCGTGGTGGTGGTTTTCCCCATCCCGTGGGGACCGTCTATATAAACCCGCAGT
    AGCGTGGGCATTTTCTGCTCCAGGCGGACTTCCGTGGCTTTTTGTTGCCGGCGAGGGCGCAACGCCGTAC
    GTCGGTTGTTATGGCCGCGAGAACGCGCAGCCTGGTCGAACGCAGACGCGTGTTGATGGCAGGGGTACGA
    AGCCATACGCGCTTCTACAAGGCGCTGGCCGAAGAGGTGCGGGAGTTTCACGCCACCAAGATCTGCGGCA
    CGCTGTTGACGCTGTTAAGCGGGTCGCTGCAGGGTCGCTCGGTA
  • Protein Sequence : Show Sequence
    >gi|9629403|ref|NP_044624.1| thymidine kinase [Human herpesvirus 1]
    MASYPCHQHASAFDQAARSRGHNNRRTALRPRRQQKATEVRLEQKMPTLLRVYIDGPHGMGKTTTTQLLV
    ALGSRDDIVYVPEPMTYWRVLGASETIANIYTTQHRLDQGEISAGDAAVVMTSAQITMGMPYAVTDAVLA
    PHIGGEAGSSHAPPPALTLIFDRHPIAALLCYPAARYLMGSMTPQAVLAFVALIPPTLPGTNIVLGALPE
    DRHIDRLAKRQRPGERLDLAMLAAIRRVYGLLANTVRYLQGGGSWREDWGQLSGAAVPPQGAEPQSNAGP
    RPHIGDTLFTLFRAPELLAPNGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQT
    HVTTPGSIPTICDLARTFAREMGEAN
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A thymidine kinase-deficient (TK) mutant was found to be attenuated in mice. This mutant induced complete protection from challenge with wild type HSV (Field and Wildy, 1978).
  • Related Vaccine(s): Herpes simplex virus 1 TK mutant vaccine
9. UL27 from Herpes simplex virus type 1
  • Gene Name : UL27 from Herpes simplex virus type 1
  • Sequence Strain (Species/Organism) : Human herpesvirus 1 (Herpes simplex virus type 1)
  • VO ID : VO_0011099
  • NCBI Gene ID : 2703455
  • NCBI Protein GI : 9629408
  • Locus Tag : HHV1gp041
  • Genbank Accession : X14112
  • Protein Accession : NP_044629
  • 3D structure: PDB ID : 2GUM
  • Taxonomy ID : 10298
  • Gene Starting Position : 53057
  • Gene Ending Position : 56079
  • Gene Strand (Orientation) : -
  • Protein Name : glycoprotein BALF4
  • Protein pI : 8.23
  • Protein Weight : 93545.07
  • Protein Length : 904
  • Protein Note : glycoprotein BALF4; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA; BALF4 is a transmembrane glycoprotein found in the lipid envelope of several herpesviruses
  • DNA Sequence : Show Sequence
    >gi|9629378:53057-56079 Human herpesvirus 1, complete genome
    TTTTATTTACAACAAACCCCCCATCACAGGTCGTCCTCGTCGGCGTCACCGTCTTTGTTGGGAACTTGGG
    TGTAGTTGGTGTTGCGGCGCTTGCGCATGACCATGTCGGTGACCTTGGCGCTGAGCAGCGCGCTCGTGCC
    CTTCTTCTTGGCCTTGTGTTCCGTGCGCTCCATGGCAGACACCAGGGCCATGTACCGTATCATCTCCCGG
    GCCTCGGCTAGCTTGGCCTCGTCAAAGTCGCCGCCCTCCTCGCCCTCCCCGGACGCGTCCGGGTTGGTGG
    GGTTCTTGAGCTCCTTGGTGGTTAGCGGGTACAGGGCCTTCATGGGGTTGCTCTGCAGCCGCATGACGTA
    GCGAAAGGCGAAGAAGGCCGCCGCCAGGCCGGCCAGGACCAACAGACCCACGGCCAGCGCCCCAAAGGGG
    TTGGACATGAAGGAGGACACGCCCGACACGGCCGATACCACGCCGCCCACGATGCCCATCACCACCTTGC
    CGACCGCGCGCCCCAGGTCGCCCATCCCCTCGAAGAACGCGCCCAGGCCCGCAAACATGGCGGCGTTGGC
    GTCGGCGTGGATGACCGTGTCGATGTCGGCGAAGCGCAGGTCGTGCAGCTGGTTGCGGCGCTGGACCTCC
    GTGTAGTCCAGCAGGCCGCTGTCCTTGATCTCGTGGCGGGTGTACACCTCCAGGGGGACAAACTCGTGAT
    CCTCCAGCATGGTGATGTTGAGGTCGATGAAGGTGCTGACGGTGGTGATGTCGGCGCGGCTCAGCTGGTG
    GGAGTACGCGTACTCCTCGAAGTACACGTAGCCCCCACCGAAGGTGAAGTAGCGCCGGTGTCCCACGGTG
    CACGGCTCGATCGCATCGCGCGTCAGCCGCAGCTCGTTGTTCTCCCCCAGCTGCCCCTCGACCAACGGGC
    CCTGGTCTTCGTACCGAAAGCTGACCAGGGGGCGGCTGTAGCAGGCCCCGGGCCGCGAGCTGATGCGCAT
    CGAGTTTTGGACGATCACGTTGTCCGCGGCGACCGGCACGCACGTGGAGACGGCCATCACGTCGCCGAGC
    ATCCGCGCGCTCACCCGCCGGCCCACGGTGGCCGAGGCGATGGCGTTGGGGTTCAGCTTGCGGGCCTCGT
    TCCACAGGGTCAGCTCGTGATTCTGCAGCTCGCACCACGCGATGGCAACGCGGCCCAACATATCGTTGAC
    ATGGCGCTGTATGTGGTTGTACGTAAACTGCAGCCTGGCGAACTCGATGGAGGAGGTGGTCTTGATGCGC
    TCCACGGACGCGTTGGCGCTGGCCCCGGGCGGCGGGGGCGTGGGGTTTGGGGGCTTGCGGCTCTGCTCGC
    GGAGGTGTTCCCGCACGTACAGCTCCGCGAGCGTGTTGCTGAGAAGGGGCTGGTACGCGATCAGAAAGCC
    CCCATTGGCCAGGTAGTACTGCGGCTGGCCCACCTTGATGTGCGTCGCGTTGTACCTGCGGGCGAAGATG
    CGGTCCATGGCGTCGCGGGCGTCCTTGCCGATGCAGTCCCCCAGGTCCACGCGCGAGAGCGGGTACTCGG
    TCAGGTTGGTGGTGAAGGTGGTGGATATGGCGTCGGAAGAGAATCGGAAGGAGCCGCCGTACTCGGAGCG
    CAGCATCTCGTCCACCTCCTGCCACTTGGTCATGGTGCAGACCGACGGGCGCTTTGGCACCCAGTCCCAG
    GCCACGGTGAACTTGGGGGTCGTGAGCAGGTTCCGGGTGGTCGGCGCCGTGGCCCGGGCCTTGGTGGTGA
    GGTCGCGCGCGTAGAAGCCGTCGACCTGCTTGAAGCGGTCGGCGGCGTAGCTGGTGTGTTCGGTGTGCGA
    CCCCTCCCGGTAGCCGTAAAACGGGGACATGTACACAAAGTCGCCAGTCGCCAACACAAACTCGTCGTAC
    GGGTACACCGAGCGCGCGTCCACCTCCTCGACGATGCAGTTTACCGTCGTCCCGTACCGGTGGAACGCCT
    CCACCCGCGAGGGGTTGTACTTGAGGTCGGTGGTGTGCCAGCCCCGGCTCGTGCGGGTCGCGGCGTTGGC
    CGGTTTCAGCTCCATGTCGGTCTCGTGGTCGTCCCGGTGAAACGCGGTGGTCTCCAGGTTGTTGCGCACG
    TACTTGGCCGTGGACCGACAGACCCCCTTGGCGTTGATCTTGTCGATCACCTCCTCGAAGGGGACGGGGG
    CGCGGTCCTCAAAGATCCCCATAAACTGGGAGTAGCGGTGGCCGAACCACACCTGCGAAACGGTGACGTC
    TTTGTAGTACATGGTGGCCTTGAACTTGTACGGGGCGATGTTCTCCTTGAAGACCACCGCGATGCCCTCC
    GTGTAGTTCTGACCCTCGGGCCGGGTCGGGCAGCGGCGCGGCTGCTCGAACTGCACCACCGTGGCGCCCG
    TGGGGGGTGGGCACACGTAAAAGTTTGCATCGGTGTTCTCCGCCTTGATGTCCCGCAGGTGCTCGCGCAG
    GGTGGCGTGGCCCGCGGCGACGGTCGCGTTGTCGCCGGCGGGGCGCGGCGGCTTTGGGGGTTTCGGTTTT
    CTGTTCTTCTTCGGTTTCGGGTCCCCCGTTGGGGGGGCGCCAGGGGCGGGCGGCGCCGGAGTGGCAGGGC
    CCCCGTTCGCCGCCTGGGTCGCGGCCGCGACCCCAGGCGTGCCGGGGGAACTCGGAGCCGCCGACGCCAC
    CAGGACCCCCAGCGTCAACCCCAAGAGCGCCCATACGACGAACCACCGGCGCCCCCGCGCGGGGGCGCCC
    TGGCGCATGGCGGGACTACGGGGGCCCGTCGTGCCCCCCGTCAGGTAGCCTGGGGGCGAGGTGCTGGAGG
    ACCGAGTAGAGGATCGAGAAAACGTCTCGGTCGTAGACCACGACCGACCGGGGGCCGATACAGCCGTCGG
    GGGCGCTCTCGACGATGGCCACCAGCGGACAGTCGGAGTCGTACGTGAGATATACGCCGGGCGGGTAACG
    GTAACGACCTTCGGAGGTCGGGCGGCTGCAGTCCGGGCGGCGCAACTCGAGCTCCCCGCACCGGTAGACC
    GAGGCAAAGAGTG
  • Protein Sequence : Show Sequence
    >gi|9629408|ref|NP_044629.1| envelope glycoprotein B [Human herpesvirus 1]
    MRQGAPARGRRWFVVWALLGLTLGVLVASAAPSSPGTPGVAAATQAANGGPATPAPPAPGAPPTGDPKPK
    KNRKPKPPKPPRPAGDNATVAAGHATLREHLRDIKAENTDANFYVCPPPTGATVVQFEQPRRCPTRPEGQ
    NYTEGIAVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINAKGVCRST
    AKYVRNNLETTAFHRDDHETDMELKPANAATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARS
    VYPYDEFVLATGDFVYMSPFYGYREGSHTEHTSYAADRFKQVDGFYARDLTTKARATAPTTRNLLTTPKF
    TVAWDWVPKRPSVCTMTKWQEVDEMLRSEYGGSFRFSSDAISTTFTTNLTEYPLSRVDLGDCIGKDARDA
    MDRIFARRYNATHIKVGQPQYYLANGGFLIAYQPLLSNTLAELYVREHLREQSRKPPNPTPPPPGASANA
    SVERIKTTSSIEFARLQFTYNHIQRHVNDMLGRVAIAWCELQNHELTLWNEARKLNPNAIASATVGRRVS
    ARMLGDVMAVSTCVPVAADNVIVQNSMRISSRPGACYSRPLVSFRYEDQGPLVEGQLGENNELRLTRDAI
    EPCTVGHRRYFTFGGGYVYFEEYAYSHQLSRADITTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLL
    DYTEVQRRNQLHDLRFADIDTVIHADANAAMFAGLGAFFEGMGDLGRAVGKVVMGIVGGVVSAVSGVSSF
    MSNPFGALAVGLLVLAGLAAAFFAFRYVMRLQSNPMKALYPLTTKELKNPTNPDASGEGEEGGDFDEAKL
    AEAREMIRYMALVSAMERTEHKAKKKGTSALLSAKVTDMVMRKRRNTNYTQVPNKDGDADEDDL
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Study demonstrated that recombinant Listeria monocytogenes (Lm) expressing the H-2K(b) glycoprotein B (gB, UL27)(498-505) peptide from HSV-1 triggers a robust CD8 T cell response to this Ag resulting in protective immunity to HSV infection in mice (Orr et al., 2007).
  • Related Vaccine(s): Herpes simplex virus DNA vaccine gB-DNA encoding gB , Herpes simplex virus DNA vaccine gBDNA encoding gB , Herpes simplex virus DNA vaccine pSIN-gB encoding gB , Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP
10. UL27 from Herpes simplex virus type 2
  • Gene Name : UL27 from Herpes simplex virus type 2
  • Sequence Strain (Species/Organism) : Herpes simplex virus type 2
  • VO ID : VO_0011097
  • NCBI Protein GI : 1869850
  • Other Database IDs : CDD:165490
    CDD:144263
    GOA:P08666
    InterPro: IPR000234
    UniProtKB/UniProt: P08666
  • Taxonomy ID : 10310
  • Gene Strand (Orientation) : ?
  • Protein Name : glycoprotein B
  • Protein Length : 904
  • Protein Note : glycoprotein BALF4; Provisional; PHA03231
  • Protein Sequence : Show Sequence
    >gi|1869850|emb|CAB06752.1| glycoprotein B [Human herpesvirus 2]
    MRGGGLICALVVGALVAAVASAAPAAPAAPRASGGVAATVAANGGPASRPPPVPSPATTKARKRKTKKPP
    KRPEATPPPDANATVAAGHATLRAHLREIKVENADAQFYVCPPPTGATVVQFEQPRRCPTRPEGQNYTEG
    IAVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINTKGVCRSTAKYVR
    NNMETTAFHRDDHETDMELKPAKVATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARSVYPYD
    EFVLATGDFVYMSPFYGYREGSHTEHTSYAADRFKQVDGFYARDLTTKARATSPTTRNLLTTPKFTVAWD
    WVPKRPAVCTMTKWQEVDEMLRAEYGGSFRFSSDAISTTFTTNLTEYSLSRVDLGDCIGRDAREAIDRMF
    ARKYNATHIKVGQPQYYLATGGFLIAYQPLLSNTLAELYVREYMREQDRKPRNATPAPLREAPSANASVE
    RIKTTSSIEFARLQFTYNHIQRHVNDMLGRIAVAWCELQNHELTLWNEARKLNPNAIASATVGRRVSARM
    LGDVMAVSTCVPVAPDNVIVQNSMRVSSRPGTCYSRPLVSFRYEDQGPLIEGQLGENNELRLTRDALEPC
    TVGHRRYFIFGGGYVYFEEYAYSHQLSRADVTTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLLDYT
    EVQRRNQLHDLRFADIDTVIRADANAAMFAGLCAFFEGMGDLGRAVGKVVMGVVGGVVSAVSGVSSFMSN
    PFGALAVGLLVLAGLVAAFFAFRYVLQLQRNPMKALYPLTTKELKTSDPGGVGGEGEEGAEGGGFDEAKL
    AEAREMIRYMALVSAMERTEHKARKKGTSALLSSKVTNMVLRKRNKARYSPLHNEDEAGDEDEL
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection (Kim et al., 2009).
  • Related Vaccine(s): Herpes simplex virus DNA vaccine ∆gB-2 encoding gB , Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis , Herpes simplex virus type 2 DNA vaccine encoding GB
11. UL29
  • Gene Name : UL29
  • Sequence Strain (Species/Organism) : Human herpesvirus 1
  • NCBI Gene ID : 2703458
  • NCBI Protein GI : 9629410
  • Locus Tag : HHV1gp41.5
  • Genbank Accession : X14112
  • Protein Accession : NP_044631
  • Taxonomy ID : 10298
  • Gene Starting Position : 58408
  • Gene Ending Position : 62052
  • Gene Strand (Orientation) : -
  • Protein Name : single-stranded DNA-binding protein
  • Protein pI : 6.48
  • Protein Weight : 119914.97
  • Protein Length : 1196
  • DNA Sequence : Show Sequence
    >gi|9629378:58408-62052 Human herpesvirus 1, complete genome
    ATTTATTTTACACACATTCCCCGCCCCGCCCTAGGTTCCCCCACCCCCCAACCCCTCACAGCATATCCAA
    CGTCAGGTCTCCCTTTTTGTCGGGGGGCCCCTCCCCAAACGGGTCATCCCCGTGGAACGCCCGTTTGCGG
    CCGGCAAATGCCGGTCCCGGGGCCCCCGGGCCGCCGAACGGCGTCGCGTTGTCGTCCTCGCAGCCAAAAT
    CCCCAAAGTTAAACACCTCCCCGGCGTTGCCGAGTTGGCTGACTAGGGCCTCGGCCTCGTGCGCCACCTC
    CAGGGCCGCGTCCGTCGACCACTCGCCGTTGCCGCGCTCCAGGGCACGCGCGGTCAGCTCCATCATCTCC
    TCGCTTAGGTACTCGTCCTCCAGGAGCGCCAGCCAGTCCTCGATCTGCAGCTGCTGGGTGCGGGGCCCCA
    GGCTTTTCACGGTCGCCACGAACACGCTACTGGCGACGGCCGCCCCGCCCTCGGAGATAATGCCCCGGAG
    CTGCTCGCACAGCGAGCTTTCGTGCGCTCCGCCGCCGAGGCTTGAGGCCGCGCACACAAACCCGGCCCGG
    GGACAGGCCAGGACGAACTTGCGGGTGCGGTCAAAAATAAGGAGCGGGCACGCGTTTTTGCCGCCCATCA
    GGCTGGCCCAGTTCCCGGCCTGAAACACACGGTCGTTGCCGGCCATGCCGTAGTACTTGCTGATGCTCAA
    CCCCAACACGACCATGGGGCGCGCCGCCATGACGGGCCGCAGCAGGTTGCAGCTGGCGAACATGGACGTC
    CACGCGCCCGGATGCGCGTCCACGGCGTCCATCAGCGCGCGGGCCCCGGCCTCCAGGCCCGCCCCGCCCT
    GCGCGGACCACGCGGCCGCAGCCTGCACGCTGGGGGGACGGCGGGACCCCGCGATGATGGCCGTAAGGGT
    GTTGATGAAGTATGTCGAGTGATCGCAGTACCGCAGAATCTGGTTTGCCATGTAGTACATCGCCAGCTCG
    CTCACGTTGTTGGGGGCCAGGTTAATAAAGTTTATCGCGCCGTAGTCCAGGGAAAACTTTTTAATGAACG
    CGATGGTCTCGATGTCCTCGCGCGACAGGAGCCGGGCGGGAAGCTGGTTGCGTTGGAGGGCCGTCCAGAA
    CCACTGCGGGTTCGGCTGGTTGGACCCCGGGGGCTTGCCGTTGGGGAAGATGGCCGCGTGGAACTGCTTC
    AGCAGAAAGCCCAGCGGTCCGAGGAGGATGTCCACGCGCTTGTCGGGCTTCTGGTAGGCGCTCTGGAGGC
    TGGCGACCCGCGCCTTGGCGGCCTCGGACGCGTTGGCGCTCGCGCCCGCGAACAACACGCGGCTCTTGAC
    GCGCAGCTCCTTGGGAAACCCCAGGGTCACGCGGGCAACGTCGCCCTCGAAGCTGCTCTCGGCGGGGGCC
    GTCTGGCCGGCCGTTAGGCTGGGGGCGCAGATAGCCGCCCCCTCCGAGAGCGCGACCGTCAGCGTTTTGG
    CCGACAGAAACCCGTTGTTAAACATGTCCATCACGCGCCGCCGCAGCACCGGTTGGAATTGATTGCGAAA
    GTTGCGCCCCTCGACCGACTGCCCGGCGAACACCCCGTGGCACTGACTCAGGGCCAGGTCCTGGTACACG
    GCGAGGTTGGATCGCCGCCCGAGAAGCTGAAGCAGGGGGCACGGCCCGCACGCGTACGGGTCCAGCGTCA
    GGGACATGGCGTGGTTGGCCTCGCCCAGACCGTCGCGAAACTTGAAGTTCCTCCCCTCCACCAGGTTGCG
    CATCAGCTGCTCCACCTCGCGGTCCACGACCTGCCTGACGTTGTTCACCACCGTATGCAGGGCCTCGCGG
    TTGGTGATGATGGTCTCCAGCCGCCCCATGGCCGTGGGGACCGCCTGGTCCACGTACTGCAGGGTCTCGA
    GTTCGGCCATGACGCGCTCGGTCGCCGCGCGGTACGTCTCCTGCATGATGGTCCGGGCGGTCTCGGATCC
    GTCCGCGCGCTTCAGGGCCGAGAAGGCGGCGTAGTTTCCCAGCACGTCGCAGTCGCTGTACATGCTGTTC
    ATGGTCCCGAAGACGCCGATGGCTCCGCGGGCGGCGCTGGCGAACTTTGGATGGCGCGCCCGGAGGCGCA
    TGAGCGTCGTGTGTACGCAGGCGTGGCGCGTGTCGAAGGTGCATAGGTTACAGGGCACGTCGGTCTGGTT
    GGAGTCCGCGACGTATCGAAACACGTCCATCTCCTGGCGCCCGACGATCACGGCGCCGTCGCAGCGCTCC
    AGGTAAAACAGCATCTTGGCCAGCAGCGCCGGGGAAAACCCACACAGCATGGCCAGGTGCTCGCCGGCAA
    ATTCCTGGGTTCCGCCGACGAGGGGCGCGGTGGGCCGACCCTCGAACCCGGGCACCACGTGTCCCTCGCG
    GTCCACCTGTGGGTTGGCCGCCACGTGGGTCCCGGGCACGAGGAAGAAGCGGTAAAAGGAGGGTTTGCTG
    TGGTCCTTTGGGTCCGCCGGGCCGGCGTCGTCCACCTCGGTGAGATGGAGGGCCGAGTTGGTGCTAAATA
    CCATGGCCCCCACGAGTCCCGCGGCGCGCGCCAGGTACGCCCCGACGGCGTTGGCGCGGGCCGCGGCCGT
    GTCCTGGCCCTCGAACAGCGGCCACGCGGAGATGTCGGTGGGCGGCTCGTCAAAGACGGCCATCGACACG
    ATAGACTCGAGGGCCAGGGCGGCGTCTCCGGCCATGACGGAGGCCAGGCGCTGTTCGAACCCGCCCGCCG
    CGCCCTTGCCGCCGCCGTCGCGCCCGCCCCGCGGGGTCTTACCCTGGCTGGCTTCGAAGGCCGTGAACGT
    AATGTCGGCGGGGAGGGCGGCGCCCTCGTGGTTTTCGTCAAACGCCAGGTGGGCGGCCGCGCGGGCCACG
    GCGTCCACGTTTCGGCATCGCAGTGCCACGGCGGCGGGTCCCACGACCGCCTCGAACAGGAGGCGGTTGA
    GGGGGCGGTTAAAAAACGGAAGCGGGTAGGTAAATTTCTCCCCGATCGATCGGTGGTTGGCGTTGAACGG
    CTCTGCGATGACACGGCTAAAATCCGGCATGAACAGCTGCAACGGGTACACGGGTATGCGGTGCACCTCC
    GCCCCGCCTATGGTTACCTTGTCCGAGCCTCCCAGGTGCAGAAAGGTGTTGTTGATGCACACGGCCTCCT
    TGAAGCCCTCGGTAACGACCAGATACAGGAGGGCGCGGTCCGGGTCCAGGCCGAGGCGCTCACACAGCGC
    CTCCCCCGTCGTCTCGTGTTTGAGGTCGCCGGGCCGGGGGGTGTAGTCCGAAAAGCCAAAATGGCGGCGT
    GCCCGCTCGCAAAGTCGCGTCAGGTTCGGGGCCTGGGTGCTGGGGTCCAGGTGCCGGCCGCCGTGAAAGA
    CGTACACGGACGAGCTGTAGTGCGAGGGCGTCAGTTTCAGGGACACCGCGGTACCCCCGAGCCCCGTCGT
    GCGAGAACCCACGACCACGGCCACGTTGGCCTCAAAGCCGCTCTCCACGGTCAGGCCCACGACCAGGGGC
    GCCACGGCGACGTCGGAATCGCCGCTGCGTGCCGACAGTAACGCCAGAAGCTCGATGCCTTCGGACGGAC
    ACGCGCGAGCGTACACGTATCCCAGGGGCCCGGGGGGGACCTTGATGGTGGTTGCCGTCTTGGGCTTTGT
    CTCCA
  • Protein Sequence : Show Sequence
    >gi|9629410|ref|NP_044631.1| single-stranded DNA-binding protein [Human herpesvirus 1]
    METKPKTATTIKVPPGPLGYVYARACPSEGIELLALLSARSGDSDVAVAPLVVGLTVESGFEANVAVVVG
    SRTTGLGGTAVSLKLTPSHYSSSVYVFHGGRHLDPSTQAPNLTRLCERARRHFGFSDYTPRPGDLKHETT
    GEALCERLGLDPDRALLYLVVTEGFKEAVCINNTFLHLGGSDKVTIGGAEVHRIPVYPLQLFMPDFSRVI
    AEPFNANHRSIGEKFTYPLPFFNRPLNRLLFEAVVGPAAVALRCRNVDAVARAAAHLAFDENHEGAALPA
    DITFTAFEASQGKTPRGGRDGGGKGAAGGFEQRLASVMAGDAALALESIVSMAVFDEPPTDISAWPLFEG
    QDTAAARANAVGAYLARAAGLVGAMVFSTNSALHLTEVDDAGPADPKDHSKPSFYRFFLVPGTHVAANPQ
    VDREGHVVPGFEGRPTAPLVGGTQEFAGEHLAMLCGFSPALLAKMLFYLERCDGAVIVGRQEMDVFRYVA
    DSNQTDVPCNLCTFDTRHACVHTTLMRLRARHPKFASAARGAIGVFGTMNSMYSDCDVLGNYAAFSALKR
    ADGSETARTIMQETYRAATERVMAELETLQYVDQAVPTAMGRLETIITNREALHTVVNNVRQVVDREVEQ
    LMRNLVEGRNFKFRDGLGEANHAMSLTLDPYACGPCPLLQLLGRRSNLAVYQDLALSQCHGVFAGQSVEG
    RNFRNQFQPVLRRRVMDMFNNGFLSAKTLTVALSEGAAICAPSLTAGQTAPAESSFEGDVARVTLGFPKE
    LRVKSRVLFAGASANASEAAKARVASLQSAYQKPDKRVDILLGPLGFLLKQFHAAIFPNGKPPGSNQPNP
    QWFWTALQRNQLPARLLSREDIETIAFIKKFSLDYGAINFINLAPNNVSELAMYYMANQILRYCDHSTYF
    INTLTAIIAGSRRPPSVQAAAAWSAQGGAGLEAGARALMDAVDAHPGAWTSMFASCNLLRPVMAARPMVV
    LGLSISKYYGMAGNDRVFQAGNWASLMGGKNACPLLIFDRTRKFVLACPRAGFVCAASSLGGGAHESSLC
    EQLRGIISEGGAAVASSVFVATVKSLGPRTQQLQIEDWLALLEDEYLSEEMMELTARALERGNGEWSTDA
    ALEVAHEAEALVSQLGNAGEVFNFGDFGCEDDNATPFGGPGAPGPAFAGRKRAFHGDDPFGEGPPDKKGD
    LTLDML
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A UL29 mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1 (Morrison and Knipe, 1994).
  • Related Vaccine(s): Herpes simplex virus 1 UL29 mutant vaccine
12. UL44 from HSV-1
  • Gene Name : UL44 from HSV-1
  • Sequence Strain (Species/Organism) : Human herpesvirus 1 (Herpes simplex virus type 1)
  • VO ID : VO_0011103
  • NCBI Gene ID : 2703410
  • NCBI Protein GI : 9629425
  • Locus Tag : HHV1gp063
  • Genbank Accession : X14112
  • Protein Accession : NP_044646
  • Taxonomy ID : 10298
  • Gene Starting Position : 96167
  • Gene Ending Position : 98667
  • Gene Strand (Orientation) : +
  • Protein Name : envelope glycoprotein C
  • Protein pI : 7.81
  • Protein Weight : 50732.05
  • Protein Length : 511
  • Protein Note : envelope glycoprotein C; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; the nonessential glycoprotein gC interacts with cell surface proteoglycans, whereas the essential glycoprotein gD is involved in stable secondary attachment
  • DNA Sequence : Show Sequence
    >gi|9629378:96167-98667 Human herpesvirus 1, complete genome
    TACCCTCACTATCGAGGGCGCTTGGTCGGGAGGCCGCATCGAACGCACACCCCCATCCGGTGGTCCGTGT
    GGAGGTCGTTTTCATGCCCGGTCTCGCTTTGCCGGGAACGCTAGCCGATCCCTCGCGAGGGGGAGGCGTC
    GGGCATGGCCCCGGGGCGGGTGGGCCTTGCCGTGGTCCTGTGGAGCCTGTTGTGGCTCGGGGCGGGGGTG
    TCCGGGGGCTCGGAAACTGCCTCCACCGGGCCCACGATCACCGCGGGAGCGGTGACGAACGCGAGCGAGG
    CCCCCACATCGGGGTCCCCCGGGTCAGCCGCCAGCCCGGAGGTCACCCCCACATCGACCCCAAACCCCAA
    CAATGTCACACAAAACAAAACCACCCCCACCGAGCCGGCCAGCCCCCCAACAACCCCCAAGCCCACCTCC
    ACGCCCAAAAGCCCCCCCACGTCCACCCCCGACCCCAAACCCAAGAACAACACCACCCCCGCCAAGTCGG
    GCCGCCCCACTAAACCCCCCGGGCCCGTGTGGTGCGACCGCCGCGACCCATTGGCCCGGTACGGCTCGCG
    GGTGCAGATCCGATGCCGGTTTCGGAATTCCACCCGCATGGAGTTCCGCCTCCAGATATGGCGTTACTCC
    ATGGGTCCGTCCCCCCCAATCGCTCCGGCTCCCGACCTAGAGGAGGTCCTGACGAACATCACCGCCCCAC
    CCGGGGGACTCCTGGTGTACGACAGCGCCCCCAACCTAACGGACCCCCACGTGCTCTGGGCGGAGGGGGC
    CGGCCCGGGCGCCGACCCTCCGTTGTATTCTGTCACCGGGCCGCTGCCGACCCAGCGGCTGATTATCGGC
    GAGGTGACGCCCGCGACCCAGGGAATGTATTACTTGGCCTGGGGCCGGATGGACAGCCCGCACGAGTACG
    GGACGTGGGTGCGCGTCCGCATGTTCCGCCCCCCGTCTCTGACCCTCCAGCCCCACGCGGTGATGGAGGG
    TCAGCCGTTCAAGGCGACGTGCACGGCCGCCGCCTACTACCCGCGTAACCCCGTGGAGTTTGTCTGGTTC
    GAGGACGACCACCAGGTGTTTAACCCGGGCCAGATCGACACGCAGACGCACGAGCACCCCGACGGGTTCA
    CCACAGTCTCTACCGTGACCTCCGAGGCTGTCGGCGGCCAGGTCCCCCCGCGGACCTTCACCTGCCAGAT
    GACGTGGCATCGCGACTCCGTGACGTTCTCGCGACGCAATGCCACCGGGCTGGCCCTGGTGCTGCCGCGG
    CCAACCATCACCATGGAATTTGGGGTCCGCATTGTGGTCTGCACGGCCGGCTGCGTCCCCGAGGGCGTGA
    CGTTTGCCTGGTTCCTGGGGGACGACCCCTCACCGGCGGCTAAGTCGGCCGTTACGGCCCAGGAGTCGTG
    CGACCACCCCGGGCTGGCTACGGTCCGGTCCACCCTGCCCATTTCGTACGACTACAGCGAGTACATCTGT
    CGGTTGACCGGATATCCGGCCGGGATTCCCGTTCTAGAACACCACGGCAGTCACCAGCCCCCACCCAGGG
    ACCCCACCGAGCGGCAGGTGATCGAGGCGATCGAGTGGGTGGGGATTGGAATCGGGGTTCTCGCGGCGGG
    GGTCCTGGTCGTAACGGCAATCGTGTACGTCGTCCGCACATCACAGTCGCGGCAGCGTCATCGGCGGTAA
    CGCAAGACCCCCCCGTTACCTTTTTAATATCTATATAGTTTGGTCCCCCCTCTATCCCGCCCACCGCTGG
    GCGCTATAAAGCCGCCACCCTCTCTTCCCTCAGGTCATCCTTGGTCGATCCCGAACGACACACGGCGTGG
    AGCAAAACGCCTCCCCCTGAGCCGCTTTCCTACCAACACAACGGCATGCCTCTGCGGGCATCGGAACACG
    CCTACCGGCCCCTGGGCCCCGGGACACCCCCCATGCGGGCTCGGCTCCCCGCCGCGGCCTGGGTTGGCGT
    CGGGACCATCATCGGGGGAGTTGTGATCATTGCCGCGTTGGTCCTCGTGCCCTCGCGGGCCTCGTGGGCA
    CTTTCCCCATGCGACAGCGGATGGCACGAGTTCAACCTCGGGTGCATATCCTGGGATCCGACCCCCATGG
    AGCACGAGCAGGCGGTCGGCGGCTGTAGCGCCCCGGCGACCCTGATCCCCCGCGCGGCTGCCAAACAGCT
    GGCCGCCGTCGCACGCGTCCAGTCGGCAAGATCCTCGGGCTACTGGTGGGTGAGCGGAGACGGCATTCGG
    GCCTGCCTGCGGCTCGTCGACGGCGTCGGCGGTATTGACCAGTTTTGCGAGGAGCCCGCCCTTCGCATAT
    GCTACTATCCCCGCAGTCCCGGGGGCTTTGTTCAGTTTGTAACTTCGACCCGCAACGCGCTGGGGCTGCC
    GTGAGGCGCGTGTACTGCGGTCTGTCTCGTCTCCTCTTCTCCCCTTCCCTCCCCCTCCGCATCCCAGGAT
    CACACCGGTCAACGAGGGTTGGGGGGGTCCGGCACGGACCCAAAATAATAA
  • Protein Sequence : Show Sequence
    >gi|9629425|ref|NP_044646.1| envelope glycoprotein C [Human herpesvirus 1]
    MAPGRVGLAVVLWSLLWLGAGVSGGSETASTGPTITAGAVTNASEAPTSGSPGSAASPEVTPTSTPNPNN
    VTQNKTTPTEPASPPTTPKPTSTPKSPPTSTPDPKPKNNTTPAKSGRPTKPPGPVWCDRRDPLARYGSRV
    QIRCRFRNSTRMEFRLQIWRYSMGPSPPIAPAPDLEEVLTNITAPPGGLLVYDSAPNLTDPHVLWAEGAG
    PGADPPLYSVTGPLPTQRLIIGEVTPATQGMYYLAWGRMDSPHEYGTWVRVRMFRPPSLTLQPHAVMEGQ
    PFKATCTAAAYYPRNPVEFVWFEDDHQVFNPGQIDTQTHEHPDGFTTVSTVTSEAVGGQVPPRTFTCQMT
    WHRDSVTFSRRNATGLALVLPRPTITMEFGVRIVVCTAGCVPEGVTFAWFLGDDPSPAAKSAVTAQESCD
    HPGLATVRSTLPISYDYSEYICRLTGYPAGIPVLEHHGSHQPPPRDPTERQVIEAIEWVGIGIGVLAAGV
    LVVTAIVYVVRTSQSRQRHRR
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
  • Related Vaccine(s): Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP , Herpes simplex virus type 1 DNA vaccine encoding GC
13. UL44 from HSV-2
  • Gene Name : UL44 from HSV-2
  • Sequence Strain (Species/Organism) : Human herpesvirus 2 (Herpes simplex virus type 2)
  • NCBI Gene ID : 1487331
  • NCBI Protein GI : 9629314
  • Locus Tag : HHV2gp47
  • Genbank Accession : AJ297389
  • Protein Accession : NP_044514
  • Taxonomy ID : 10310
  • Gene Starting Position : 96978
  • Gene Ending Position : 99298
  • Gene Strand (Orientation) : +
  • Protein Name : envelope glycoprotein C
  • Protein pI : 9.89
  • Protein Weight : 47108.15
  • Protein Length : 480
  • Protein Note : envelope glycoprotein C; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; the nonessential glycoprotein gC interacts with cell surface proteoglycans, whereas the essential glycoprotein gD is involved in stable secondary attachment
  • DNA Sequence : Show Sequence
    >gi|9629267:96978-99298 Human herpesvirus 2, complete genome
    CATGGCCCTTGGACGGGTGGGCCTAGCCGTGGGCCTGTGGGGCCTGCTGTGGGTGGGTGTGGTCGTGGTG
    CTGGCCAATGCCTCCCCCGGACGCACGATAACGGTGGGCCCGCGGGGGAACGCGAGCAATGCCGCCCCCT
    CCGCGTCCCCGCGGAACGCATCCGCCCCCCGAACCACACCCACGCCCCCCCAACCCCGCAAGGCGACGAA
    AAGTAAGGCCTCCACCGCCAAACCGGCCCCGCCCCCCAAGACCGGGCCCCCGAAGACATCCTCGGAGCCC
    GTGCGATGCAACCGCCACGACCCGCTGGCCCGGTACGGCTCGCGGGTGCAAATCCGATGCCGGTTTCCCA
    ACTCCACCCGCACGGAGTTCCGCCTCCAGATCTGGCGTTATGCCACGGCGACGGACGCCGAGATCGGAAC
    GGCGCCTAGCTTAGAGGAGGTGATGGTAAACGTGTCGGCCCCGCCCGGGGGCCAACTGGTGTATGACAGC
    GCCCCCAACCGAACGGACCCGCACGTGATCTGGGCGGAGGGCGCCGGCCCGGGCGCCAGCCCGCGGCTGT
    ACTCGGTCGTCGGGCCGCTGGGTCGGCAGCGGCTCATCATCGAAGAGCTGACCCTGGAGACCCAGGGCAT
    GTACTACTGGGTGTGGGGCCGGACGGACCGCCCGTCCGCGTACGGGACCTGGGTGCGCGTTCGCGTGTTC
    CGCCCTCCGTCGCTGACCATCCACCCCCACGCGGTGCTGGAGGGCCAGCCGTTTAAGGCGACGTGCACGG
    CCGCCACCTACTACCCGGGCAACCGCGCGGAGTTCGTCTGGTTCGAGGACGGTCGCCGGGTGTTCGATCC
    GGCCCAGATACACACGCAGACGCAGGAGAACCCCGACGGCTTTTCCACCGTCTCCACCGTGACCTCCGCG
    GCCGTCGGCGGCCAGGGCCCCCCGCGCACCTTCACCTGCCAGCTGACGTGGCACCGCGACTCCGTGTCGT
    TCTCTCGGCGCAACGCCAGCGGCACGGCATCGGTGCTGCCGCGGCCAACCATCACCATGGAGTTTACGGG
    CGACCATGCGGTCTGCACGGCCGGCTGTGTGCCCGAGGGGGTGACGTTTGCCTGGTTCCTGGGGGACGAC
    TCCTCGCCGGCGGAGAAGGTGGCCGTCGCGTCCCAGACATCGTGCGGGCGCCCCGGCACCGCCACGATCC
    GCTCCACCCTGCCGGTCTCGTACGAGCAGACCGAGTACATCTGCCGGCTGGCGGGATACCCGGACGGAAT
    TCCGGTCCTAGAGCACCACGGCAGCCACCAGCCCCCGCCGCGGGACCCCACCGAGCGGCAGGTGATCCGG
    GCGGTGGAGGGGGCGGGGATCGGAGTGGCTGTCCTTGTCGCGGTGGTTCTGGCCGGGACCGCGGTAGTGT
    ACCTCACCCACGCCTCCTCGGTGCGCTATCGTCGGCTGCGGTAACTCCGGGGCCGGGCCCGGCCGCCGGT
    TGTCTTCTTTTCCACCCCTTCCGTCCCCCGTACCCACCACACCCCACCCCACCCCCCCGCCGTCCCCCGG
    GCGTTATAAGCCGCCGCACTCGCTTTTCCCACCGGAAAATCCTCGGCCCGATCCGAACGGCGCACGCCGC
    GTGGGCTCCAAACGCCTCCGGAAGAGAGCGCCCCGCCCCGATATTCAAGCCCGCGGTGGTGCTATGGCTT
    TCCGTGCTTCGGGACCCGCCTACCAGCCCCTCGCCCCCGCGGCCTCCCCGGCGCGGGCTCGTGTTCCGGC
    CGTGGCCTGGATCGGCGTCGGAGCGATCGTCGGGGCCTTTGCGCTCGTCGCCGCGTTGGTTCTCGTACCC
    CCTCGGTCCTCGTGGGGACTCTCGCCGTGCGACAGCGGCTGGCAGGAATTCAACGCGGGATGCGTCGCGT
    GGGACCCCACCCCCGTCGAGCACGAGCAGGCGGTCGGCGGCTGCAGCGCGCCGGCCACCCTTATCCCCCG
    TGCGGCCGCCAAGCACCTGGCCGCTCTGACACGCGTCCAGGCGGAGAGATCGTCGGGTTACTGGTGGGTG
    AACGGAGACGGCATCCGGACCTGTCTGAGACTCGTCGACAGCGTCAGTGGCATCGACGAGTTTTTCGAGG
    AGCTCGCGATCCGCATATGCTACTACCCACGAAGCCCCGGCGGGTTTGTCCGCTTCGTAACTTCGATACG
    TAACGCCCTGGGGTTGCCGTGAGGCGCGCGTCCGACGGTCCCGCTTCTCGCCTCTCTTCTTCCCCCACCC
    CACCCACCGACCAACGACGGCGTTTGGCCAATACCCTCCTTTTTTCTTTTTCTCTTCCCCCCCCCCCAAA
    AAAAACAATAA
  • Protein Sequence : Show Sequence
    >gi|9629314|ref|NP_044514.1| envelope glycoprotein C [Human herpesvirus 2]
    MALGRVGLAVGLWGLLWVGVVVVLANASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATK
    SKASTAKPAPPPKTGPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTEFRLQIWRYATATDAEIGT
    APSLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRLIIEELTLETQGM
    YYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATCTAATYYPGNRAEFVWFEDGRRVFDP
    AQIHTQTQENPDGFSTVSTVTSAAVGGQGPPRTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTG
    DHAVCTAGCVPEGVTFAWFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGI
    PVLEHHGSHQPPPRDPTERQVIRAVEGAGIGVAVLVAVVLAGTAVVYLTHASSVRYRRLR
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Balb/c mice were immunized with either pgB-2 or pgC-2 plasmids intramuscularly (IM) or intradermally (ID). IM immunization of latently infected guinea pigs with a combined gB-2 and gC-2 plasmid vaccine significantly reduced the number of subsequent HSV-2 recurrences (Mester et al., 1999).
    Another study also found that antibodies produced by gC-2 immunization blocked the interaction between gC-2 and complement C3b, and passive transfer of gC-2 antibody protected complement-intact mice but not C3 knockout mice against HSV-2 challenge (Awasthi et al., 2011). Therefore, gC-2 antibody is effective, at least in part, because it prevents HSV-2 evasion from complement.
14. US4
  • Gene Name : US4
  • Sequence Strain (Species/Organism) : Human herpesvirus 2 (Herpes simplex virus type 2)
  • VO ID : VO_0011102
  • NCBI Gene ID : 1487356
  • NCBI Protein GI : 9629334
  • Locus Tag : HHV2gp67
  • Genbank Accession : X04798
  • Protein Accession : NP_044534
  • Taxonomy ID : 10310
  • Gene Starting Position : 137877
  • Gene Ending Position : 140054
  • Gene Strand (Orientation) : +
  • Protein Name : envelope glycoprotein G
  • Protein pI : 8.54
  • Protein Weight : 68471.88
  • Protein Length : 699
  • Protein Note : gD family
  • DNA Sequence : Show Sequence
    >gi|9629267:137877-140054 Human herpesvirus 2, complete genome
    CATGCACGCCATCGCTCCCAGGTTGCTTCTTCTTTTTGTTCTTTCTGGTCTTCCGGGGACACGCGGCGGG
    TCGGGTGTCCCCGGACCAATTAATCCCCCCAACAGCGATGTTGTTTTCCCGGGAGGTTCCCCCGTGGCTC
    AATATTGTTATGCCTATCCCCGGTTGGACGATCCCGGGCCCTTGGGTTCCGCGGACGCCGGGCGGCAAGA
    CCTGCCCCGGCGCGTCGTCCGTCACGAGCCCCTGGGCCGCTCGTTCCTCACGGGGGGGCTGGTTTTGCTG
    GCGCCGCCGGTACGCGGATTTGGCGCACCCAACGCAACGTATGCGGCCCGTGTGACGTACTACCGGCTCA
    CCCGCGCCTGCCGTCAGCCCATCCTCCTTCGGCAGTATGGAGGGTGTCGCGGCGGCGAGCCGCCGTCCCC
    AAAGACGTGCGGGTCGTACACGTACACGTACCAGGGCGGCGGGCCTCCGACCCGGTACGCTCTCGTAAAT
    GCTTCCCTGCTGGTGCCGATCTGGGACCGCGCCGCGGAGACATTCGAGTACCAGATCGAACTCGGCGGCG
    AGCTGCACGTGGGTCTGTTGTGGGTAGAGGTGGGCGGGGAGGGCCCCGGCCCCACCGCCCCCCCACAGGC
    GGCGCGTGCGGAGGGCGGCCCGTGCGTCCCCCCGGTCCCCGCGGGCCGCCCGTGGCGCTCGGTGCCCCCG
    GTATGGTATTCCGCCCCCAACCCCGGGTTTCGTGGCCTGCGTTTCCGGGAGCGCTGTCTGCCCCCACAGA
    CGCCCGCCGCCCCCAGCGACCTACCACGCGTCGCTTTTGCTCCCCAGAGCCTGCTGGTGGGGATTACGGG
    CCGCACGTTTATTCGGATGGCACGACCCACGGAAGACGTCGGGGTCCTGCCGCCCCATTGGGCCCCCGGG
    GCCCTAGATGACGGTCCGTACGCCCCCTTCCCACCCCGCCCGCGGTTTCGACGCGCCCTGCGGACAGACC
    CCGAGGGGGTCGACCCCGACGTTCGGGCCCCCCGAACCGGGCGGCGCCTCATGGCCTTGACCGAGGACAC
    GTCCTCCGATTCGCCTACGTCCGCTCCGGAGAAGACGCCCCTCCCTGTGTCGGCCACCGCCATGGCACCC
    TCAGTCGACCCAAGCGCGGAACCGACCGCCCCCGCAACCACTACTCCCCCCGACGAGATGGCCACACAAG
    CCGCAACGGTCGCCGTTACGCCGGAGGAAACGGCAGTCGCCTCCCCGCCCGCGACTGCATCCGTGGAGTC
    GTCGCCACTCCCCGCCGCGGCGGCGGCAACGCCCGGGGCCGGGCACACGAACACCAGCAGCGCCTCCGCA
    GCGAAAACGCCCCCCACCACACCAGCCCCCACGACCCCCCCGCCCACGTCTACCCACGCGACCCCCCGCC
    CCACGACTCCGGGGCCCCAAACAACCCCTCCCGGACCCGCAACCCCGGGTCCGGTGGGCGCCTCCGCCGC
    GCCCACGGCCGATTCCCCCCTCACCGCCTCGCCCCCCGCTACCGCGCCGGGGCCCTCGGCCGCCAACGTT
    TCGGTCGCCGCGACCACCGCCACGCCCGGAACCCGGGGCACCGCCCGTACCCCCCCAACGGACCCAAAGA
    CGCACCCACACGGACCCGCGGACGCTCCCCCCGGCTCGCCAGCCCCCCCACCCCCCGAACATCGCGGCGG
    ACCCGAGGAGTTTGAGGGCGCCGGGGACGGCGAACCCCCCGAGGACGACGACAGCGCCACCGGCCTCGCC
    TTCCGAACTCCGAACCCCAACAAACCACCCCCCGCGCGCCCCGGGCCCATCCGCCCCACGCTCCCGCCAG
    GAATTCTTGGGCCGCTCGCCCCCAACACGCCTCGCCCCCCCGCCCAAGCTCCCGCTAAGGACATGCCCTC
    GGGCCCCACACCCCAACACATCCCCCTGTTCTGGTTCCTAACGGCCTCCCCTGCTCTAGATATCCTCTTT
    ATCATCAGCACCACCATCCACACGGCGGCGTTCGTTTGTCTGGTCGCCTTGGCAGCACAACTTTGGCGCG
    GCCGGGCGGGGCGCAGGCGATACGCGCACCCGAGCGTGCGTTACGTATGTCTGCCACCCGAGCGGGATTA
    GGGGGTGGGGGTGGGGGGCGAGAAACGATGAAGGACGGGAAAGGGAACAGCGACCAAATGTCACGATAAG
    AACAATAA
  • Protein Sequence : Show Sequence
    >gi|9629334|ref|NP_044534.1| envelope glycoprotein G [Human herpesvirus 2]
    MHAIAPRLLLLFVLSGLPGTRGGSGVPGPINPPNSDVVFPGGSPVAQYCYAYPRLDDPGPLGSADAGRQD
    LPRRVVRHEPLGRSFLTGGLVLLAPPVRGFGAPNATYAARVTYYRLTRACRQPILLRQYGGCRGGEPPSP
    KTCGSYTYTYQGGGPPTRYALVNASLLVPIWDRAAETFEYQIELGGELHVGLLWVEVGGEGPGPTAPPQA
    ARAEGGPCVPPVPAGRPWRSVPPVWYSAPNPGFRGLRFRERCLPPQTPAAPSDLPRVAFAPQSLLVGITG
    RTFIRMARPTEDVGVLPPHWAPGALDDGPYAPFPPRPRFRRALRTDPEGVDPDVRAPRTGRRLMALTEDT
    SSDSPTSAPEKTPLPVSATAMAPSVDPSAEPTAPATTTPPDEMATQAATVAVTPEETAVASPPATASVES
    SPLPAAAAATPGAGHTNTSSASAAKTPPTTPAPTTPPPTSTHATPRPTTPGPQTTPPGPATPGPVGASAA
    PTADSPLTASPPATAPGPSAANVSVAATTATPGTRGTARTPPTDPKTHPHGPADAPPGSPAPPPPEHRGG
    PEEFEGAGDGEPPEDDDSATGLAFRTPNPNKPPPARPGPIRPTLPPGILGPLAPNTPRPPAQAPAKDMPS
    GPTPQHIPLFWFLTASPALDILFIISTTIHTAAFVCLVALAAQLWRGRAGRRRYAHPSVRYVCLPPERD
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 (Grabowska et al., 2000).
  • Related Vaccine(s): Herpes simplex virus type 2 vaccine using phage displaying GG protein
15. US5
  • Gene Name : US5
  • Sequence Strain (Species/Organism) : Human herpesvirus 1
  • VO ID : VO_0011098
  • NCBI Gene ID : 2703406
  • NCBI Protein GI : 9629447
  • Locus Tag : HHV1gp094
  • Genbank Accession : L00036
  • Protein Accession : NP_044668
  • Taxonomy ID : 10298
  • Gene Starting Position : 137595
  • Gene Ending Position : 141047
  • Gene Strand (Orientation) : +
  • Protein Name : mRNA
  • Protein pI : 7.82
  • Protein Weight : 40766.56
  • Protein Length : 394
  • DNA Sequence : Show Sequence
    >gi|9629378:137595-141047 Human herpesvirus 1, complete genome
    TTAAATACATGCCCGGGACCCATGAAGCATGCGCGACTTCCGGGCCTCAGAACCCACCCGAAACGGCCAA
    CGGACGTCTGAGCCAGGCCTGGCTATCCGGAGAAACAGCACACGACTTGGCGTTCTGTGTGTCGCGATGT
    CTCTGCGCGCAGTCTGGCATCTGGGGCTTTTGGGAAGCCTCGTGGGGGCTGTTCTTGCCGCCACCCATCG
    GGGACCTGCGGCCAACACAACGGACCCCTTAACGCACGCCCCAGTGTCCCCTCACCCCAGCCCCCTGGGG
    GGCTTTGCCGTCCCCCTCGTAGTCGGTGGGCTGTGCGCCGTAGTCCTGGGGGCGGCATGTCTGCTTGAGC
    TCCTGCGTCGTACGTGCCGCGGGTGGGGGCGTTACCATCCCTACATGGACCCAGTTGTCGTATAATTTCC
    CCCCCCCCCCCCCTTCTCCGCGTGGGTGATGTCGGGTCCAAACTCCCGACACCACCAGCTGGCATGGTAT
    AAATCACCGGTGCGCCCCCCAAACCATGTCCGGCAGGGGGATGGGGGGGCAATGCGGAGGGCACCCAACA
    ACACCGGGCTAACCAGGAAATCCGTGGCCCCGGCCCCCAATAAAGATCGCGGTAGCCCGGCCGTGTGACA
    CTATCGTCCATACCGACCACACCGACGAATCCCCCAAGGGGGAGGGGCCATTTTACGAGGAGGAGGGGTA
    TAACAAAGTCTGTCTTTAAAAAGCAGGGGTTAGGGAGTTGTTCGGTCATAAGCTTCAGCGCGAACGACCA
    ACTACCCCGATCATCAGTTATCCTTAAGGTCTCTTTTGTGTGGTGCGTTCCGGTATGGGGGGGGCTGCCG
    CCAGGTTGGGGGCCGTGATTTTGTTTGTCGTCATAGTGGGCCTCCATGGGGTCCGCAGCAAATATGCCTT
    GGTGGATGCCTCTCTCAAGATGGCCGACCCCAATCGCTTTCGCGGCAAAGACCTTCCGGTCCTGGACCAG
    CTGACCGACCCTCCGGGGGTCCGGCGCGTGTACCACATCCAGGCGGGCCTACCGGACCCGTTCCAGCCCC
    CCAGCCTCCCGATCACGGTTTACTACGCCGTGTTGGAGCGCGCCTGCCGCAGCGTGCTCCTAAACGCACC
    GTCGGAGGCCCCCCAGATTGTCCGCGGGGCCTCCGAAGACGTCCGGAAACAACCCTACAACCTGACCATC
    GCTTGGTTTCGGATGGGAGGCAACTGTGCTATCCCCATCACGGTCATGGAGTACACCGAATGCTCCTACA
    ACAAGTCTCTGGGGGCCTGTCCCATCCGAACGCAGCCCCGCTGGAACTACTATGACAGCTTCAGCGCCGT
    CAGCGAGGATAACCTGGGGTTCCTGATGCACGCCCCCGCGTTTGAGACCGCCGGCACGTACCTGCGGCTC
    GTGAAGATAAACGACTGGACGGAGATTACACAGTTTATCCTGGAGCACCGAGCCAAGGGCTCCTGTAAGT
    ACGCCCTCCCGCTGCGCATCCCCCCGTCAGCCTGCCTCTCCCCCCAGGCCTACCAGCAGGGGGTGACGGT
    GGACAGCATCGGGATGCTGCCCCGCTTCATCCCCGAGAACCAGCGCACCGTCGCCGTATACAGCTTGAAG
    ATCGCCGGGTGGCACGGGCCCAAGGCCCCATACACGAGCACCCTGCTGCCCCCGGAGCTGTCCGAGACCC
    CCAACGCCACGCAGCCAGAACTCGCCCCGGAAGACCCCGAGGATTCGGCCCTCTTGGAGGACCCCGTGGG
    GACGGTGGCGCCGCAAATCCCACCAAACTGGCACATACCGTCGATCCAGGACGCCGCGACGCCTTACCAT
    CCCCCGGCCACCCCGAACAACATGGGCCTGATCGCCGGCGCGGTGGGCGGCAGTCTCCTGGCAGCCCTGG
    TCATTTGCGGAATTGTGTACTGGATGCGCCGCCACACTCAAAAAGCCCCAAAGCGCATACGCCTCCCCCA
    CATCCGGGAAGACGACCAGCCGTCCTCGCACCAGCCCTTGTTTTACTAGATACCCCCCCTTAATGGGTGC
    GGGGGGGTCAGGTCTGCGGGGTTGGGATGGGACCTTAACTCCATATAAAGCGAGTCTGGAAGGGGGGAAA
    GGTGGACAGTCGATAAGTCGGTAGCGGGGGACGCGCACCTGTTCCGCCTGTCGCACCCACAGCTTTTTTT
    GCGAACCGTCCCGTTCCGGGATGCCGTGCCGCCCGTTGCAGGGCCTGGTGCTCGTGGGCCTCTGGGTCTG
    TGCCACCAGCCTGGTTGTCCGTGGCCCCACGGTCAGTCTGGTATCAAACTCATTTGTGGACGCCGGGGCC
    TTGGGGCCCGACGGCGTAGTGGAGGAAGACCTGCTTATTCTCGGGGAGCTTCGCTTTGTGGGGGACCAGG
    TCCCCCACACCACCTACTACGATGGGGGCGTAGAGCTGTGGCACTACCCCATGGGACACAAATGCCCACG
    GGTCGTGCATGTCGTCACGGTGACCGCGTGCCCACGTCGCCCCGCCGTGGCATTCGCCCTGTGTCGCGCG
    ACCGACAGCACTCACAGCCCCGCATATCCCACCCTGGAGCTCAATCTGGCCCAACAGCCGCTTTTGCGGG
    TCCAGAGGGCAACGCGGGACTATGCCGGGGTGTACGTGTTACGCGTATGGGTCGGTGACGCGCCAAACGC
    CAGCCTGTTTGTCCTGGGGATGGCCATAGCCGCCGAAGGGACTCTGGCGTACAACGGCTCGGCCTATGGC
    TCCTGCGACCCGAAACTGCTTCCGTCTTCGGCCCCGCGTCTGGCCCCGGCGAGCGTATACCAACCCGCCC
    CTAACCAGGCCTCCACCCCCTCGACCACCACCTCCACCCCCTCGACCACCATCCCCGCTCCCTCGACCAC
    CATCCCCGCTCCCCAAGCATCGACCACGCCCTTCCCCACGGGAGATCCAAAACCACAACCTCCCGGGGTC
    AACCACGAACCCCCATCTAATGCCACGCGAGCGACCCGCGACTCGCGATACGCGCTAACGGTGACCCAGA
    TAATCCAGATAGCCATCCCCGCGTCCATCATAGCCCTGGTGTTTCTGGGGAGCTGTATTTGCTTTATACA
    CAGATGTCAACGCCGCTACCGACGCTCCCGTCGCCCGATTTACAGCCCCCAGATGCCCACGGGCATCTCA
    TGCGCGGTGAACGAAGCGGCCATGGCCCGCCTCGGAGCCGAGCTCAAATCGCATCCGAGCACCCCCCCCA
    AATCCCGGCGCCGGTCGTCACGCACGCCAATGCCCTCCCTGACGGCCATCGCCGAAGAGTCGGAGCCCGC
    TGGGGCGGCTGGGCTTCCGACGCCCCCCGTGGACCCCACGACACCCACCCCAACGCCTCCCCTGTTGGTA
    TAGGTCCACGGCCACTGGCCGGGAGCACCACATAACCGACCGCAGTCCCTGAGTTGGGAATAAACCGGTA
    TTATTTACCTATATCCGTGTATG
  • Protein Sequence : Show Sequence
    >gi|9629447|ref|NP_044668.1| envelope glycoprotein D [Human herpesvirus 1]
    MGGAAARLGAVILFVVIVGLHGVRSKYALVDASLKMADPNRFRGKDLPVLDQLTDPPGVRRVYHIQAGLP
    DPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTIAWFRMGGNCAIPITVMEY
    TECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
    KGSCKYALPLRIPPSACLSPQAYQQGVTVDSIGMLPRFIPENQRTVAVYSLKIAGWHGPKAPYTSTLLPP
    ELSETPNATQPELAPEDPEDSALLEDPVGTVAPQIPPNWHIPSIQDAATPYHPPATPNNMGLIAGAVGGS
    LLAALVICGIVYWMRRHTQKAPKRIRLPHIREDDQPSSHQPLFY
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 (Jamali et al., 2009).
  • Related Vaccine(s): Herpes simplex virus type 1 DNA vaccine encoding GD
16. US6
  • Gene Name : US6
  • Sequence Strain (Species/Organism) : Human herpesvirus 2
  • VO ID : VO_0011096
  • NCBI Gene ID : 1487358
  • NCBI Protein GI : 9629336
  • Locus Tag : HHV2gp69
  • Genbank Accession : AY779754
  • Protein Accession : NP_044536
  • Taxonomy ID : 10310
  • Gene Starting Position : 141015
  • Gene Ending Position : 143591
  • Gene Strand (Orientation) : +
  • Protein Name : envelope glycoprotein D
  • Protein pI : 7.84
  • Protein Weight : 40611.38
  • Protein Length : 393
  • Protein Note : gD family
  • DNA Sequence : Show Sequence
    >gi|9629267:141015-143591 Human herpesvirus 2, complete genome
    CATGGGGCGTTTGACCTCCGGCGTCGGGACGGCGGCCCTGCTAGTTGTCGCGGTGGGACTCCGCGTCGTC
    TGCGCCAAATACGCCTTAGCAGACCCCTCGCTTAAGATGGCCGATCCCAATCGATTTCGCGGGAAGAACC
    TTCCGGTTTTGGACCAGCTGACCGACCCCCCCGGGGTGAAGCGTGTTTACCACATTCAGCCGAGCCTGGA
    GGACCCGTTCCAGCCCCCCAGCATCCCGATCACTGTGTACTACGCAGTGCTGGAACGTGCCTGCCGCAGC
    GTGCTCCTACATGCCCCATCGGAGGCCCCCCAGATCGTGCGCGGGGCTTCGGACGAGGCCCGAAAGCACA
    CGTACAACCTGACCATCGCCTGGTATCGCATGGGAGACAATTGCGCTATCCCCATCACGGTTATGGAATA
    CACCGAGTGCCCCTACAACAAGTCGTTGGGGGTCTGCCCCATCCGAACGCAGCCCCGCTGGAGCTACTAT
    GACAGCTTTAGCGCCGTCAGCGAGGATAACCTGGGATTCCTGATGCACGCCCCCGCCTTCGAGACCGCGG
    GTACGTACCTGCGGCTAGTGAAGATAAACGACTGGACGGAGATCACACAATTTATCCTGGAGCACCGGGC
    CCGCGCCTCCTGCAAGTACGCTCTCCCCCTGCGCATCCCCCCGGCAGCGTGCCTCACCTCGAAGGCCTAC
    CAACAGGGCGTGACGGTCGACAGCATCGGGATGCTACCCCGCTTTATCCCCGAAAACCAGCGCACCGTCG
    CCCTATACAGCTTAAAAATCGCCGGGTGGCACGGCCCCAAGCCCCCGTACACCAGCACCCTGCTGCCGCC
    GGAGCTGTCCGACACCACCAACGCCACGCAACCCGAACTCGTTCCGGAAGACCCCGAGGACTCGGCCCTC
    TTAGAGGATCCCGCCGGGACGGTGTCTTCGCAGATCCCCCCAAACTGGCACATCCCGTCGATCCAGGACG
    TCGCGCCGCACCACGCCCCCGCCGCCCCCAGCAACCCGGGCCTGATCATCGGCGCGCTGGCCGGCAGTAC
    CCTGGCGGTGCTGGTCATCGGCGGTATTGCGTTTTGGGTACGCCGCCGCGCTCAGATGGCCCCCAAGCGC
    CTACGTCTCCCCCACATCCGGGATGACGACGCGCCCCCCTCGCACCAGCCATTGTTTTACTAGAGGAGTT
    TCCCCGCTCCCGTGTACCTCTGGGCCCGTGTGGGAGGGTGGCTGGGGTATTTGGGTGGGACTTGGACTCC
    GCATAAAGGGAGTCTCGAAGGAGGGAAACTAGGACAGTTCATAGGCCGGGAGCGTGGGGCGCGCACCGCT
    GTCCCGACGATTAGCCACCGCGCCCACAGCCACCTCGACCCGTCCGATCCCGGTATGCCCGGCCGCTCGC
    TGCAGGGCCTGGCGATCCTGGGCCTGTGGGTCTGCGCCACCGGCCTGGTCGTCCGCGGCCCCACGGTCAG
    TCTGGTCTCAGACTCACTCGTGGATGCCGGGGCCGTGGGGCCCCAGGGCTTCGTGGAAGAGGACCTGCGT
    GTTTTCGGGGAGCTTCATTTTGTGGGGGCCCAGGTCCCCCATACAAACTACTACGACGGCATCATCGAGC
    TGTTTCACTACCCCCTGGGGAACCACTGCCCCCGCGTTGTACACGTGGTCACACTGACCGCATGCCCCCG
    CCGCCCCGCCGTGGCGTTCACCTTGTGTCGCTCGACGCACCACGCCCACAGCCCCGCCTATCCGACCCTG
    GAGCTGGGTCTGGCGCGGCAGCCGCTTCTGCGGGTTCGAACGGCAACGCGCGACTATGCCGGTCTGTATG
    TCCTGCGCGTATGGGTCGGCAGCGCGACGAACGCCAGCCGGTTTGTTTTGGGGGTGGCGCTCTCTGCCAA
    CGGGACGTTTGTGTATAACGGCTCGGACTACGGCTCCTGCGATCCGGCGCAGCTTCCCTTTTCGGCCCCG
    CGCCTGGGACCCTCGAGCGTATACACCCCCGGAGCCTCCCGACCCACCCCTCCACGGACAACGACACCCC
    CGTCCTCCCCCCGAGACCCGACCCCCGCCCCCGGGGACACAGGGACGCCCGCGCCCGCGAGCGGCGAGAT
    AGCCCCGCCCAATTCCACGCGATCGGCCAGCGAATCGAGACACAGGCTAACCGTAGCCCAGGTAATCCAG
    ATCGCCATACCGGCGTCCATCATCGCCTTTGTGTTTCTGGGCAGCTGTATCTGCTTCATCCATAGATGCC
    AGCGCCGATACAGGCGCCCCCGCGGCCAGATTTACAACCCCGGGGGCGTTTCCTGCGCGGTCAACGAGGC
    GGCCATGGCCCGCCTCGGAGCCGAGCTGCGATCCCACCCAAACACCCCCCCCAAACCCCGACGCCGTTCG
    TCGTCGTCCACGACCATGCCTTCCCTAACGTCGATAGCTGAGGAATCGGAGCCAGGTCCAGTCGTGCTGC
    TGTCCGTCAGTCCTCGGCCCCGCAGTGGCCCGACGGCCCCCCAAGAGGTCTAGGTCCAAGCGGGCCGTTC
    GGCAGGCCCGCCCCACCGCCCCCATCGTGGTTATTTCCCCCCCCCCCCCCCCAATAA
  • Protein Sequence : Show Sequence
    >gi|9629336|ref|NP_044536.1| envelope glycoprotein D [Human herpesvirus 2]
    MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLE
    DPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEY
    TECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA
    RASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPP
    ELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALAGST
    LAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome. Expression of gD2 in cells infected with the recombinant Oka strain VZV (ROka-gD2) was confirmed by antibody staining of fixed cells and by immunoblot analysis. Forty days after the third inoculation, guinea pigs were challenged intravaginally with HSV-2. Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001) (Heineman et al., 1995).
17. US7
  • Gene Name : US7
  • Sequence Strain (Species/Organism) : Human herpesvirus 1 strain McKrae
  • NCBI Protein GI : 388525000
  • Other Database IDs : CDD:165548
    CDD:145044
  • Taxonomy ID : 10298
  • Gene Strand (Orientation) : ?
  • Protein Name : gI
  • Protein Length : 413
  • Protein Note : type: 1
  • Protein Sequence : Show Sequence
    >gi|388525000|gb|AFK50416.1| gI [Human herpesvirus 1]
    MQGLVLVGLWVCATSLVVRGPTVSLVSNSFVDAGALGPDGVVEEDLLILGELRFVGDQVPHTTYYDGVVE
    LWHYPMGHKCPRVVHVVTVTACPRRPAVAFALCRATDNTHSPAYPTLELNLAQQPLLRVRRATRDYAGVY
    VLRVWVVDAPNASLFVLGMAIAAEGTLAYNGSAHGSCDPKLLPYSAPRLAPASVYQPAPNPASTPSTTTS
    TPSTTTSTPSTTTSTPSTTTSTPSTTTSTPSTTTSTPSTTIPAPQASTTPFPTGDPKPQPHGVNHEPPSN
    ATRATRDSRYALTVTQIIQIAIPASIIALVFLGSCICFIHRCQRRYRRSRRPIYNPQIPTGISCAVNEAA
    MARLGAELKSHPSTPPKSRRRSSRTPMPSLTAIAEESEPAGAAGLPTPPVDPTTSTPTPPLLV
  • Molecule Role : Protective antigen
  • Related Vaccine(s): Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP
18. US8
  • Gene Name : US8
  • Sequence Strain (Species/Organism) : Human herpesvirus 1 (Herpes simplex virus type 1)
  • VO ID : VO_0011104
  • NCBI Gene ID : 2703448
  • NCBI Protein GI : 9629449
  • Locus Tag : HHV1gp101
  • Genbank Accession : AJ626491
  • Protein Accession : NP_044670
  • Taxonomy ID : 10298
  • Gene Starting Position : 141138
  • Gene Ending Position : 143692
  • Gene Strand (Orientation) : +
  • Protein Name : envelope glycoprotein E
  • Protein pI : 6.08
  • Protein Weight : 54133.1
  • Protein Length : 550
  • DNA Sequence : Show Sequence
    >gi|9629378:141138-143692 Human herpesvirus 1, complete genome
    GCATTTAAGGCGTTGTTGTGTTGACTTTGCCTCTTCTGGCGGGTTGGTGCGGTGCTGTTTGTTGGGCTCC
    CATTTTACCCGAAGATCGGCTGCTATCCCCGGGACATGGATCGCGGGGCGGTGGTGGGGTTTCTTCTCGG
    TGTTTGTGTTGTATCGTGCTTGGCGGGAACGCCCAAAACGTCCTGGAGACGGGTGAGTGTCGGCGAGGAC
    GTTTCGTTGCTTCCAGCTCCGGGGCCTACGGGGCGCGGCCCGACCCAGAAACTACTATGGGCCGTGGAAC
    CCCTGGATGGGTGCGGCCCCTTACACCCGTCGTGGGTCTCGCTGATGCCCCCCAAGCAGGTGCCCGAGAC
    GGTCGTGGATGCGGCGTGCATGCGCGCTCCGGTCCCGCTGGCGATGGCGTACGCCCCCCCGGCCCCATCT
    GCGACCGGGGGTCTACGAACGGACTTCGTGTGGCAGGAGCGCGCGGCCGTGGTTAACCGGAGTCTGGTTA
    TTCACGGGGTCCGAGAGACGGACAGCGGCCTGTATACCCTGTCCGTGGGCGACATAAAGGACCCGGCTCG
    CCAAGTGGCCTCGGTGGTCCTGGTGGTGCAACCGGCCCCAGTTCCGACCCCACCCCCGACCCCAGCCGAT
    TACGACGAGGATGACAATGACGAGGGCGAGGACGAAAGTCTCGCCGGCACTCCCGCCAGCGGGACCCCCC
    GGCTCCCGCCTCCCCCCGCCCCCCCGAGGTCTTGGCCCAGCGCCCCCGAAGTCTCACATGTGCGTGGGGT
    GACCGTGCGTATGGAGACTCCGGAAGCTATCCTGTTTTCCCCCGGGGAGACGTTCAGCACGAACGTCTCC
    ATCCATGCCATCGCCCACGACGACCAGACCTACTCCATGGACGTCGTCTGGTTGAGGTTCGACGTGCCGA
    CCTCGTGTGCCGAGATGCGAATATACGAATCGTGTCTGTATCACCCGCAGCTCCCAGAATGTCTGTCCCC
    GGCCGACGCGCCGTGCGCCGCGAGTACGTGGACGTCTCGCCTGGCCGTCCGCAGCTACGCGGGGTGTTCC
    AGAACAAACCCCCCACCGCGCTGTTCGGCCGAGGCTCACATGGAGCCCGTCCCGGGGCTGGCGTGGCAGG
    CGGCCTCCGTCAATCTGGAGTTCCGGGACGCGTCCCCACAACACTCCGGCCTGTATCTGTGTGTGGTGTA
    CGTCAACGACCATATTCACGCCTGGGGCCACATTACCATCAGCACCGCGGCGCAGTACCGGAACGCGGTG
    GTGGAACAGCCCCTCCCACAGCGCGGCGCGGATTTGGCCGAGCCCACCCACCCGCACGTCGGGGCCCCTC
    CCCACGCGCCCCCAACCCACGGCGCCCTGCGGTTAGGGGCGGTGATGGGGGCCGCCCTGCTGCTGTCTGC
    ACTGGGGTTGTCGGTGTGGGCGTGTATGACCTGTTGGCGCAGGCGTGCCTGGCGGGCGGTTAAAAGCAGG
    GCCTCGGGTAAGGGGCCCACGTACATTCGCGTGGCCGACAGCGAGCTGTACGCGGACTGGAGCTCGGACA
    GCGAGGGAGAACGCGACCAGGTCCCGTGGCTGGCCCCCCCGGAGAGACCCGACTCTCCCTCCACCAATGG
    ATCCGGCTTTGAGATCTTATCACCAACGGCTCCGTCTGTATACCCCCGTAGCGATGGGCATCAATCTCGC
    CGCCAGCTCACAACCTTTGGATCCGGAAGGCCCGATCGCCGTTACTCCCAGGCCTCCGATTCGTCCGTCT
    TCTGGTAAGGCGCCCCATCCCGAGGCCCCACGTCGGTCGCCGAACTGGGCGACCGCCGGCGAGGTGGACG
    TCGGAGACGAGCTAATCGCGATTTCCGACGAACGCGGACCCCCCCGACATGACCGCCCGCCCCTCGCCAC
    GTCGACCGCGCCCTCGCCACACCCGCGACCCCCGGGCTACACGGCCGTTGTCTCCCCGATGGCCCTCCAG
    GCTGTCGACGCCCCCTCCCTGTTTGTCGCCTGGCTGGCCGCTCGGTGGCTCCGGGGGGCTTCCGGCCTGG
    GGGCCGTCCTGTGTGGGATTGCGTGGTATGTGACGTCAATTGCCCGAGGCGCATAAAGGGCCGGTGGTCC
    GCCTAGCCGCAGCAAATTAAAAATCGTGAGTCACAGCGACCGCAACTTCCCACCCGGAGCTTTCTTCCGG
    CCTCGATGACGTCCCGGCTCTCCGATCCCAACTCCTCAGCGCGATCCGACATGTCCGTGCCGCTTTATCC
    CACGGCCTCGCCAGTTTCGGTCGAAGCCTACTACTCGGAAAGCGAAGACGAGGCGGCCAACGACTTCCTC
    GTACGCATGGGCCGCCAACAGTCGGTATTAAGGCGTCGACGCAGACGCACCCGCTGCGTCGGCATGGTGA
    TCGCCTGTCTCCTCGTGGCCGTTCTGTCGGGCGGATTTGGGGCGCTCCTGATGTGGCTGCTCCGCTAAAA
    GACCGCATCGACACGCGCGTCCTTCTTGTCGTCTCTCTTCCCCCCCATCACCCCGCAATTTGCACCCAGC
    CTTTAACTACATTAAATTGGGTTCGATTGGCAATG
  • Protein Sequence : Show Sequence
    >gi|9629449|ref|NP_044670.1| envelope glycoprotein E [Human herpesvirus 1]
    MDRGAVVGFLLGVCVVSCLAGTPKTSWRRVSVGEDVSLLPAPGPTGRGPTQKLLWAVEPLDGCGPLHPSW
    VSLMPPKQVPETVVDAACMRAPVPLAMAYAPPAPSATGGLRTDFVWQERAAVVNRSLVIHGVRETDSGLY
    TLSVGDIKDPARQVASVVLVVQPAPVPTPPPTPADYDEDDNDEGEDESLAGTPASGTPRLPPPPAPPRSW
    PSAPEVSHVRGVTVRMETPEAILFSPGETFSTNVSIHAIAHDDQTYSMDVVWLRFDVPTSCAEMRIYESC
    LYHPQLPECLSPADAPCAASTWTSRLAVRSYAGCSRTNPPPRCSAEAHMEPVPGLAWQAASVNLEFRDAS
    PQHSGLYLCVVYVNDHIHAWGHITISTAAQYRNAVVEQPLPQRGADLAEPTHPHVGAPPHAPPTHGALRL
    GAVMGAALLLSALGLSVWACMTCWRRRAWRAVKSRASGKGPTYIRVADSELYADWSSDSEGERDQVPWLA
    PPERPDSPSTNGSGFEILSPTAPSVYPRSDGHQSRRQLTTFGSGRPDRRYSQASDSSVFW
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
  • Additional Molecule Role : Virmugen
  • Additional Molecule Role Annotation : An HSV-1 gE (Us8) deletion strain, NS-gEnull, was used as a live attenuated vaccine. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice (Brittle et al., 2008).
  • Related Vaccine(s): GSK1437173A , Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP , Herpes simplex virus type 1 DNA vaccine encoding GE
1. IgG
  • Gene Name : IgG
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 16059
  • Genbank Accession : AF010213
  • Taxonomy ID : 10090
  • Chromosome No : 12
  • Gene Starting Position : 881411
  • Gene Ending Position : 914690
  • Gene Strand (Orientation) : +
  • Protein Name : immunoglobulin heavy chain (V7183 family)
  • Protein Note : Also known as IgG; IgH; VI24H; VH7183; B9-scFv; IgVH1(VSG)
  • DNA Sequence : Show Sequence
    >gi|94393741:881411-914690 Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig, MGSCv37 alternate locus group 129/SvJ
    CATGGACTTTGGGCTCAGCTGTGTTTTCCTTGTCCTCATTTTAAGAGGTAATTTGTAGAAATAAGATCCT
    GCCAGTATTGTGTACAGGAGAAATAGAAAAATTTTTCTTTCCTCTATTTTGTTTTGTTTTGTTAGTGACA
    GTTTACAAATAAGCATTCTCTGTTGTGAGGTGCCCAGTGTGAGGTGAAGATGGTGGAGTCTGTGGGAGGC
    TTAGTGCAGCCTGTAGGGTCATTGAAACCCTCCTGTGCAGCCTCTGGATTCATTCTCACTGACTACTGAA
    TGACCTGGATCCTTCAGGCTTCAAAGAAAAGGATGGAGAGGGTGACAATAAAATTTTTCCCACTCACACC
    CACTTGCTGGCCCTGGCGTTCCCCTGTAATGAGGCACATAAAGTTTGCAAAACCAAGGGGCCTCTCTTCT
    CAATGATGGCTGACTAGGACATCTTCTGATACATATGCAGCTAGAGACATGAGCTCCCGGGATACTGGTT
    ACTTCATATTGTTGTTCCCCCACAACAGTTGCAGACCCTTTTATTTCTGTGGGTACTTTCACTAGCTCCT
    CCATTGGGGGCCCTGTGTTCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTAGTTGCTAGGCCCCGG
    CATAGCCTCACAAGAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTTGCTGGTGTATGCAATGGTGTC
    AGAGTTTGGAGTCTGATTATGGGATGGATCCCCAGGTATGGCAAACTCTAGATGGTCCATCCTTTCCCAA
    CAATAATTTTTAATGGTGGAGATAGCACCTACTATCCAGACACAATGAAGGGCCAATTCACTATCTCTAG
    AGATGATGCCAAAAACACACTTTACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTATACA
    TATATTCCTAAGCTTGAGTAAGTGGACTTAAACTGATTCCATCACAACTTGCATGAGATGGATATTCCCC
    AGTGTTAAGACCTGTCACCATCACTGTCAATCAGAAGACAAAGTTTATGCACAACAAAACAAAAAAACCA
    AAAGCAGAGGCCTCCAATTACAAGTAATAGACCCAGACCCACAGTCTCTGAAAACTGACTGTACAGTTGG
    ATCCAGTCTTTTACTTCTTTTCCCTGGATTTTATATTACTGAGGAAATGAGGAAAGCTCTACAATATCTG
    TTCTCCATAGTGCTCAACACCTCCAAGCACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTTCTT
    GTCTTGTAGACTACTTCAACCTATTTTGTACTCCAGTTAATGAAACTCAAGTCTAGCAGCCTGTCACTGT
    TTATTCTAAAGTATTATGAACAGGTGACCTCCCATCCTTCCCCAACGCAATAATCATATTTAGGAATTTG
    AGGTTTTATGAGATATGATCTCAGGGTAGAGAGAGAAAGCAAACTACATAGAAATATAGACTGACATAAA
    TCAAGACTTGCATAAGCTAGTCCCCAAGTTCCATGTCCCTAAGTGGCAAGGACTATCTTCTGAGCCTAAT
    GAGATGAGATCCAAATCAAACCTCCTGGGTCTTTTTAGATAAACATGTGAGATCAATAGACTAAATGCTT
    TGGCTGGGCTTCCTTGCAATCCAATTCCCAAACAAAAATGGATCTGGCTCCACAGACACCACAAGAATAG
    TCTTAAATAGTTCTTTAAGTAGAATGTCTGATCACTACGAGCCCAATTCCATCCTAAATACTCTTCTGGA
    TTATACATAAATAAAAATTGAACATAGGGCATGGGGCACTGATCTCCCTGTGCTACATGAATGGGGGCTC
    ATTTACTAAATGTTCCCATTTTTCTTTCTAGCGCTGCACAGTGCAAATCCTACAACTTCCTGTTTATCTA
    CAATGTGAACTCCAAACAGTACAAGAAAAAACGTTCCTTATGTTCCTCTCCAGGTTCTCCAACAAGCACA
    GAGCAACCTTCTGTCACCAGGACGGAAAACTGGAAACCTTGCTCACTGCTTCCTTTTATTCCCTCGGGAA
    CCTCCCCCAATGCAAAGCAGCCCTCAGGCAGAGGATAAAAGCTCACACAAAGACGAGAAGCCCCATCCTC
    TTCTCATAGAGCATCCATCAGAGCATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACTTTCCCAAGCT
    GTAAGTGTTTCAGGGTTTCAGAAGAGGGACTAAGACATGTCAGCTAGAAGATGTGTGACTAATGGTGATG
    TTGCTTGTCCCCAGGTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCA
    CAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCC
    AGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGC
    TCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTC
    CAAACTGATGACACAGCCATGTACTACTGTGCCAGAAACACAGTGTGGGAAGTCCAATGTGAGCCTGCAC
    AAATACTTCTCTGCAGGGATGATCACAACCAGCAGGGGGCGCTGATGACCCAAAGGGACTTCCCAGGATC
    TCTTCTGGAATCTAGGGAGTTCTGGCCTGTGTCTATCAGCATGTGTTTCAATGTTAGAGTTGTGAGTTTT
    CCTTCCAGCAACAGAGATATTTTAGAGCCCACTTTTCATGGTCATTCTACTAAATTTGTTCACATAGTGG
    AAAGATTTGTTAAATGATTCTATAGTCTAATAGGGTCAAACAAAAACAAATAATTGAGTTCATATCTACC
    AAAAAAAAAAAAATTCCCTCAAAGTGGACAACTGTGTAGGTGAGGAAAACCAGGGGGATTTGGGAATAGA
    TTATTTCTCTCCCGACTGTGGTGTTAGTCACCTTTCAGCCATTTACTGTATTTAATTCATGTTTAAAGTT
    AATTGTATTCATCTTCCCTAACATGAAGTTTTCAAACACATGTCCACAATTTAATGATGACACAGTTATC
    ATTGTGAATGATAACTCATAAGATCTCTCTCCATATATGAAACACACGATATTCTGTTATTAGCTATAGC
    CAACAAAGTTACATATCATTATTATTACTGAAATAATTCTTCCCATCTAACTGAATAGTTTTCTCACTCG
    ACACTGCCTATGCTGCGATCAGCCTGCTCTAATTTTACCTTTGCTCAGAGCACTGCTTTCTGTTTCATTT
    GATAAGATGGTGCCTGGTTGTCACTGAAAATGTGTCCTCCAGTTTCACAGTGATTAATGTGATTTTCAGT
    ACATTGAGAACAGAGCCACAGCAAAAATGAGATGGAATGTCATCATTTTTACGCCAGGTGCTGCAGAAAT
    AGCTAGGTGGTTAAGAGAGAATATTGAACTTTGAGGGGTTCAGATTAAATTCCTGATACCCACAATGTGC
    ACCTCATAACCACATGTACATATAGAAAACTCAGTATAAATGTGGCCTCCGTGAGCACCACACTACTCCC
    ACAAACACATATACACATAATTAAAAGTAAAGATTTTAGAAAAATGGCTAATCTAATGATAGGAAGTAGT
    CAAAAAGAGAGTTCTTTTGTCATGTACATATGTGTAGCAGACTTAAATGTTAAACATTCAAGAATACATT
    CCTCGATCCACATTAAAATTTTGCAAAGAGTAGCACAGACGGTGGCAATTGCTAAACTTATATCTAGAAA
    CACAATTATGTGTGGTGATATTTAATTACACATTTATACCAGGACATATGACAATATGGAAACCAAACAT
    GTTGTATCCACATGCTCTAAGGAAAACTAAATGGAGTGTGATAAAACCAAAGAAAATGTGAATATGAAAT
    ATTTTTCCAACTCTGCATCTTAAAACGGTTTCTTTCATGTGTCATATCTGCTATGAGGACTTTCTTCTGC
    CCATGTCCAACTCCAGAGCATGCCACAGCAGGAAGACCTACAGGTATTACTTCTCTGCACCCAGGAAAAC
    CACCTCTGTCCTGACCCTGCAGCTCTCAGAAGAGCCCAGACCTTCATTCTCAGGCCCTCATCCAGTAATC
    AGCACTGAATACAGAGCACTCACCATGGACTTTGGGCTCAGCTTGGTTTTCCTTGTCCTTATTTTAAAAG
    GTAATTCATAGAGATAAGATTCTATCTGTTTTGTGTACATGAGAAACAGAAAAATTGTATTGTTTCTCTA
    TTTTGTTTTGTTTTGTTAGTGACAGTTTCTGACTCAAGATTCTCTGTTTGAAGGTACCCAGTGTGAGGTG
    AAGCTGGTGAAGTCTAAGGGGAGGCATAGTGCAGCCTAGAAGGTCCATGATACTCTACTGTGCAGCCTCG
    GATTCACTGTAAGTGACGACTGGTTTGTCCGTGTTTGCCAGGCTCCAAAGAAGGGGCTGCAGTGGGGGAT
    GGGAATAATTTTTCATGGTTGTGGTAGCCCCTCTTATGCAGACACCTTGAAGAAGTGGGTTGGACGTAAC
    ATATTCAGAATCAATATTTAAAGATTCTAATCCTTGAAGATATCACTTTTGACCAAGTATATATGAACCA
    TGTTACTGAGGTTTATGGAGGTTTGAGTATGTTAGGTCCATGGATAGGGAAAATATTAGGGGATTTTAGG
    AGTAACTGAGGCTTGTTGTAGGAAGGACATCACTGTAGGGGTAGGCTCCGTGTTCCTATCTTCAAGCTCT
    ACCCAGTGCAGAATAGAGCCCTCTTCTGCCGGCAAGTGGAAAGAGTTTCTCTTCCTGGCTGCCTTCAATC
    CAAGTTGTAGAATATCAAATCTCCTAACACTATGACTGCGAGCATGCTGACATGCGTCCCACCATAAAAA
    TAGACTGAACCTCTGAAGCTTTAAGCCAGCCTCTAGTAACTGTATTCTTTAATAAGACTGAACTTGGCTA
    TGGTGTCTTTTCACAGTAAAATGGAAACATAGACAAGGTTCTAACTCTCTGTACTAGAGGACCATCTCTA
    TGTCCTTGGTGTTGTATGTAAATTATTGAACAAATACTATAGACAAGTTGTATGGCCAAAAGTCCATCCC
    CTTCAACAATCTACTATCTGGAACCATATAGATTAGATTCCTTTCCTGCACTCATTTCCCTTACTTGCTG
    AGACATTTTGAAGACATGCTCAGAATCCCTGAACTTCCTGCTGAAAAAAAAATACCCCTCCAATTTGAAG
    ACAGTTCTCTTCCAAAATTCATCATAAATACTGATCCACATGTCCAGGCATATCATGTAGTTTTAAAAAA
    CAAACCAATCAATGCTAAAGTGGGTAAGTGCCTACATCATTGGTTTATGTCTGTTCATAACCTGGTATAT
    AGCTAGAGACCAGGACTGCATGTTTCTCCTAGGCCACACCTCTCCCACAAATGCTGGCTCTGCCTCTCCA
    GAATTCCAAGATCATGGATCTCTGGGTCCCCAAGGAACAATAAGTGTGCACTCTTGCCAGCCTGTACACT
    ACTGCACTAGCTTCTCCCCCTGGAGCTTGGTCATTGCTCAATCTTCCCTTTCCAAAGCCTGGCCAAATTC
    CTCCTACCTTTTGTTCTTTCAGTCAGGCCACCTAAGTCATCTTGAATGAAAAACAACACAAAATCTGAAC
    TTAAAATCAACAAATAATACAAGTGCTGCGCACAAAATCAATCATTCTAAACTCATCAACTATTTTATGA
    TGGAAATCTTCCAACATACAAGCTACCACCAGGTCTAAGAATTACTCATCTACATGTTGCTTCCTCTCAC
    TCACAGCCTAACCATAAAAGGGCTGTTTCTTCCTCCCATGTCCCCTCTTTTGCCTTCAGAAGCAGAAGCT
    CCACCTCCTCCTCTTTGCCCAGCAATTGGCTTCTTGTCGTCTTTATTATCATATTAATTACTTAGGGGAA
    AATCCCGTGTAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGG
    AAGGCTCACCAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAG
    CCATAGGGGCTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACG
    CCTTTCATCTGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAA
    TATAAGGACATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTG
    AGTAACTGCTAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGA
    CTCTAAGTCATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTG
    ACTAATACAGAAGTTGGTACCAGGAGTGGTTCTAGAGTAACAGAAGTACAAGGATGAATCTTTTAAAATA
    CTGGAATTGGCTTGTTGATCCACCAGCACTTTCAACTATTGAAACCTCTCCAGATTCTCTCCCTCCTGGG
    AGCTCAGAGAATTTTGAAGACCCATGGTTGAAACTATATTCCGAACTTAAAGAAGCAAATGCCCTTGATT
    TTCTTAATGAATTAGGTGATTCAGTGCACAAAGCTTTCTACAAGATGGGGAAAAAATTGGAAAATGATTT
    TACTGGCTGGCTGCTCTTAGTATCTGTGGAAAAAATGATGAATGAAAGGAAGGAGTTGTGTGATAAAATC
    GAAAGGCTCCAGACACAAGTAAACGATCTAAAAGTTGCTAAGTGTGTCCTTGAGGAGAATCTTCTCTCTT
    GTAGCAATAGAGCTCAAGTTGCAGAAAATCAAACAGAAACTCTCATTGTAAGGTTGGCTGAACTACAGCG
    AAAATTCAAGTCTCAGCCTCAGAGTGTGTCAACAGTTAAAGTAAGGGCTCTAATTGGCAAAGAATGGGAT
    CCTACAACATGGGACGGGGATGTGTGGGAAGACCATGTTGAAGCTGAGAATTTTGAATCTTCAGATTCTC
    AAGGGTTTGCCCCACCTGAGGAAGTAGTACCCTCAGCCCCACCCCTTGAAATAATGCCTTCCCCACATGA
    GGAAATTAATTTTGCAGAGTCTGATAAACCAGCAATGATTTTCACTACTGATGTTTCTCAAGGCCCACCA
    ATAGTTTCTTCTAGACCTGTAACCAGACTCAAAGCAAAACAGGCTCCTAGAGGGGAGGTAGAAAGTGTAG
    TCCATGAGGAAATTCGCTACACTACTAAGGAGCTTAATGAGTTTGCTAATTCATTCAAGCAGAAACCTGG
    TGAATATGTGTGGGAATGGATTTTAAGGGTGTGGGATAAGGGTGGAAGGAACATAAGACTAGAGCAGGCT
    GAGTTTATTGACATGGGTCCTCTGAGTAGAGATTCTAGGTTTAATACGGAAGCTCGCATAATTAAAAAAG
    GTGTCAAAAGTTTGTTTGAATGGTTGGCTGAGGTGTTTATCAAAAGATGGCCTACTGGAAATGACTTGGA
    GATGCCTGATATTCCGTGGCTTAGTGTTGATGAAGGGATTTTAAGACTTAGGGAAATTGCAATGCTAGAG
    TGGATATATTGTGTAAAGCATAATTGTCCACAATGGGAAGGTCCAGAAGATATGCCTTTCACTAGCTCTA
    TAAGACGCAAATTGGTGAGAGGGGCACCAGCACATTTGAAGGGTTTTGTTCTTTCCCTTTTCCTTGTACC
    AGATCTTAGCATTGGAGATGCTTCTGCTCAATTAGATGAATTAAATTCACTGGGTTTAGTTGGATTCCGA
    GGTAACAAGGGCCAGGTGGCAGCATTGAATCGCCGGAGACAAGGTGATTCTAGTTATTATAATGGACAGC
    GTAGACAAAAGAATGTTTATAATAACATACCCAGCAATGGTCAGCACAGGAGAGGTGAAATTTATAATGG
    CATGACTCGGTTGGACCTTTGGTACTGGCTAACCAATCATGGTGTTTCCAGGAATGAAATACATAGGAAG
    CCTACTGCATATTTGTTTGATCTGTATAAGCAGAAAAATTCTCAAACAAATGAAAGAAAGGCTACATTAG
    ATCATGGTAAACAGCAATCTCGGCCAGTGAATCAATTTCCAGACTTGAGACAGTTTGCAGATCCAGAACC
    CCTTGAATGAAGGGGTGGCCAGGTTCCGCTGAGGAAGGATCTTGATAAGACACCCAAAGGTTTTGCTGTT
    ACCCTTTCTCCAGTTCTTCCCCAGAGGGACCTAAGGCCTTTTACAAGGGTAACTGTACACTGGGGAAAAG
    GAAATAATCAGACTTTTCAGGGTCTGCTGGATACTGGTTCTGAGTTGACACTGATTCCAGGGGATCCCAA
    GAAACATTGTGGCCCTCCAGTTAAAGTAGAGGCTTATGGAGGGCAGGTGATTAATGGAGTTTTGACTGAT
    GTCCGACTCACAATAGGTCCAGTAGGTCCCCAGACACATCCTGTGGTGATTTCCCCAGTTCCAGAATGTA
    TAATTGGGATAGATATACTCAGAAATTGGCAGAATTCTCATATTGGTTCCCTGAACTGTAGAGTGAGGGC
    TATTATGGTTGGAAAGGCCAAATGGAAACCTTTAGAGTTGCCTCTGCCAAAGAAAATAGTGAATCAAAAA
    CAGTATCGTATTCCTGGAGGCATTGCAGAAATTACTGCCACTATCAAGGACTTGAAAGATGCAGGGGTGG
    TGGTTCCCACCACATCTCCGTTTAACTCTCCTATCTGGCCAGTGCAGAAAACAGATGGATCATGGAGAAT
    GACAGTTGATTATCGAAAACTAAATCAGGTAGTAACTCCAATTGCAGCTGCTGTACCAGATGTAGTTTCA
    TTACTTGAGCAAATTAACACATCTCCTGGCACCTGGTATGCGGCTATTGATCTGGCAAATGCCTTCTTCT
    CAGTACCTGTCCATAAGGACCACCAGAAGCAATTTGCTTTCAGTTGGCAAGGCCAACAGTATACTTTCAC
    AGTTTTGCCTCAAGGATATATTAACTCTCCTGCCCTGTGTCATAATTTAGTTAGAAGGGATCTTGATCGT
    TTGGATCTTCCACAAAATATCACATTGGTGCACTATATTGATGACATTATGCTGATTGGACCAAGTGAGC
    AGGAAGTAGCAACCACTTTGGACTCATTGGTAACACATATGCGTATCAGAGGATGGGAAATAAATCCAAC
    CAAAATTCAAGGACCATCTACCTCAGTGAAATTCTTAGGAGTCCAGTGGTGTGGAGCATGCAGAGATATT
    CCTTCTAAGGTGAAAGATAAGTTATTGCACCTGGCCCCTCCTACAACCAAGAAAGAAGCACAACGTTTAG
    TGGGTCTATTTGGATTCTGGAGACAACACATCCCTCACTTGGGTGTGTTACTTAGGCCTATTTACCAAGT
    GACTCGGAAAGCTGCTAGCTTTGTGTGGGGCCTGGAACAGGAGAAGGCCCTTCAACAGGTCCAGGCTGCT
    GTGCAGGCTGCACTACCACTTGGACCATATGACCCAGCAGACCCGATGGTACTTGAGGTGTCTGTGGCTG
    ATAGAGATGCTGTTTGGAGCCTCTGGCAGGCCCCTGTAGGTGAATCACAGAAAAGACCTTTGGGATTTTG
    GAGCAAAGCTCTACCATCATCTGCAGACAACTATTCTCCCTTTGAAAAACAGCTCTTGGCCTGCTATTGG
    GCCTTAGTGGAAACTGAACGTTTGACAATAGGACACCAAGTTACTATGCGACCTGAACTACCCATCATGA
    GCTGGGTACTATCAGACCCTGCAAGTCATAAAGTGGGACGCGCACAGCAGCAGTCTGTTATCAAATGGAA
    GTGGTATATACGTGATCGGGCCAGAGCAGGTCCTGAAGGCACAAGCAAGTTACATGAAGAAGTTGCTCAA
    ATGCCTATGGTTTCTACTCCTGTTACACTGCCATCTGCTGCCAAACATGTGCCTATAGCCTCATGGGGTG
    TTCCCTATGATCGACTGACCGAAGAGGAAAAGACTAGAGCCTGGTTTACTGATGGCTCTGCACGTTATGC
    AGGCACCACCCAGAAGTGGACAGACAGCTGCAGCATTACAACCCCTTTCTGGGACAACCCTGAAAGACAC
    AGGTGAAGGGAAATCTTCACAGTGGGCAGAACTTCGGGCAGTACACATGGTATTACAGTTTGTTTGCAAG
    AAGAAATGGCCAGATGTACGATTATTCACTGACTCATGGGCTGTAGCCAATGGATTGGCTGGATGGTCAG
    GGACTTGGAAAGATCACAATTGGAAAATTGGTGAGAAAGACATCTGGGGAAGAAGTATGTGGATAGATCT
    CTCCAAATGGGCAAAGGATGTGAAGATATTTGTGTCCCATGTAAATGCTCACCAAAAGGTGACTTCAGCT
    GAGGAGGAGTTCAATAATCAAGTGGATAAGATGACCCGTTCTGTGGACAGTCAGCCTCTCTCCCCAGCCA
    TCCCTGTCATTGCTCAATGGGCACATGAACAAAGTGGCCATGGTGGTCGAGATGGAGGTTATGCTTGGGC
    TCAGCAACACGGGCTTCCACTCACCAAGGCTGACCTGGCTACAGCTGCTGCTGATTGCCAGATCTGCCAA
    CAGCAGAAACCAACACTGAGTCCCAGATATGGCACCATTCCTCGAGGTGACCAGCCAGCAACCTGGTGGC
    AGGTTGACTACATTGGACCACTTCCTTCGTGGAAAGGACAGCGTTTTGTTCTTACTGGAGTAGATACTTA
    TTCTGGTTATGGATTTGCCTTTCCTGTACGTAATGCCTCTGCTAAAACCACCATTAACGGACTGACAGAA
    TGCCTTATCTATCGTCATGGTATTCCACACAGTATTGCTTCTGACCAAGGAACTCATTTCACAGCCAGAG
    AAGTACGACAGTGGGCCCACGATCATGGAATTCACTGGTCTTACCACATTCCCCATCATCCTGAAGCAGC
    TGGTCTGATAGAAAGATGGAATGGCCTTCTGAAGACGCAGTTACAGCGCCAATTAGGTGGTAACAGCTTG
    GAAGGCTGGGGTAGAGTTCTTCAGAAGGCAGTATATGCTTTGAATCAGCGCTCGATATATAGTACAGTTT
    CACCCATAGCCAGGATTCATGGGTCCAGGAATCAAGGGGTGGAAAAAGGAATAGTTCCACTTACTATCAC
    TCCTAGTGACCCTCTAGGAAAATTTTTGCTTCCTGTCCCCATAACTCTAGGTTCTGCTGGCTTAGAAGTT
    TTGGCTCCAGAGAGGGGAGTGCTCCTACCAGGAGCTACAACAAACATTCCATTGAACTGGAAGCTCAGAC
    TTCCCCCTGGTCATTTTGGGCTTCTAATGCCCTTAAACCAACAGGCTAAAAAAGGAGTAACAGTGTTAGG
    AGGGGTGATAGATCCAGATTACCATGGGGAAATTGGATTACCTCTTCACAATGGTGGTAAGCAAGATTAT
    GTCTGGAGTGTAGGAGATCCCTTAGGGCGTCTCTTAGTACTACCATGTCCTGTGATTAAAGTCAATGGGA
    AACTACAACAGCCTAATCCAAGCAGGATGACAAAGGACACAGACCCATCAGGAATGAAGGTATGGGTCAA
    TCCTCCAGGAAAAGAGCCAAGACCTGCTGAGGTGCTGACTGAAGGAGAAGGAAATATAGAATGGGTAGTA
    GAGGAAGGTAGTTATAAATACCAATTAAGGCCACGTAACCAGTTGCAGAAACGAGGATTATAAAGTAATA
    TGAATGCCCATTGTAAATTTACTAATGCGTTTGCGATTGTACGAGGGATAGTTATATCATGTTAGGCGTA
    TTTACAAACTTGTTATTGTTTTATGTGAACATGAGATATTATTTGTGTCAAGTTGACAAGGGGTGGATTG
    TAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGGAAGGCTCAC
    CAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAGCCATAGTGG
    CTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACGCCTTTCATC
    TGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAATATAAGGAC
    ATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTGAGTAACTAC
    TAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGACTCTAAGTC
    ATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTGACTAATACA
    TCCCTACATACAGGAAACTTGATGTATAAGTAAAGAAAATAGTAAATCTAAAAATTTCCTTATCAAATAC
    ATGCAAGAAATCCAAAATACCATGAAAAGACCTGATCTAAAAATAGTAGGAACTGAAGGTGAAGTGTCCC
    AGCTCTGAAAACTAGAAAATGTTTTCAATATTTTTCCTAACAGTGAAGACATGGATCTAATGAGGCCACC
    TCTTATAGCCATGCAAGACTGACAGTGGAGGGATAAGGACACCAATCCACCCACAAAACTTTTGACCCTA
    AATCAGTTTTATCTAAAAGCAATGCAGGGGCACAAATGGAGCAGAGACTGGAGGAATGGTCAAACAATAA
    CCTGTCATATCTGAGACCCACCTAATTGGCATACACCAGTCACTGACATTATTAATAATGTTCCATTATG
    CTTACAGGCATTTCTCTAGCATTACTATTCTTGGAGAGACTTCACACAGCATCTTATTGAAACAGATGCA
    GACACCCAGAACCAAACATTGGATGGAGATTGGGATCCTTAAAGAAGAGTTGGGAGGATAATTGAGAGAC
    CTCAAAGGAATAGCAACCCCATAGAAAGACACGAACAGGGTCAGTAAACCTGGACCCATGGGGTATCTCA
    GAGACTGATCACCAACCAAAAATCACAGAGGGCCTGGATTGATTCCCCTGGCACACATGTAGCAGAGGTC
    TGCCTTGTCCTTCAGTAGGTGAAGATGAGCCTAAGGCTTCAGAGACTTGATATATCAGCATACAGCAACA
    CCCAAGTGTGTCCCACTATCTCAGAGGTGAAGGGGTGGAGATGGGCAGAAGGGTCCTGATAGGGGACAAC
    TGCAAAGAGGCAATATTTGGGACAGAAAGAAAGGAAGAGAGAGGAAGATAAAGAGAGAGATGAAGGAAGG
    AAACAAACAAACCAAGATGAAGAGAGAGAAAAGGGGGAAAATAGCCTTGAATGGTTCAGGGATTCAAAGG
    GACATACCTAAGCATGGTAAAACAATGCACATAATGGCAGCAAGTAGCTAACACTGAATTAAATAGAAAG
    ACACATAAAGCAGTTCTACTAAAGTAAGAGACAGAGTTGCCCAATCTCACCCTATTTATTCAATAATAAT
    GTACTTGAAGTTCTAGCTAGGGCTGTAAGACAACTCAAGGAGATCGGAGGATACAAATTAGAAAGAAAAA
    TTCAAAGAATTGTAATTGGTAGATGATAGGATAATATACATAAATGACCTCAAAATTCTTCCAGAGAACT
    CTGAAAGCTGATAAATACCTTCAGCAAAGTGGCTAGAAACAAAATTACTTCATAGAATTCAGGAGCTATC
    CTTTATAGAAAAGTTAAAGTGGCTGAGAAAGAAATTAGGAAAATCACATTCTTTGCAATAACCAAAAATA
    ATATGAATTAGCTTGGTGTGACTCTAATCTTGCAAGTGAAAGATGTGTGTGACAAGAGCTTCAGGACCCT
    GAAGAAAGAAATCAAAGAACTCAAAGATGCAAAGTACTCTAATGCTCATGGATAGGCAGAATTAACATAA
    TGAAAATGCCAAATTTAACAATTCAATCTACAGATTCAGTGGAATTCCCATTAAATATCCAACCCAATTT
    ATTACATTCTTGAAAAAGCAAATCTCAACTTCATATAGAAAAACAAGAAATTGAGGGTAGCTAACAAAAT
    CCTGAACAATGAAAACACTTCAGGAGAATTCACCATCCCCTACCTCAAGCTGTATTTTAGAGCAATAGTT
    ATTAAAACTGCATGGTATTTGTATAGAAACAGATATGATGATCAATGTAATTGAATTGAATACACTGACA
    TAAAACCACACTGTTATGGACACTTGATTTTTGACAAAGAACCCAATAATCATAATAAAAATCATAATAA
    GAATGCATCCCCCAACAAATGGTCCTGATCTAAATGCAAATAGATTCATATCTATCATCCTGCACGAAAT
    TCAAATCAAAGTGAATTGCAGACTTCGACCTAATACTGGATTAACTAAATCTAAATGAACAAAAAGTAGA
    GAATAGTTTTGAACTCATTGATGCAGGATTCAATTTCCTGAACAGAACCACAATGGCTCAGGCTCTAGGA
    TCATAAATTGGTAGATAGGATCTCATGAAACTGAAAAACTTCTGTAAGGCAAAGGCAATAAAACAAAATG
    GCAACCTACAGATTGGAAAAAAAATAATCTTCAGTATCCCTAAATCCCATTGAAGGCCAATATGCAAAGT
    ATATAAAGAACTCAAGATGTTATCCTCCACAAAACCAAATAAATCAATTAAAAATGAACTACAGAGCTAA
    CAAGAGAATTCTCAACAGAGGAATCACCAATGACTGAGAATCACTTAAAGAAACATTCAATATTTGTAGT
    CACCAGAGAATTGCAAATCAAAACTACCCTGAGATTCTACTTTATACCAATCATAATGGTCAAGATAAAA
    ATTCAAATGACAGCGCATGTTGGTGAGGATGTGTATACTTTTGCATTGCTGGTGAGGAAAACAATCTGGC
    AGCTCCTCAGAAAATTGTAAATAATTCTACCTGAAGATCCAGCCATACCACTCCTGTGCATATACATAAA
    ATGTGCTCCACCATACCACTAGGAGATATGTGCCACTATGCCCATAGCAGCCTTATTTGTTAATAGCCAA
    AAGATGGATACAACCCTGATGTGCCTCAAACAAAGATTGTATATAGAAAATATGGGTTCCCTTACACAAT
    GGTATTCTACTCAGCAATTAAAACGTGAGAACATCATAAAGTTTTCAGGCAAACTGATCAAATGAAAAAG
    TATAATCTTGAGTGAGGTAACAGAACCAAAATGACCTGCATGGGATGTACTCACTGGTAAGTGAATATTA
    GACTAAAAGTATAGAATATCAATGATGAAAGCCACAGACCATAAAGAGTTTAATAAGATGGAAAGCTCAA
    GTACGGATTCTTCAATCCAATATAGAAAGAGGGACAAAATAATCAGGGGAGGCAGAGGGAGAGAGAGACA
    TTTGGTGGAAATGGGAGAAGAAGGGAGAAAGGCAGAAAGGATCAGGCGTTGGGGAACACTGGAAAGCAGC
    CCAGGGGTCCTGGTAAATGGATTAAATATTCAGCTGAATGGAGGTGGGAGGCAGGGGGAAGCTCTGCAAA
    GTCCAAGAGACCTGGGATGTGAGAGGCTCCCCAGATGATAATCTTAGCCTTCATGCCTAACAGTTGTAGA
    TAAACCCTGAAGAGATCACTTCCAATAGATGCAGAGGGCCCTAAGTGGTTGGATGGAGTCCCCCAACTTA
    CCTCAAAATTGTCAATACTCATAGAAATTAGGACAATGAAAATCAAAACACCCTGAGATTGTATCTTATG
    TCTGTCACAATGGTTAAGACCAAAACCTCAAGTGATGGCTTGTGCTGGCAAAGATTCAGAATAGTAAAAG
    TCTCCCCATGGCTTGTGGGAATGCAAACTCTTACAACCTCTTTGGAAGTATATTTGATTGTTACCTGGTA
    TAAAATGGCAAAAAAAAAAAATGGTTGAAGGGGGACTAAAAAAGGAAGAAAGGGGAGAACTATGGGATGC
    GAAACAAGAAAGTTTGTTGCAAAAGAAATATGTTTCCACTGCAAACCCTGAGTCTCAGACAGAAGGGGAC
    CTGGAATTCTTCAGATACAAAGAATCTCTAAACCCTGAGGACATTCTATCACAAATAAGTAAAATTCAGA
    AAATTCTGAGTGCTCCCATCACGGAGATGAATCTGCTATGAACAGCTCATAGGTGTGACCCTCTACAAAA
    GCCATATTATTGAAAAGCCACATTGTGCCCAGACTTTGGAAAGACTGAGCTCATATCCTGAAATACAGTT
    ATGTGTGGTTCTATTTAATTACACATTTACACTAAGAAAACATGGCAGTATGGGAATGAAGCTTGTTCTG
    TACACATTAACAGAGGGAAACTAAACAAAGTATGGTGAATCCCTAACCAAAAGTAAAAAAAAAAAAAGAA
    AGAAAAGAAAATAAAAGTGAAACTACAATATGTTTCAAATGCTGTAACTGAAATCTGGTTTTTTGATGCT
    TATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACTCCAGAGCATGGTATAGCAGAAAGACATGCA
    AATAAGCCTTCTCTCTGCCCATGAAAAACACCTCGGCCCTGACCCTGCAGCTCTGACAGAGGAGGCCAGT
    CCTGGATTCGATTCCCAGTTCCTCACATTCAGTGATCAGCACTGAACACGGACCCCTCACCATGAACTTG
    GGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTAATTTATTGAGAAGAGATGACATCTGTTGTA
    TGCTCATGAGACAGAAAAATTGTTTGTTTTGTTAGTGACAGTTTTCCAACCAGTATTCTCTGTTTGCAGG
    TGTCCAGTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTC
    TCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGA
    GGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG
    ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGAC
    ACAGCCATGTATTACTGTGCAAGACACACAATGAGGAAATGTTACTGTGAGCTCAAACTAAAACCTCCTG
    CAGAGCACCCAGGACCAGCAGGGGGCGCAGAGAGCACATGGAGTTCTGATTCACAGAAGAGTTACAGCCT
    GTACAATTAGACCCAATCTTCAACAAACCGTCAAAATATTCGATCCAAAATTGTTCCTGTCTAAAAGTAA
    TTCAAGGACAAAATGGACCAGAGACTGAAGAAATGGCTGACCTGTGACCCTCCCAACTTTGGATCTATCT
    CATAGGCAGGTACCAAACCTTGACATTTGTCACTGACACTGTATTGTGCTTGCAGACAGGAGCATAGCAT
    GGCTGACCTCTAAGAGGCTCTGCAAGCACCTGAATGAGACAGATGTAAATAGAGTGTACAACTGGATTAA
    GTTTGAAGACTGCAATGGAAGAGTTAGAGGAAGGAATGAAAAATCTGAAGGGGATCACAACCCCAGAAGA
    AGACCAACAGTGCCAATTAAACTGGATGCCTGGGAACTCCCAGAGACTAAGCCACAAACCAAGAATCATG
    CAGGCTGGTCTGAGAATCCTGGCACCCAAGTCTCAAGGAACTGCCTTTTCTTGGCTCAGATGGGAGAAGA
    TGAGCCTAAAGCTTTAGACTTGACGCCCCAGGGATGGGCAATACAAAGTTGAGTTTCTTGGGAAAGTGAA
    GAGGATGGTGGGAGGAGGAATAAATCTGGGAAGTGGGACTGGTTGGGGACAACATATTGGTCCTAAATTT
    ATGAAATAATTATCTAATTGATAAAAAGAGTCCTTGGGGTAATGGAGGGCTAGACTCCTCTGTGCCTAGT
    TTGTAACTCTACAGGGATCCTCTTTAAAAGAATAGGGTGCACATAGAGTATATGTGTGTGACACTAATAC
    AGGGGTAAGTGTTTCTGTAAGAACTTTATGAATAAACTTTATTAAAACATCAAAAAGTATAGGTTGTAGC
    AACCCTTGACCTGTACGAATGTTTATAAAACTTTCTATTTTCCTTAATTATATCTGTTTTGCATTTGTTT
    ATTTATTTATTTACTTACTTACTTATTTATGATTTCACTGTGTCTTTCTGTAGTCCTGTATGTGTTTATT
    TGTCTCTTTATTGCTCTGTTTCTGTTTCTTTCTCTCTGTCTAGTATTGTATCTCTCTGTGTCTCTATGTC
    GCCGATTGTGTCTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATATTGAAA
    TGAGATCTCTTCTTCTATCAGTGTACATAATGACTTTGAAATAAAGTCCATCACTGGGCTTGGATATCAC
    TATCTTGTTAGAATGGTTGCCCAAAGTGTTCCAACCATCACACTGTTTCTACATATAATAGATGGGTTTA
    TTGATTTACTACCAAAACTACCCCATCTTAAGTTATGGATATTAAACACAGATCCTCATGGTGTGTTAAG
    AACTTGAAGCACAGAGCTATATGTACAGCCCACTAAAAATGACTTAAATATAAGATAAACTCTGGCTTGA
    ACAAAACACAGAGCATCACACGAGGCAGAAGTGAATCTCTATGAGGACCAGGATCACATCCCAAAGAACC
    AAAGAACACTTGAGACTGTGGAACCCTAGAGTCAGGGCTGACACTCAGTAAGATTTACTTCATAGAGCAT
    GATGTGGGATTCAAGAAGAAATCAGGCAGGGCCTGTGACCCATGAACCAGATGACTTCCAGTCTCTCCAT
    CATCCTCACACAAACCATAGGCAACAGCTCAGCACTGACTCACCTGTGATGCTGGTGACAAAATGTGTGC
    AAAGCCTCAGAACTGAGACGTGAGGCCAATGTTGCTACCGACACTCAGTGAGCTTCAATTTGCTGCAAAC
    TGCTCCAAAACAACTCAAAGGGTAACTTCTTCTTTTTCTATTTGTACTTGTGATGCCTTGGTAGATATAG
    TTCCCCAATAATTTAATAGGACAAATCATTTTTCCTTTTAACACATTAATCCCCTTTCCTTCCCCCAAGA
    TTCTAAAATTTTTCTTTAACACTGATGTCTGAGAGATATGGCATAATAGATGTTTGTCTTATTCTGAGTT
    GTTCCTTATCAAAAGAAATCAGCTGTGGCACTTTGAACCTAAATATAACAATATTTCACAAAGGCATTCT
    GGGAATATATAGATGGTATTGCTACAAAAGAATAGGAGGATCTATGGCCATACCACCCTTAATGAACCAG
    ATACTATCTAAAAGATTAGGACAGCTGGGCATGTTGGCACAGGCCTTTAATCCCAGCACTAAGGAGGCAG
    AGGCAGGCAGATTTCTGATTCGAGGCCAGACTGGACTACAAAGTGAGTTCCAAGACAACCAGGGCTATAC
    AGAGAAACCCTGTCTCGAAAAAACAAAACAAAACAAAACAAGAGTAGGAGGGTATTAGATGCGAGGTGAT
    GATGGCCATTCAATCAAACCAGAATGTGACCTGAGAAAAGGTCTAAGTTTGTCAGCTTGTCCTGGAGATG
    TGTTGCCTCTGATAAATGCAGAGCTGGAACTGCAATACATTGGATTCCTGTGAGTTACGGAGAAATAAAA
    GGAATAGCCTCTGTTTCCTTTGGTTCATCAAGTTGGCAGTGAGCTAGAAGATGATACTGGGAACCATCAC
    ATGTACTTCTACAGAGTTATTCTACATTCTACAAGTCAGTCTTGCTTGCTTTCGTTTCTGTGAGGAGCTA
    AATACAGAATGTTTTCAATGTCTCATAATGTTCTGTGCACACCCATGGGTGCCTAGCCAAGGATAGAAAC
    TTGTATCTGATAAGGAAAGAGGATGCTGCAGTGGCCACACTCTGAGATCACCTCCTGCCAAATTATACTA
    GAGTGTTTTACATAGTCTTGAAAACACTAGGTCAAATATGTTGTCATCCAGATATGAAAACTCTGTGCAA
    CAATTCAGAAATACAGTGGTCAGGACAACTGGTATGTAACACTTTAGTTCCAGCCCACATTAATCTCACA
    TCTTTTCTGTGGTTTCAATAAAGAGCACACATGTTTGGAACACCATCTCCACTTTGTATGCTTATCCTTA
    TGCATCAAACTTTTCCTGTAATTTCCTACCCCGCACAGGTTCCTGTCTTGATCTCTTTTTCTAATGAACA
    GCAATACAGAAGTGTTGGCCAAATGAACACTTTCACCCCAAGTTGCTTTGCCATTGTGTTTCATCACAGC
    ATTAGTAACTCCCAGTAAGGCTACTGGTTACCCTGCATCTTCTATGTAGATCTTTTGATGAAGTTCCAGG
    CTTGGGGTCTTTATCTGACTGTTATCCTGGTTAATTCATGTCCACCAATAGAATATTGTTCTCATTTTCA
    ATATCATATGAAGTTACCTGTTTATAGGATCTTCCTAAAGCAGAAAACTATATAAAATGTCTGCTTACTT
    TAAGAAAAGTATGTGTCCTTGGAGGTAAATGGAGGAAAGGGTGGAGGATGTTGAGTAATGGAAGACTGGC
    TAATACAGGAAGGTCACAGAATTGAATGATTTTAAAAATTTTAACTCCTCATCAATGAGGTACTTCAAGT
    TGAGGCAGGAGTCCTTGATGCACAGGTGACCCAAAGGCCCCAGCCTCTGTTTCTTGGTCTGCTCCAGTCT
    CCCGGCTCAGCACAGTTCACTGAGTGACAATCTTTAAGATAGTCTTTCAGGATACAGTTATCACAGTTTT
    CAAACTCTCTTCATTGAAACAATATAATGAGTCAGAGTCCAGTGTGCCATTAATAGGCCCTATGCAATAG
    GATTTTACTTCATCTGTGGAAAGAAACCACCATGGCCTCATCAAGGCCTCATTTGATGATTAGTGTAGAA
    AGCGTCCCCAGAGCTTTGCTGGGATGAAAACCCTGGCAAGATGTTTAGGGCACTCTCCATCTGACAGGAC
    AATTCTATCAAGGGTTGCTTCCATATAGAGAGAAATCTCCACATCTGCAGTATTTCCCGATTTATCAACA
    GTTCTTTACCCCGTGTCATATGCATAAAATCTTTTCTCTGTAGAATTTTCAGTACTAAAAACTAACAAGG
    ATGTTGGTCCTGATATCAGACATAATAAATAAATAAACATCAAATTATACCCTAAACATGTGGAGATGGT
    TTTCTGTTATGAATTTATTGGCTCTCTAAAAAGTGTTAATTAAGCCAGGCGTGATGGCACATGCCTTTAA
    TCCCAGCACTTGTGAGGCAGAGGCAGGCGAATTTCTGAGTTTGAGGCCAAACTGATCTACAGAGTGATTT
    CCAGGACAGCCAGGGTTACACAAAAAAACCCTGTCTCCAAAAAGTAACAAAAAGAAAGTGTTAATTAACA
    TCTACACTTTAAGATAATTTGGTGGCAAAGGTTAATAGTCTGAAATACTAGATATGAAAGTATGACACCT
    AAATTGCATGCAGAGAATAAAGCTGAATTCCAATGAGATTCATGCCTTGTGAATCCATTCCAATCTGATC
    TCAATCTTCAAACATGTTTGTGCATAATTTACATCTTAATCAGTTGCTGGAAATTAAAAGGACATAAGCT
    AAACTTAAAACTCTTTCTATTTAATGTGTCAGAATAGAATATGTGCACTGAAGTTTTCATGTGCATAGGA
    TATCATTGTTACAATGATGGTTCAAATACGCACCAGTAGCACAGGTGATGCTTGACATGAAAAAAACTGT
    GACCAGAGCCCAGACGTTGATGTTGGCTGAAAGAGCCTAGTGTCTCACATTTGATCAAGCAAAGTGTTAT
    TCAGAGAAGCAGTGCCAGATTTGGGATCCTTCTTAATGGATCAAGAACATGAGGAAGATTTGGAAGCCAG
    ATTGATGAGATTACTAGAATCCTGGATCTGAACACACAACACACAATAGTAAGTTGAACTTTTCCACGCA
    ATGCTAAAGATAAAGCATCCAGTATCATGTTATACAGGACCAAGGTGAGGATCAGTCTGTGGGTGAAGTA
    CAATGAACTGGAAATTGTTTGGATTTTAAATGTTGGTTTTTAAATTATATATAAAATATATATATATATA
    TATATATATACATATATATATATATATATATATATATATATATATCGGAACCAACATTTAAAATTTGGAT
    TTTAAATGTTGGTTTTTAAATTATATATAAATTATATATATATATATATATATATATATATATATATATA
    TATATATATATATATCGGAACCAACATTTAAATTCCTAATTCTTAAGGACTTCACTTTTGACCAAAAATA
    TTTGAAATGGGTTATTTAGGTCTGTGGTGGTTTGAATATGCATAGCCTATAGGAAGTGGAAGTATGGCCA
    TTTTGTAGTATGTGTAGCCTTGATGGAGGAAGTACATCACTATATGGTGTTGTGAGAGTTGAGATCCTAT
    GTTCAAGTTCTGCCAAAAACAGAAGAGAGTCCCCTCCTGGATATTTGAAACAGATGCAGAGGCCCAAAGC
    CAAACATTGGGTATATCTCAGGGTTTCTTATGGAAAAGTTGGCTGAAGGATTGAAGGCCTTAAAGGGGAT
    AGGAACTTCACAGGAAAACCAACAGATTCATCTAACCTAGACTCTAGGGGTCTTTCAAAGGTTGAGTCAC
    CATACAAAAAGGACACAATGGCTAGACCTAGGTCCCTGATACATATGTAGCAAATGTGCAGCTTAGACTC
    CATGTGGATTCCCCAACGACTAGAGCAGGTATTGTCCCTGAAGTTATTGCTTGTCTGTAGAATACATTTC
    CCAACATAATTGTCTTGTCTGGCCTCAGTAGGAGAGTATGTTCCAATCCTGGAGAGACTTGATATGCCAG
    GATTGAGAGATTAAGGGTCTCCCACCATCTCAAAGTTCATGGGTATGACAGGGGAGGGGCAGTGCAGGTT
    TTCCCCATCTCTGATTTCCAGCATTTGCACCCCCAATATTGAGGGGGAGGTCTAGCAATTGGAGGGGGGA
    CAAACAGTATGAGAAAGCTAACTTTAGTGGTGTTGTCACAGTGTGGGGTATTGTGGGTGGGAGTGGAGAT
    GAATCCTCCTCCTCCTCAGGAGGCTGTAGCAGGTGCTTGCCCTCTTTTGGGACAGTAGAGCTGTGGTCAG
    TACTGGCCTGTTCCTGACAAATTTATTCTGTGCTGTGACCATTTATTCAAGGGAGGAAGATTTAAGACTT
    GCTATGATAACCTGACGAATCTGGACAAACAAGAGACAGGAGGTAACACCTGAGTTACTCTTTTGCTTGC
    TAGTACAGAAGAGCACTATAATCCACAAATTGGGGTCCCACATATTCTTGAGTGGGATCCAAGGTGCCAT
    AATTTCAGCCACATTCCAAAGTCCCTCAAGGTCTGACAGTTTAGTCTTTAGGCTTCTCCTAACCAAATCA
    TATTTGGAGTTCTTTAACATAAAAGGGTAGTTTCCCCATATCACTGCCAGCAAAACAGGTTGAATTTGGA
    CAGACAAGCAAAACTATCACAAACAAGACAGACTATGTGTGCGATCCAAATGTCTTGTGATTAGAGGGGA
    AGTTCTGCAGCTTATTAGGCTGTGTCCTTATGCCCACAAATGTCTTCAGATAGGAAAGGGCCATTGGGTG
    CCAATCCTTAGTTCTTCTGTTTCCTGGGCTGTCAGTTTTTATGTGGAGAAGACATGAACCAAATGCAAAG
    TCATGTATCCTACAAGAACTGACATACACAGACAAACAAGGAATAACAATGAGCTCTCTCATTCACCTAA
    GGGGGTCTTATAACATAGAACAGAAAGGGGCCAACTTAGCAAGAATTGACCAAAAGGTGGTCACCTAGAC
    CACACCACAATGCAGGAAGGATATCAATGAAGGAAGAACAAAGGAAAGGCCAAATCAAGTTTGTTGGCAC
    ATGACATAAAACAGTGCTCAAAAAACAATAGATGCGAGCAAAATGAAGCATTGGAATCATATCGGGGTAC
    ATAGGGGTCACTCTTACCCCTGTTCAAGTGCCAGATGTTGTTTTAGCCTTAGGCTCCCTGAGTTTGTCTT
    TAGGGGAAATGGGTAAGAATACACAAAAATAATGTCACAGAATCTTAGAGGCAGATGAGAAGTCAAAGCA
    GACTCATTTATTGCTATAGAAAAGAATGCCTTTATACCTTCTGTCCATAACACCTCTGCCCATATATGCT
    CATCTCTGTGAGGCAATGGACTACCTGCAGACAGGCTGGTATCCAGTCAAGCTGAGGTCTGAACCACAAT
    GGTCGTAACTCACCTAAAGGACGTGGTAGGCATGACGCGATAGGCGTTCCCTCATGCTCCTGGAACTCCG
    GCCCCTGCCTAAGGTACCACCTCCCACAGCCCCCACAAGAGAAGCATGGTCAGTAGTCATGTAAGCAATG
    GCCCAAGCTTCTGACCTTCAGCCTAAACTCCTCCCCAGTTACCTAGCAACAGTGAAGACCATAAAATGGG
    ATGTTAGGCCCCCACCTCACTCTCTTACTCCTTTGTTCCTTTACCTCTCACTTCTCTCAATTCTCTCTCC
    TCTTCCCTTTCTTTGTCTTCTTCTTTCCTTGTCTCTCTGTCTTTCTCTTTCTCTCTAGCCTTCTCTGCCT
    CTCTCTCTCTCTCTGTCTCTCTGTCTCTCTCTTCTCTCTTTCCCTTGAATTTCTTTTTTTCTTTTTTCTT
    TTTTTGATGAGCACAGTATAAATAGTTTATTGCATTGTTTCTGAATGTGGCTGTATTCTCTATTGTTCTC
    TTTCTTATTTTTTTTCTTTTTTTGGTTGTTTTTGTTTTTATAGTCTCGCACAGAATTCTACATCTACCAA
    ATCCCCATTGTGTACTTTAGTTTTGTCTTGTATTCAAAGGTTCTTTCAGAAAGAATCTTAAAGATGAAAT
    TTGCCTTCCAACTTTTCAAAAATACATATAAAGATAGATGTTACATAGTTCACGGAATAGACACATATAC
    GGAGATGCAGCAATATCTCCTTTGTGCCTCTTGTATATTCATGTTATTTCCTCAACTAAAAATACATAGC
    CACAAAGACATACAATGAGCACTCCACTTAGGAAAATATGGCCATATTTTTTTACATTTTTATGATTTTA
    TGATTAGGTATATTCTTCATTTACATTTCCAATGCTACCCCAAAAGTCCCCCAACCCTTCCCTCACTCCC
    CTTCCCCACTCCCACTTGTTGGCCCTGGAGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAATG
    GGCCTCTCTTTCCACTGATGGCCCACAAGGTCATCTTCTGATACATATGCAGCTAGATACATATACATAC
    ACGAGCTCCAGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGCAGATCCCTTCAGCTC
    CTTGGGTACTTTCTCTAGCTCCTCCATTGAGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCA
    CTTCTGTGTTTGCTAGGCCCCATTATAGCCTTGCAAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTT
    GCTAGTGTGTGCAATGGTGTCAGCATTTGGGGGCTGATTATGGCATGGATCCCCGGATATGGCAGTCTCT
    AGATGGTCCATCCTTTCATCTCAGCTCCAATCTTTGTCTCTGTAACTCTTTCCATGGGTGTTTTGTTCCC
    AATTCTAAGAAGGAGCAAAGTGTCCACACATTTGTATTCATTACTCTTGAGTTTCATGTGTTTCCCTTGC
    ATTTCTATAATAAACCATAAGGAGTCTCTGCTCTACCAAGACCCGCTGCACACTCTGGTCAGTGTTGGGA
    ACTTTTCCCCTATTCCCTCTCTCCTATAACTCCGGGGCTACAGGGTGTCTCCTTTGGGTCCCGGTTGGGA
    GCTGTCTCTTCTCAACCCCCTGACTCATGGGTCAGAGGCCTAAATCTCCACCCAAGGCTGTGTGAAAAGC
    ACCGGGTGGTCTCCCCATATCTCCCTGTCCAGAGCACAGGAACTCTGGCCGGACATGGCATATTTTTCCT
    CCCCAACTTCTTCCCCGGCCTCCTCAGGGCTGTCCCTTCATTTTGTTCCCCACACATCTCCACATGGCTG
    CCACCATCCAATTGGCTGCTGAGGTCACACACTCTGTCTTTGTTCTTCTCTGAGTCTCATGCAGGTTTTG
    TGTTAGTAAATGCAAAAGTGCCTGCTGTGCATGCATGAACCATTACAGGCTGCTAGGCAGAACATGCTGA
    CTTGCTCCTGGATTATAAATCCATCACTGTGATAGCAGGACATATCCAGAAGACATTATTTAACAACACT
    CCTCTTCGTGCTCAACCTCTCATGGTCTTTCTACCTCCTCTTTCTTAGTGTTCTCTGAGCCTACATGAAA
    TGTGAACAAACCTGAAAAAAATCTCTGTGTCAAATACATAGTGTGGATTGGGAAGGAAAAACCCTGCACT
    TGTGTGTGGGCAGGGAAATGCTGGTGCTTTAACAGGACAAGTGCGGTGTGGCTAGAGAAAGTGATGAGAA
    GAAGGGAAGCATGAGAACTGGGTGGGTGGATCCCATGTCTACTGAAAATGCTATGTTGATGTCAAGATAT
    TGTGTCTTGTTACAAAAATTCATTGAGTACCTAGGTTATTCTCAGTATATAAAAGGGGAGGAATGAAACT
    AGAATTAAACACACACACACACACACACACACACACACACAAACACACACACACGAGTAGAGAAAAGAAA
    TAGTCATGAGTTGCCTAGTGAATGAAGAGCGGAAAATGGTGCAGTTAATAGGGATCATAGAAAGAACTGG
    GGGATGCACACGAATGGGTTTCCTGTAATTATGTCTTCATAGTAATCTCTGCTCAATAATCAGACAGTGA
    CAATGTATGCCTCATTTACAAGCCCTGATGGCCTCTCAGAGGAAAGCATCTCTCTGAAATGAATAAAGTT
    CAGAAATGTCCTAAGTGTCCCTGTCACAGGAAAGCAGTGTTGGTAACGTTTCCAGGAAGCTCAGTCTTTG
    TCAAATATCCACAACAAGAAGAAGCCATGTCTAGACAGACAACAGACTGGGAAAGACTGAGCTCATGTAT
    GGAAACACAACTATGTGTCATGCTTTTATTTTCACATTATACTGAGGGGATATGACATTATAGAAACACA
    GTTTGTTCTTTGCATATGCTGAGAGAGGAACTAGATGAAGTGTGCTAATTCTTAGCAATAAAAAGATATA
    CAAAGTGGTACTTTACTGTTTCAATTTTTGTAACTGGCATCATTGTCTTTGATATTTTATATCTTCCTTG
    AGCACTGCCTTCTCTCAAGTGTCCAACTTCAGAGTATGCTATAGCAGGAAGACTACCAAATAAGATTAAT
    TTTTTTGTACCCATGAAAAAATTATGTGCCCTGACCCCTGTTCTCTGAAAGAGGAGCCAAGTTCTGGATT
    CCCAGATCCTCATATTCATTGATCAGCAGTGAACACAGATCATTCACCATGGACATGGGGCTCATCTGGA
    TTCTCCTTATTGTTTTTAAAAAAGGATTTCATTGGGAAAAGCTGCCTCATATTTCTATGACCAGGAGAGG
    AAGATACAGCTAGAGACACAAGCCCCACCATGTAAAATCTGTATGGTACTCTCGTTTTCATTTTACAACA
    TTTTGCTTTTGCATTGCAAAGGAGCAATAAGGGTTCAGCAATCAGCACTGTAACTGTACTTTTAAAATTT
    CCACCTCTACCCTCTGTGTCCTCTATCTAGTGATAGAAAGTGAAATAAGCACATAAAGCATGGGACAAGA
    AGAACACACAGAGGAGCAGAGACTGGCTACAAGTGGCAGCCAGCATGGAGCTGGACAGAATTTAAAAAGA
    TAAAGAGAAATGTCATGGCATGAAGCAGTGACTTTTTCTGTTCACAATGCCTGCAAAAACTTTATGGAGC
    CTACTACTGCTGAGATATGCAGGTTTGGTTCCAGAGAGGATTTTCTGTTTTATTTAATTTGCTTTTAAAT
    TTTTCTTCTTTGTATAGTCTGTATTTTTAAAAAGGGGTTGAATGAATACCTAAGCAGTTGGAAAATTTGT
    GAGTAGAAACCGAGGGCCTGAGAAACAAATAAATCAAAATTTTGAAATGGCAAAAGAAAGGGTTCATTCT
    ATTTTCTCTTTTCAGAAAAGGTTGCAAAGTTGGATGTGCAAATGGAGATGTTATGGGTGGACTTGGAACA
    TCTTGGGAAGGAAGGAACCCAGGAAAAGAAAGAATGAAATGGCTCAGCCTCAATGACTGAGCAAGAGAGT
    TAGAGTCACCCACAGGAGAAAAGAAGAAAATAAACAGCACTGGGGTGAATTTGGGTCAGAGAAAACCTTA
    AAATGCCAGAGGACAATGTGATGAAAGAGACCATTTGAAAGAAAGGGTTAACCTCATTCCATCAGTCATG
    CCAGAGTTAGAGAATGGGCAGTCTGGAGTTACAAGATCACGATTAGCCTTCCCAGTATGTATACAGCATA
    TTCCTGATAATGAGATGAAGCAAAGTTTGACAAGGTAAGATTGTATCCTATAGTAATATATAGATCAAAG
    GCATGTTGCAGTAAATCTCCAACAGAAATAAGCCCGGGCAATGAAAACACAACTCAATTAATATGAATAC
    GTGCTGTGCACCTAGACTGGGCAGATCTACCACTCCACTACCATATGAGAGATCCCTTATAACTTGTGGT
    TTCTCCAGGCCAGCTGCTTCTGCTCTACTTTCCTTCCTCCTCCTCCTATGTCATCCTCTCCCTCACTCTT
    TCTCTCCCAAAACTTTCAGCTGCACCTTCCCCTCTTCATCCCCCAATCAGTGGCTCTAGCCTTTATTTAT
    AAATTAAGGTAGGAAGAAGGTTTATAGGAAATTACCTGAGTGTTGACGTGTTGATAACCCCACACAAGAG
    AACAAAATTAATATCAAATATGATTAGCTCCAGGGTTATATGCAACAAAGGCATGATAAAGTGGTCATGA
    TTTCATATGAGATGTACTGGACTCATGTGAAAAAACGTTTAAATACATGGGCTTACTCAAAATATAGACT
    CATACCCCCAAGATGGGAAGAGACTGGTAACATTTGTACTGGAGGCTGGTCTGCTGTGGCAGCCATTAAC
    ACAGTGGAGGGAAGAGCCTCAAAGAGTGAAATAGAGGAAGGGGAACAAATACAGTAAACCACCAGTTACT
    ACTTAAAGGGCAGTGTTCTGATGTCCTAGGGAGGGCACTCCAAAATACCAATGGCCTTATCCTTAAATTT
    ATTGTTTAATGAGCCTACACTGATCTCAGTGGCCCACTACTAAGGAGAAATGACAGGCACTTGAACAGCT
    GATATGAGAACAGCTGGAGGCACAGTATACAGAAGAGTTTACAAGCCTATGGAACTCCCCTGTATTTTTT
    TATGATGAGGAAATCTGAAAAATGTAAAATGTTGAAAGATTTAAGAGCAGTTATTAGAGTAGATCAACCA
    ATGAGTCTCTTGCAGCCTGGAATTCTTTTATCTTGTTTGTAACAACAATCAGGCTCCATAAATTATAAAC
    TATAAAAATTTACTTTATAAATTATAAATATATATATATGTGTGTCTGTAGATAGATAGATAGATAAATA
    GATAGATAGATAGATAGATAGATAGATAGATATATGGATTTGATGGTTGCAGCAAATTCTAATTGGTTCC
    AACAACCCTACTCACATAATACATTCATACAGGTTTGATAGATGGAGCTAAGTTTTAAATAAATTATTTT
    TCTCCCATGGCTTATATATACACCACCAAAATTCTCAAAAATTAAAATGTGATTGTGTTGTATTTTTCTT
    TTACTGAATGACTATAAAAAGTTACAACATTCTCCATAAATTTACATGAAAAAATATTATGTAGTGCAGG
    TAAAGAAAACAAATTGACCCAAGAATGGTGTATATTCATTACTAAGCAACTTTTTAGATTCACAAAGTGT
    GGGTAAACAAGGTAATTTTTTCAATCAGTTTTTTTTAACTGGCAGGCAGCAATTCAGAGTTACAATGAGA
    AGATTAATAATTTTATTGTGTATTTTAAAATAAATCTTACAAAAATATTAATAGAATCACAAATTTATAC
    CTTTGTATAAAAACAATCAGTCATTTCTACTTTAAGAAACAGAACTCACATCTACTCATCAATCATTTTA
    TTAAGTCATATTACAAAGCTGAGTGCTAACATGGGTATAAGAAAACCATAACCTTATTCACCAGCCCAGC
    GTCAAAAAGAAAAAAACCAGTCATATCAGCTGCTGCTTCAAGAGTTCTTGTTCCTTGACATTAACAAAAT
    CCCTAGCTTAACTATTAAATTTTTTTTCAAAACTTCTAATTGATCCCTTAGATAAATGTTTGTGCTAACC
    ATCGGGACACATCCCATGAGTTCTGAAGCAGTGTGTTGTTCTTCATGCATGGCCCTTTTGTAGAGCTGTG
    AGTGTAGGGGAAGAGGGGGGAGAGAGAGCCCGTGTCCAGCCAGAGATCCTGTGCTCTGGGCAGGCAGACA
    CGGGAGGACAACGGAACACTTTTCACTCGGCCTTTGGTGGGCATCTGGCTGTGTGAAGTTACTGACCCCA
    CATGGTGGGGGATGGACAAGGGGCAGCCCCTGGTACCAGGAGCCCCAGGGCTACACTCTCGGCCCCAGAT
    ATACAAGAAGAGGGCAGAGGGAGAGAGGCTCCCACACAGGCGAGAGTCCTTAGTCTGGTCTGTGGCTGGA
    GCAGGGGAATTCCTTCTGATTGGAGATTAGGCACAGCTGATTAGGGGAAAGCCTACCCCATCATCCAAGC
    ACAATGGACTTTGAGGAACAGAGCCAGTCTAAGCTTTTATAGCTTTATGGTAGAAAGGCAGGGAGAAAGG
    AGAGAATGTGGAGAGAGACAGAGAGAGACTGGCCATGGCCAAGAGGAGGGAAGGGGGAAGAGAGAGAAAC
    AGGAAAAGCTAGAAAGTAAGATAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCAAAGTG
    GGGCCAAGCAGCCCCTTTTCTAGTGAGCTTGTCATCTCACAGTTGCTAGGTAACTGGGGAGGAGTTTAGT
    CTGAAGGTCAGAAGCTTGGGACCTTGTGTATGTGACTACTAACCACAGCTTCTCCTGTCGGGACTGTGGG
    AGCAGTAACTTTGACAGGAGACAGGGATCCAGGAGACATGAGGGAACACCTTCTGTCCCACATAGGTGGA
    ATCGGTTGTACCAGGGTTCAGAACTCAACTCCACTGGAGACCAGCCTATGTGTGCATAGCCCATTGCCCT
    ACAGCCTTTGACATTCTACAGAGTTCTGAGACTGGTAGAGATACAAAATAGCTAGGATTACACAGAGAAA
    CACTGGCTTGACAATAAAACTTCCAAAACAAATATAAATGAATAAATACACAAATTGGAGCAAGTGAACT
    TGCACTAAATCCATCAAAACTTGCACAGGATGGCTGTCTCCATAATGTTCAGATCTACTTCTATTAATGT
    CATTAAGAAGACAAAGATTATGCACAAAAAGAAACAAAACAAGAAACCCAAAAGGTAAAGGCTCCAATTG
    TAAGTAATAGACCCACAGTCTCTGAGGCCTGACTGTGCAGGTCCTCACCTTTGGTAATCAGCACTGAATG
    CAGACCACTCCTCATGGACTTTGGGCTCAGGTTTGTTTTCCTTGTCCTTATTTTAAAAGGTAATTCATAG
    AAATGAGATCCTGCCAGTATTGTGTACATGAGAAATAGAAAAATTGGTTTTCTTTGCTCTATTTTGTTTT
    GTTTGGTTAATGACAGTTTCCAAATCAGCATTCTTTGCTTTGAGGTGCCCAGTGTGAGGTGAAGCTGGTA
    GGGTCAGGGCAGCCTGGAGGGTCCCTGAAACACTCCTGTGCAGCCTCTGTAGTCACTGTGAGTGACTACT
    GAATGACCTGGGTCCTTCAGGCTCTAAAGAAGGGGCTGGAGAGGGTGGAAATAATTTTTAATGGTGGAGG
    TAGCACCTATTATCCAGACACCATGAAGGGCTGATTCACCATCTACAGAGATGATGCCAGAAACACACTT
    TACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
    TGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTATTCATATATATATATATAGTGTGTATGTATATTCATAT
    ATATATGTATATTCATAAGGTTGAGTAAATGGACTTAAACTGATTCCATCACAACTTCCATGGGATGGAT
    ATTTCCCAGTGTTAAGACCTGTCAACATCACTGTCATTCAGGAGACAATGATTATGCACAACAAAACAAG
    AAACCCAAAAGCAGAGGACTCCAATTACAATAGACCCAGACCCACAGTCTCTGAAGATTGACTGTACAGT
    TCAACCCAGCCCTGTACTTCTCTTCCCTAGAATTTACATTACTGAGTAACTGAGGAAAGCTCTACAATAT
    CTGTTCTCTATAGTGGTCAACACCTCCAAACACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTT
    CTTGCCATAATGTAGACTACTTCAGCCTATTTTGTACTCCAGTTAACGAAACTCAAGACTAGCTGCATGT
    TAGTCCTTATTCTGAAATATTATGAACAGGTGACCTCCCATCATTCACCAATGCAATAATCATATTTAGG
    AATATGAGGTTTTATGAGATATAAGCACAAGGGAGAGAAAGTAAGAAAACTACATAGATATATAGACTGA
    CATAAATCAAGACTTGCATGAGCTAGTGCCCAAGTACCATGTCCCTAAGTGGCAAGGAGTATCTTTTGAG
    CCTAGTGAGATGAGGTACAAATCGGACTCTTACATCTTTTTAGATAAACATGTGAGATCAATGGACTAAA
    GGCGTGAGCTGGGCTTCCTTGCAATCCATTTTCCATACAAGATAACAATAGATCTGGCTCCACAGACACG
    ATGAGAATAGTCTTAATTAGTTCTTTAAGTAGAATGACTGATCACTAAGAGCCCAATTCCATACTAAATA
    CTCTTCTGGATTATGCACAGATAAAAATTGCACATAGGGCATGGGGCACTGATCTCCCTGCACTACATGA
    ATGGGGGCTCATTTACTAAATGTTCCCATGTTTCTTCCTAGTGCTGCACAGAGCAAATCCTACAACTTCC
    TGCTTGTCTACAATGTAAACTCCAGACAGTACCAGAAAATCATTCCTTATGTTCCTCTCCAGGTGCTTCA
    ACAAGCACAGTGCAAATTTCTGTCACCCTG
  • Molecule Role : Vaximmutor
  • Additional Molecule Role : Vaximmutor
  • Related Vaccine(s): Herpes simplex virus 2 ICP0 mutant vaccine
2. Ighv1-9
  • Gene Name : Ighv1-9
  • Sequence Strain (Species/Organism) : Mus musculus
  • NCBI Gene ID : 668478
  • Genbank Accession : AC073561
  • Taxonomy ID : 10090
  • Chromosome No : 12
  • Gene Starting Position : 114583568
  • Gene Ending Position : 114583861
  • Protein Name : immunoglobulin heavy variable V1-9
  • Protein Note : Also known as Igg2a; Gm16697
  • DNA Sequence : Show Sequence
    >gi|372099098:114583568-114583861 Mus musculus strain C57BL/6J chromosome 12, GRCm38 C57BL/6J
    GTCTTGCACAGTAATAGATGGCAGAGTCCTCAGTTGTCAGGCTGCTGAGTTGCATGTAGGCTGTGTTGGA
    GGATGTATCTGCAGTGAATGTGGCCTTGCCCTTGAACTTCTCATTGTAGTTAGTACTACCACTTCCAGGT
    AAAATCTCTCCAATCCACTCAAGGCCATGTCCAGGCCTCTGCTTTACCCACTCTATCCAGTAGCCAGTGA
    ATGTGTAGCCAGTAGCCTTGCAGGAAAGCTTCACTGAGGCCCCAGGCTTCATCAGCTCAGCTCCAGACTG
    CTGCAGCTGAACCT
  • Molecule Role : Vaximmutor
  • Related Vaccine(s): Herpes simplex virus type 1 DNA vaccine encoding GE
IV. Vaccine Information
1. GSK1437173A
a. Product Name:
Herpes Zoster vaccine GSK1437173A
b. Vaccine Ontology ID:
VO_0004598
c. Type:
Subunit vaccine
d. Status:
Clinical trial
e. Antigen
Glycoprotein E (gE) (Chlibek et al., 2013)
f. Gene Engineering of US8
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
g. Immunization Route
Intramuscular injection (i.m.)
h. Baboon Response
  • Vaccination Protocol: This project was a phase II, observer-blind, randomized, multinational study. Adults ≥50 years old were randomized 4:4:2:1 to be vaccinated at months 0 and 2 with gE combined with a higher (AS01B) or lower (AS01E) dose adjuvant, unadjuvanted gE, or saline (Chlibek et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Cell-mediated and humoral immune responses immune responses were significantly enhanced by AS01B and AS01E compared to unadjuvanted gE. gE/AS01B induced stronger immune responses than gE/AS01E (Chlibek et al., 2013).
  • Side Effects: No vaccine-related severe adverse events were reported, and solicited adverse events were generally mild to moderate and transient. For all gE-based vaccines, pain was the most common local symptom and fatigue the most common general symptom (Chlibek et al., 2013).
2. Herpes simplex virus 1 gD mutant vaccine
a. Product Name:
KOS-gDA3C
b. Vaccine Ontology ID:
VO_0002970
c. Type:
Live, attenuated vaccine
d. Status:
Research
e. Host Species as Laboratory Animal Model:
Mouse
f. Gene Engineering of gD
g. Immunization Route
Flank scratch
h. Mouse Response
3. Herpes simplex virus 1 gH mutant vaccine
a. Vaccine Ontology ID:
VO_0002971
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of gH
f. Immunization Route
Ear pinna
g. Mouse Response
4. Herpes simplex virus 1 TK mutant vaccine
a. Vaccine Ontology ID:
VO_0002973
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of TK
f. Immunization Route
Intracerebral immunization
g. Mouse Response
5. Herpes simplex virus 1 UL29 mutant vaccine
a. Vaccine Ontology ID:
VO_0002974
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of UL29
f. Immunization Route
subcutaneous injection
g. Mouse Response
6. Herpes Simplex Virus 2 DNA Vaccine encoding gD
a. Vaccine Ontology ID:
VO_0004522
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
pDNAVACC (Tirabassi et al., 2011)
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccination Protocol: gD DNA vaccine or empty plasmid was administered intramuscularly on days 0 and 2. gD-liposomes or empty liposomes were administered 3 weeks after the DNA prime (50 μl total dose per mouse per time point in both nostrils) (Tirabassi et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The vaccine stimulated high titers of serum neutralising antibodies, a DNA priming dose dependent T helper type response, enhanced mucosal immune responses and potent protective immunity at the vaginal cavity, the portal of entry for the virus (Tirabassi et al., 2011).
  • Challenge Protocol: The clinical isolate, HSV-2 strain MS was grown and titered in Vero cells. LD50 was titrated in Balb/c mice prior to the challenge experiments. Five days prior to infection, mice were injected subcutaneously with 2 mg of medroxyprogesterone. On the day of infection, animals were anesthetised intraperitoneally with a ketamine/xylazine mixture and instilled intravaginally with a 20 μl suspension containing the indicated virus dose (Tirabassi et al., 2011).
  • Efficacy: The vaccine induced durable protection in mice, demonstrated by a 60% survival rate when lethal infections were performed 20 weeks after the immunisation primed with 0.5 μg of DNA vaccine (Tirabassi et al., 2011).
7. Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L
a. Vaccine Ontology ID:
VO_0004523
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
pCDNA3-CD40L (Sin et al., 2001)
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccination Protocol: The quadriceps muscles of BALB/c mice were injected with 10–60 mg of pgD DNA constructs formulated in a final volume of 100 ml of phosphate-buffered saline and 0.25% bupi- vacaine-HCl, using a 28-gauge needle. Forty micrograms of CD40 and CD40L gene expression cassettes was mixed with pgD plasmid solution prior to injection (Sin et al., 2001).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: When coinjected with CD40L plus pgD vaccines, a significant increase in Th cell-proliferative responses was observed. Specifically, CD40L drives immune responses toward a Th1 phenotype (Sin et al., 2001).
  • Challenge Protocol: After DNA injection, mice were challenged intravaginally with HSV-2 strain 186 with some modification. Before inoculating the virus, the intravaginal area was
    swabbed with a cotton-tipped applicator soaked with 0.1 M NaOH solution and then cleared with dried cotton applicators (Sin et al., 2001).
  • Efficacy: When mice were immunized with gD plasmid DNA and then challenged with 4 LD50, 60% survival of gD plasmid-vaccinated animals was noted. When covaccinated with CD40L, 100% of the challenged animals survived (Sin et al., 2001).
8. Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2
a. Vaccine Ontology ID:
VO_0004521
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
VR1012 (Shlapobersky et al., 2012)
f. Immunization Route
Intravaginal injection
g. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Both FL and S forms of gD2 formulated with Vaxfectin showed significantly higher antibody titres, compared with gD2 alone (Shlapobersky et al., 2012).
  • Efficacy: At a high viral challenge, the 0.1 µg dose of FL gD2 Vaxfectin-formulated pDNA yielded 80 % survival. In addition, 40 % of mice vaccinated with adjuvanted FL pDNA had no detectable HSV-2 viral genomes in the dorsal root ganglia (Shlapobersky et al., 2012).
9. Herpes simplex virus 2 ICP0 mutant vaccine
a. Vaccine Ontology ID:
VO_0002972
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of ICP0
f. Immunization Route
Vaginal immunization
g. Mouse Response
  • Persistence: An ICP0 mutant is attenuated in mice (Halford et al., 2011).
  • Efficacy: An ICP0 mutant induces protection in mice from challenge with wild type HSV-2 (Halford et al., 2011).
  • Host Gene Response of IgG
    • Gene Response: Immunization with the live-attenuated HSV-2 0ΔNLS virus elicited a significant IgG antibody response directed against HSV-2's entry receptor, gD-2. gD-2 specific IgG antibodies were detected at levels significantly higher than levels detected in naive mice at day 50 after inoculation (Halford et al., 2011).
    • Detailed Gene Information: Click here.
10. Herpes simplex virus DNA vaccine ∆gB-2 encoding gB
a. Vaccine Ontology ID:
VO_0004366
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse, guinea pig
e. Gene Engineering of UL27 from Herpes simplex virus type 2
f. Vector:
V1Jns (McClements et al., 1996)
g. Immunization Route
Intraperitoneal injection (i.p.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The DNA immunization has the capacity to elicit cell-mediated, as well as humoral immune responses. In addition, injection of mice showed that each construction induced neutralizing serum antibodies (McClements et al., 1996).
  • Efficacy: Immunized and control (saline-injected) mice were challenged by i.p. injection of HSV-2 and observed daily for survival. Significant protection from death was found for each dose tested (P< 0.01 for the 30, 10, and 3 ug groups, and P = 0.027 for the 1 ug group) (McClements et al., 1996).
11. Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis
a. Vaccine Ontology ID:
VO_0004370
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse, guinea pig
e. Antigen
gD and gB from HSV-2 strain Curtis (McClements et al., 1997)
f. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description: Vector V1Jns expressed HSV envelope glycoproteins D (gD) (McClements et al., 1997).
  • Detailed Gene Information: Click here.
g. Gene Engineering of UL27 from Herpes simplex virus type 2
  • Type: DNA vaccine construction
  • Description: Vector V1Jns expressed HSV envelope glycoprotein B (UL27) (McClements et al., 1997).
  • Detailed Gene Information: Click here.
h. Vector:
V1Jns (McClements et al., 1997)
i. Immunization Route
Intramuscular injection (i.m.)
j. Guinea pig Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Immunization with a plasmid expressing gB induced humoral immune responses and virus neutralization (McClements et al., 1997).
  • Efficacy: When the gB plasmid was combined with a plasmid expressing full-length gD, immunized guinea pigs developed humoral responses to both proteins and were also significantly protected from viral challenge. In addition, immunized animals were partially protected from genital herpes, exhibiting significantly reduced primary and subsequent recurrent disease (McClements et al., 1997).
12. Herpes simplex virus DNA vaccine gB-DNA encoding gB
a. Vaccine Ontology ID:
VO_0004368
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of UL27 from Herpes simplex virus type 1
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: The majority of mice immunized with plasmid DNA encoding gB resisted challenge with 10 ID50 of virus (Manickan et al., 1997).
13. Herpes simplex virus DNA vaccine gBDNA encoding gB
a. Vaccine Ontology ID:
VO_0004369
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of UL27 from Herpes simplex virus type 1
  • Type: DNA vaccine construction
  • Description: This DNA vaccine expressed glycoprotein B of HSV (gBDNA) (Toka and Rouse, 2005).
  • Detailed Gene Information: Click here.
f. Vector:
pIL-15 (Toka and Rouse, 2005).
g. Immunization Route
intranasal immunization
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: pIL-15 generated memory CD8 T cell responses that were threefold higher and mainly maintained in the spleen, but high levels of immunoglobulin A antibodies were induced and maintained long-term in the vaginal mucosa (Toka and Rouse, 2005).
  • Efficacy: The enhanced immune responses ensuing from this strategy of immunization were protective upon lethal challenge with HSV-1. Five out of six mice survived after challenge (Toka and Rouse, 2005).
14. Herpes simplex virus DNA vaccine gD-2 encoding gD
a. Vaccine Ontology ID:
VO_0004365
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse, guinea pig
e. Gene Engineering of gD
f. Vector:
V1Jns (McClements et al., 1996)
g. Immunization Route
Intraperitoneal injection (i.p.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The DNA immunization has the capacity to elicit cell-mediated, as well as humoral immune responses. In addition, injection of mice showed that each construction induced neutralizing serum antibodies (McClements et al., 1996).
  • Efficacy: Immunized and control (saline-injected) mice were challenged by i.p. injection of HSV-2 and observed daily for survival. Significant protection from death (P< 0.001) was achieved for each dose. Eighty-two of eighty-six gD-2 DNA-immunized mice survived challenge (McClements et al., 1996).
15. Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27
a. Vaccine Ontology ID:
VO_0004367
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of ICP27 from Herpes simplex virus type 1
  • Type: DNA vaccine construction
  • Description: This DNA vaccine expresses infectious cell polypeptide 27(ICP-27) (Manickan et al., 1997).
  • Detailed Gene Information: Click here.
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: DC-delivered DNA appeared to be associated mainly with an increased Thi CD4 T cell response (Manickan et al., 1997).
  • Efficacy: The majority of mice immunized with plasmid DNA encoding ICP 27 resisted challenge with 10 ID50 of virus (Manickan et al., 1997).
16. Herpes simplex virus DNA vaccine pCI-gB encoding gB
a. Vaccine Ontology ID:
VO_0004412
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of gB from HSV-1 KOS
  • Type: DNA vaccine construction
  • Description: Vector pCI expressed glycoprotein B of herpes simplex virus type 1 (Hariharan et al., 1998).
  • Detailed Gene Information: Click here.
f. Vector:
pCI (Hariharan et al., 1998)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: A single intramuscular immunization of BALB/c mice with pSIN vectors expressing the glycoprotein B of herpes simplex virus type 1 induced a broad spectrum of immune responses, including virus-specific antibodies, cytotoxic T cells, and protection from lethal virus challenge in two different murine models (Hariharan et al., 1998).
  • Efficacy: 100% of the mice surviving the lethal i.p. McKrae challenge, demonstrating complete protection. None of the mice immunized with 100-μg doses of either negative control plasmid (pCI-HBVe or pSIN1.5-HBVe) survived (Hariharan et al., 1998).
17. Herpes simplex virus DNA vaccine pSIN-gB encoding gB
a. Vaccine Ontology ID:
VO_0004411
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of UL27 from Herpes simplex virus type 1
  • Type: DNA vaccine construction
  • Description: Vector Sindbis virus-based (pSIN vectors) expressed glycoprotein B of herpes simplex virus type 1 (Hariharan et al., 1998).
  • Detailed Gene Information: Click here.
f. Vector:
Sindbis virus-based (pSIN vectors) (Hariharan et al., 1998)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: A single intramuscular immunization of BALB/c mice with pSIN vectors expressing the glycoprotein B of herpes simplex virus type 1 induced a broad spectrum of immune responses, including virus-specific antibodies, cytotoxic T cells, and protection from lethal virus challenge in two different murine models (Hariharan et al., 1998).
  • Efficacy: 100% of the mice surviving the lethal i.p. McKrae challenge, demonstrating complete protection. None of the mice immunized with 100-μg doses of either negative control plasmid (pCI-HBVe or pSIN1.5-HBVe) survived (Hariharan et al., 1998).
18. Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP
a. Vaccine Ontology ID:
VO_0004520
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of UL27 from Herpes simplex virus type 1
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Gene Engineering of UL44 from HSV-1
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of US8
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of US7
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Vector:
VR-1055 (Osorio et al., 2004)
j. Immunization Route
Intramuscular injection (i.m.)
k. Mouse Response
  • Vaccination Protocol: The complete open reading frame for each of the five HSV-1 glycoproteins (gB, gC, gD, gE, and gI) was cloned into the VR-1055 expression vector and grown in bacteria. Plasmid DNA encoding each glycoprotein was purified on a cesium chloride gradient. In each experiment, 10 mice per group were inoculated intramuscularly (IM) into each quadriceps on days 0, 21, and 42 with a cocktail consisting of 10 μg of each cesium chloride–purified DNA (Osorio et al., 2004).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: All immunized groups had significantly higher neutralizing antibody titers than mock-vaccinated mice (Osorio et al., 2004).
  • Challenge Protocol: Ocular challenge was performed 3 weeks after the final immunization. An inoculum of 2 × 105 or 2 × 106 pfu of HSV-1 strain McKrae in 5 μL tissue culture medium was placed in each eye without anesthesia and without corneal scarification, and the lid was gently rubbed for 30 seconds (Osorio et al., 2004).
  • Efficacy: In all vaccine groups, 10 of 10 (100%) of the mice survived, whereas only 15 of 70 (21%) mock groups showed similar survival patterns after ocular infection (Osorio et al., 2004).
19. Herpes simplex virus type 1 DNA vaccine encoding GC
a. Vaccine Ontology ID:
VO_0011408
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
Herpes simplex virus type 1 envelope glycoprotein C
e. Gene Engineering of UL44 from HSV-1
  • Type: DNA vaccine construction
  • Description: The HSV-1 KOS gC gene was isolated by PCR. Each gene was initially cloned into a TA cloning vector and then into a eukaryotic plasmic expression vector that uses the cytomegalovirus immediate-early promoter for expression (pRc/CMV for gC) (Nass et al., 1998).
  • Detailed Gene Information: Click here.
f. Vector:
pRc/CMV
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of 5 BALB/cByJ mice received 100-uL injections of purified plasmids into the quadriceps muscles of the hind legs. In most cases, injections were 3 weeks apart; blood samples were taken from the tail vein 1 day before injection or challenge, and approximately equal volumes of blood from individual mice were pooled within a group (Nass et al., 1998).
  • Challenge Protocol: Three weeks after the final injection, mice were challenged ip with 5 x 104 pfu of HSV-1 McKrae, which was ~10 LD50S, as determied in BALB/cByJ mice (Nass et al., 1998).
  • Efficacy: Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 104 pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
20. Herpes simplex virus type 1 DNA vaccine encoding GD
a. Vaccine Ontology ID:
VO_0011421
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
Herpes simplex virus type1 glycoprotein D
e. Gene Engineering of US5
  • Type: DNA vaccine construction
  • Description: Plasmid DNA encoding HSV-1 glycoprotein D1 (gD1) was constructed by insertion of the gD1 gene into pcDNA3 (Jamali et al., 2009).
  • Detailed Gene Information: Click here.
f. Vector:
pcDNA3
g. Immunization Route
Intradermal injection (i.d.)
h. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: BALB/c mice were immunized three times intra-dermally with 50 µg of pcDNA3 gD1 in a total volume of 100 µl on days 0, 21 and 42 (gD1 group). NLX (Sigma) was dissolved in 100 µl PBS containing 50 µg of the pcDNA3 gD1 construct at a concentration of 5 mg kg–1 and injected to each mouse with the same protocol, i.e. NLX was administered intra-dermally in combination with the pcDNA3 gD1 on days 0, 21 and 42 (NLX-gD1 group). PBS was injected according to the same protocol into the third group of mice as a negative control (PBS group). Finally, the last control group of mice was inoculated according to the same protocol with 100 µl of inoculums containing 105 plaque-forming units (pfu) of KOS strain virus (KOS group) (Jamali et al., 2009).
  • Challenge Protocol: Three weeks after the last immunization, mice were challenged with a low dose [four mouse lethal dose fifty percent (MLD50) = 1 x 105 pfu] or a high dose (10 MLD50 = 1 x 105 pfu) of wild-type virus. The mortality rate was followed for 2 weeks (Jamali et al., 2009).
  • Efficacy: BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 (Jamali et al., 2009).
21. Herpes simplex virus type 1 DNA vaccine encoding GE
a. Vaccine Ontology ID:
VO_0011423
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
Herpes simplex virus type 1 glycoprotein E
e. Gene Engineering of US8
  • Type: DNA vaccine construction
  • Description: The HSV-1 KOS gE gene was isolated by PCR. Each gene was initially cloned into a TA cloning vector and then into a eukaryotic plasmic expression vector that uses the cytomegalovirus immediate-early promoter for expression (pRc/CMV for gE) (Nass et al., 1998).
  • Detailed Gene Information: Click here.
f. Vector:
pRc/CMV
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of 5 BALB/cByJ mice received 100-uL injections of purified plasmids into the quadriceps muscles of the hind legs. In most cases, injections were 3 weeks apart; blood samples were taken from the tail vein 1 day before injection or challenge, and approximately equal volumes of blood from individual mice were pooled within a group (Nass et al., 1998).
  • Challenge Protocol: Three weeks after the final injection, mice were challenged ip with 5 x 104 pfu of HSV-1 McKrae, which was ~10 LD50S, as determied in BALB/cByJ mice (Nass et al., 1998).
  • Efficacy: Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 104 pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
22. Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21
a. Vaccine Ontology ID:
VO_0004519
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Immunization Route
Eye-drop immunization
f. Mouse Response
  • Vaccination Protocol: For the vaccination experiments, Balb/c mice were randomly divided into pRSC-group (mock plasmid), pRSC-gD group, pRSC-gD-IL-21 group and pRSC-gD-IL-21+ nanoparticles group in order. 12 mice per group were used routinely. In the nanoparticles group, 20 μl (40 μg DNA) of the nanoparticles containing DNA vaccine pRSC-gD-IL-21 were topically dropped into the eye of each mouse on days 0, 14 and 28. In other groups, each mouse was inoculated topically into the eye with 40 μg DNA vaccine pRSC-gD-IL-21 or pRSC-gD or mock plasmid in 20 μl PBS 3 times at two week intervals (Hu et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: The nanoparticles containing DNA vaccine pRSC-gD-IL-21 induced mice to generate higher levels of specific neutralizing antibody, sIgA in tears, and IFN-γ, IL-4 in serum (Hu et al., 2011).
  • Challenge Protocol: Three weeks after the final immunization, 6 mice per group were sacrificed and used for detecting immune efficiency, and the other 6 mice were used for HSV-1 challenge experiments. Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (1.5 mg/0.15 ml) and the corneas of mice were scarified 10 times with 1 ml needle and the ocular mucosa of each eye were dropped with HSV-1 (10 μl of 5 × 106 plaque forming unit (PFU)/ml) (Hu et al., 2011).
  • Efficacy: On day 10 after viral challenge, there was no keratitis in the mouse of the pRSC-gD-IL-21+ nanoparticles group, demonstrating that the pRSC-gD-IL-21+ nanoparticles vaccine was efficient to inhibit HSK in a mouse model (Hu et al., 2011).
23. Herpes simplex virus type 2 DNA vaccine encoding GB
a. Vaccine Ontology ID:
VO_0011406
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
Herpes simplex virus type 2 glycoprotein B (UL27)
e. Gene Engineering of UL27 from Herpes simplex virus type 2
  • Type: DNA vaccine construction
  • Description: The plasmid DNA used for immunization was purified by polyethylene glycol precipitation. Briefly, the cellular proteins were precipitated with 1 volume of 7.5 M ammonium acetate. The supernatant was then precipitated with isopropanol, after which the plasmids were extracted three times with phenol-chloroform and then precipitated with pure ethanol. The DNA quality was then checked by electrophoresis in 1% agarose gel. Next, the concentration of the plasmid DNA was measured using a GeneQuant RNA/DNA calculator (Biochrom, Cambridge, UK). The amount of endotoxin was then determined using the Limulus amebocyte lysate (LAL) test (< 0.05 EU/µg) (Kim et al., 2009).
  • Detailed Gene Information: Click here.
f. Vector:
cytomegalovirus promoter (pCI)
g. Immunization Route
Intranasal
h. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of 5- to 6-week old female mice (n = 7) were co-immunized intranasally (i.n.) with 100 µg of pCIgB in the presence of β2-adrenergic agonist, salbutamol (10, 50, 100, and 200 µg). To examine the effect of plasmid DNA backbone (e.g. CpG motif), some of mice were immunized i.n. with 100 µg of the control vector (pCI-neo) in parallel. The i.n. immunization was performed three times at 7-day intervals (days 0, 7, and 14) by depositing pCIgB dissolved in a total volume of 20 µl of PBS (pH 7.2) containing the indicated dose of salbutamol onto the nares of deeply anesthetized mice (Kim et al., 2009).
  • Challenge Protocol: BALB/c mice were subcutaneously injected with Depo-Provera (DP) (Upjohn Co., Kalamazoo, MI) at 2 mg per mouse. Five days following the injection of DP, the mice were challenged intravaginally with 106 PFU of HSV-1 McKrae. The mice were examined daily for vaginal inflammation, neurological illness, and death (Kim et al., 2009).
  • Efficacy: The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection (Kim et al., 2009).
24. Herpes simplex virus type 2 DNA vaccine encoding ICP27
a. Vaccine Ontology ID:
VO_0011405
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
Herpes simplex virus type 2 transcriptional regulator ICP27
e. Gene Engineering of ICP27 from Herpes simplex virus type 2
  • Type: DNA vaccine construction
  • Description: The plasmid-encoding HSV-2 ICP27 was generated by inserting a PCR fragment incorporating the entire ICP27 gene (UL54) into pTarget (Promega, Madison, WI) (Haynes et al., 2006).
  • Detailed Gene Information: Click here.
f. Vector:
pTarget, and a plasmid vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT)
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Each immunization of 6–8-week-old female Balb/c mice consisted of a single PMED™ delivery to the ventral abdominal skin in which each delivery contained 0.5 mg of gold coated with a total of 0.5 μg of the DNA vaccine-DEI vector formulation. Two such “single shot” immunizations were administered 4 weeks apart and animals were sacrificed or challenged 2 weeks following the second immunization (Haynes et al., 2006).
  • Challenge Protocol: Anesthetized Balb/c mice were intranasally challenged with 30 μl of PBS containing approximately 50 LD50 (2 × 106 PFU) of HSV-2 strain MS. Mice were followed for 20 days after infection and scored for morbidity and mortality (Haynes et al., 2006).
  • Efficacy: Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality (Haynes et al., 2006).
25. Herpes simplex virus type 2 vaccine using phage displaying GG protein
a. Vaccine Ontology ID:
VO_0011420
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Antigen
Herpes simplex virus type 2 envelope glycoprotein G (US4)
e. Gene Engineering of US4
  • Type: Recombinant protein preparation
  • Description: Phage clones were isolated that express peptides that mimic single epitopes of the glycoprotein G of HSV-2, gG2 (Grabowska et al., 2000).
  • Detailed Gene Information: Click here.
f. Vector:
Filamentous phage
g. Immunization Route
Subcutaneous injection
h. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: BALB/c mice were obtained from a randomly bred, closed colony at the Sheffield University animal facility. Immunisations were administered subcutaneously at 2-week intervals. The dose given is the quantity of phage used per mouse per immunisation in a 200 ml volume of TBS. Prebleeds were obtained from a random selection of the mice prior to immunisation, and further bleeds were taken from all mice 2 weeks after each immunisation (Grabowska et al., 2000).
  • Challenge Protocol: Four weeks after the last immunisation, mice were challenged with 5±6 mouse lethal doses of HSV-2 (strain 333). Survival of the mice was monitored daily (Grabowska et al., 2000).
  • Efficacy: In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 (Grabowska et al., 2000).
26. HSV 2 DNA vaccine pVAX–HSV–2gD–Hsp70
a. Vaccine Ontology ID:
VO_0004578
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Antigen
HSV–2gD gene fragment and Tubercle bacillus Hsp70 gene (Fan and Yang, 2010)
f. Gene Engineering of gD
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Vector:
pVAX (Fan and Yang, 2010)
h. Immunization Route
Intramuscular injection (i.m.)
i. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: The IgG response in serum in vaccinated mice with pVAX–HSV–2gD and pVAX–HSV–2gD–Hsp70 differed significantly (P < 0.05) from those in immunized mice with pVAX and pVAX–Hsp70, which did not generate antibody levels above background. The highest IgG concentration was observed in serum of mice immunized with pVAX–HSV–2gD–Hsp70, which showed significant differences compared with the other three groups (P < 0.05) (Fan and Yang, 2010).
  • Efficacy: Eight of the animals (8/10) have survived in group pVAX–HSV–2gD–Hsp70. Only one survived in the pVAX and pVAX–Hsp70 groups (Fan and Yang, 2010).
27. HSV glycoproteins subunit vaccine
a. Vaccine Ontology ID:
VO_0004267
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
gB2t + gD2t (Burke et al., 1994)
e. Adjuvant: MTP-PE Liposomes
f. Adjuvant: MF59
g. Immunization Route
not specified
28. pRP-RSV-HSV-1-gB
a. Vaccine Ontology ID:
VO_0004723
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of gB from HSV-1 KOS
  • Type: Recombinant vector construction
  • Description: The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV (Manservigi et al., 1990).
  • Detailed Gene Information: Click here.
f. Preparation
The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, deleted of 639 nucleotides that encode the transmembrane anchor sequence and reconstructed with the extramembrane and intracytoplasmic domains, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV (Manservigi et al., 1990).
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccination Protocol: Mice were immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies (Manservigi et al., 1990).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged with HSV-1 or LV (Manservigi et al., 1990).
  • Efficacy: Mice immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies and were protected against HSV-1 lethal, latent, and recurrent infections (Manservigi et al., 1990).
29. rOka-gD2- HSV-2
a. Vaccine Ontology ID:
VO_0004710
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Gene Engineering of gD
  • Type: Recombinant vector construction
  • Description: The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
  • Detailed Gene Information: Click here.
f. Preparation
Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
g. Immunization Route
Intramuscular injection (i.m.)
h. Guinea pig Response
  • Vaccination Protocol: The guinea pigs were inoculated with three doses of uninfected human fibroblasts, fibroblasts infected with ROka VZV, or fibroblasts infected with ROka-gD2 (Heineman et al., 1995).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The guinea pigs were challenged intravaginally with HSV-2 (Heineman et al., 1995).
  • Efficacy: Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001). These experiments demonstrate that the Oka strain of VZV can be used as a live virus vector to protect animals from disease with a heterologous virus (Heineman et al., 1995).
V. References
1. Awasthi et al., 2008: Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine. 2008; 26(9); 1195-1203. [PubMed: 18243431].
2. Awasthi et al., 2011: Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. Journal of virology. 2011; 85(20); 10472-10486. [PubMed: 21813597].
3. Brittle et al., 2008: Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. Journal of virology. 2008; 82(17); 8431-8441. [PubMed: 18562543].
4. Burke et al., 1994: Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. The Journal of infectious diseases. 1994; 170(5); 1110-1119. [PubMed: 7963702].
5. Chlibek et al., 2013: Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. The Journal of infectious diseases. 2013; ; . [PubMed: 23904292].
6. Fan and Yang, 2010: Fan J, Yang H. Construction and immune response of HSV-2gD-Hsp70 DNA vaccine. Journal of dermatological science. 2010; 57(1); 64-66. [PubMed: 19942410].
7. Farrell et al., 1994: Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, Minson AC. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. Journal of virology. 1994; 68(2); 927-932. [PubMed: 8289395].
8. Field and Wildy, 1978: Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. The Journal of hygiene. 1978; 81(2); 267-277. [PubMed: 212476].
9. GlaxoSmithKline, 2013: Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [http://clinicaltrials.gov/ct2/show/study/NCT01165177]
10. Goel et al., 2005: Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Frontiers in bioscience : a journal and virtual library. 2005; 10; 966-974. [PubMed: 15569635].
11. Grabowska et al., 2000: Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology. 2000; 269(1); 47-53. [PubMed: 10725197].
12. Halford et al., 2011: Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PloS one. 2011; 6(3); e17748. [PubMed: 21412438].
13. Hariharan et al., 1998: Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belli BA, Catton DJ, Hsu D, Mittelstaedt D, McCormack JE, Karavodin L, Dubensky TW Jr, Chang SM, Banks TA. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. Journal of virology. 1998; 72(2); 950-958. [PubMed: 9444987].
14. Haynes et al., 2006: Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine. 2006; 24(23); 5016-5026. [PubMed: 16621198].
15. Heineman et al., 1995: Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of virology. 1995; 69(12); 8109-8113. [PubMed: 7494331].
16. Hu et al., 2011: Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine. 2011; 29(7); 1455-1462. [PubMed: 21185849].
17. Huilan et al., 2010: Huilan Y, Cui Z, Jianyong F, Lei G, Wei Q. Construction of, and T-helper (Th)1/Th2 immune responses to, a herpes simplex virus type 2 glycoprotein D-cytotoxic T-lymphocyte epitope DNA vaccine. Clinical and experimental dermatology. 2010; ; . [PubMed: 20497188].
18. Jamali et al., 2009: Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, Soleimanjahi H, Motazakker M, Shahabi S. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. International immunology. 2009; 21(3); 217-225. [PubMed: 19174474].
19. Kim et al., 2009: Kim SB, Han YW, Rahman MM, Kim SJ, Yoo DJ, Kang SH, Kim K, Eo SK. Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist. Experimental & molecular medicine. 2009; 41(11); 812-823. [PubMed: 19641376].
20. Manickan et al., 1997: Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. Journal of leukocyte biology. 1997; 61(2); 125-132. [PubMed: 9021916].
21. McClements et al., 1996: McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(21); 11414-11420. [PubMed: 8876149].
22. McClements et al., 1997: McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine. 1997; 15(8); 857-860. [PubMed: 9234533].
23. Mester et al., 1999: Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine. 1999; 18(9-10); 875-883. [PubMed: 10580201].
24. Morrison and Knipe, 1994: Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. Journal of virology. 1994; 68(2); 689-696. [PubMed: 8289372].
25. Nass et al., 1998: Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. The Journal of infectious diseases. 1998; 178(3); 611-617. [PubMed: 9728527].
26. Orr et al., 2007: Orr MT, Orgun NN, Wilson CB, Way SS. Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. Journal of immunology (Baltimore, Md. : 1950). 2007; 178(8); 4731-4735. [PubMed: 17404252].
27. Osorio et al., 2004: Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Investigative ophthalmology & visual science. 2004; 45(2); 506-514. [PubMed: 14744892].
28. Shlapobersky et al., 2012: Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. The Journal of general virology. 2012; 93(Pt 6); 1305-1315. [PubMed: 22398318].
29. Sin et al., 2001: Sin JI, Kim JJ, Zhang D, Weiner DB. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Human gene therapy. 2001; 12(9); 1091-1102. [PubMed: 11399230].
30. Tirabassi et al., 2011: Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, Nie S, Guberski DL, Yang K. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine. 2011; 29(5); 1090-1098. [PubMed: 21134447].
31. Toka and Rouse, 2005: Toka FN, Rouse BT. Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. Journal of leukocyte biology. 2005; 78(1); 178-186. [PubMed: 15817700].
32. Veselenak et al., 2012: Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine. 2012; 30(49); 7046-7051. [PubMed: 23041125].
33. Wiki: Herpes simplex virus: Herpes simplex virus [http://en.wikipedia.org/wiki/Herpes_simplex_virus]